fbpx
Wikipedia

Fibromyalgia

February 15, 2024

Not to be confused with myalgic encephalomyelitis/chronic fatigue syndrome nor with myelofibrosis.

Fibromyalgia is a medical condition defined by the presence of chronic widespread pain, fatigue, waking unrefreshed, cognitive symptoms, lower abdominal pain or cramps, and depression.[9] Other symptoms include insomnia[10] and a general hypersensitivity.[11][12]

Fibromyalgia
Other namesFibromyalgia syndrome
The nine possible pain sites of fibromyalgia according to the American Pain Society.
Pronunciation
SpecialtyRheumatology, neurology[2]
SymptomsWidespread pain, feeling tired, sleep problems[3][4]
Usual onsetMiddle age[5]
DurationLong term[3]
CausesUnknown[4][5]
Diagnostic methodBased on symptoms after ruling out other potential causes[4][5]
Differential diagnosisAnemia, autoimmune disorders (such as ankylosing spondylitis, polymyalgia rheumatica, rheumatoid arthritis, scleroderma, or multiple sclerosis), Lyme disease, osteoarthritis, thyroid disease[6][7]
TreatmentSufficient sleep and exercise[5]
MedicationDuloxetine, milnacipran, pregabalin, gabapentin[5][8]
PrognosisNormal life expectancy[5]
Frequency2%[4]

The cause of fibromyalgia is unknown, but is believed to involve a combination of genetic and environmental factors.[4] Environmental factors may include psychological stress, trauma, and certain infections.[4] The pain appears to result from processes in the central nervous system and the condition is referred to as a "central sensitization syndrome".[4][13]

The treatment of fibromyalgia is symptomatic[14] and multidisciplinary.[15] The European Alliance of Associations for Rheumatology strongly recommends aerobic and strengthening exercise.[15] Weak recommendations are given to mindfulness, psychotherapy, acupuncture, hydrotherapy, and meditative exercise such as qigong, yoga, and tai chi.[15] The use of medication in the treatment of fibromyalgia is debated,[15][16] although antidepressants can improve quality of life.[17] The medications duloxetine, milnacipran, or pregabalin have been approved by the US Food and Drug Administration (FDA) for the management of fibromyalgia. Other common helpful medications include serotonin-noradrenaline reuptake inhibitors, nonsteroidal anti-inflammatory drugs, and muscle relaxants.[18] Q10 coenzyme and vitamin D supplements may reduce pain and improve quality of life.[19] While fibromyalgia is persistent in nearly all patients, it does not result in death or tissue damage.[16]

Fibromyalgia is estimated to affect 2–4% of the population.[20] Women are affected about twice as often as men.[4][20] Rates appear similar in different areas of the world and among different cultures.[4] Fibromyalgia was first defined in 1990, with updated criteria in 2011,[4] 2016,[9] 2019,[12] and 2024.[21] The term "fibromyalgia" is from Neo-Latin fibro-, meaning "fibrous tissues", Greek μυο- myo-, "muscle", and Greek άλγος algos, "pain"; thus, the term literally means "muscle and fibrous connective tissue pain".[22]

Classification edit

Fibromyalgia is classed as a disorder of pain processing due to abnormalities in how pain signals are processed in the central nervous system.[23] The International Classification of Diseases (ICD-11) includes fibromyalgia in the category of "Chronic widespread pain", code MG30.01.[24]

Signs and symptoms edit

The defining symptoms of fibromyalgia are chronic widespread pain, fatigue, and sleep disturbance.[12] Other symptoms may include heightened pain in response to tactile pressure (allodynia),[12] cognitive problems,[12] musculoskeletal stiffness,[12] environmental sensitivity,[12] hypervigilance,[12] sexual dysfunction,[25] and visual symptoms.[26] Post-Exertional Malaise (PEM) is also recognised as a symptom of Fibromyalgia.[27]

Pain edit

Fibromyalgia is predominantly a chronic pain disorder.[12] According to the NHS, widespread pain is one major symptom, which could feel like an ache, a burning sensation, or a sharp, stabbing pain.[28]

Fatigue edit

Fatigue is one of the defining symptoms of fibromyalgia.[12] Patients may experience physical or mental fatigue. Physical fatigue can be demonstrated by a feeling of exhaustion after exercise or by a limitation in daily activities.[12]

Sleep problems edit

Sleep problems are a core symptom in fibromyalgia.[12] These include difficulty falling asleep or staying asleep, awakening while sleeping and waking up feeling unrefreshed.[12] A meta-analysis compared objective and subjective sleep metrics in people with fibromyalgia and healthy people. Individuals with fibromyalgia had lower sleep quality and efficiency, as well as longer wake time after sleep start, shorter sleep duration, lighter sleep, and greater trouble initiating sleep when objectively assessed, and more difficulty initiating sleep when subjectively assessed.[10] Sleep problems may contribute to pain by decreased release of IGF-1 and human growth hormone, leading to decreased tissue repair.[29] Improving sleep quality can help people with fibromyalgia minimize pain.[30][31]

Cognitive problems edit

Many people with fibromyalgia experience cognitive problems (known as fibrofog or brainfog). One study found that approximately 50% of fibromyalgia patients had subjective cognitive dysfunction and that it was associated with higher levels of pain and other fibromyalgia symptoms.[32] The American Pain Society recognizes these problems as a major feature of fibromyalgia, characterized by trouble concentrating, forgetfulness and disorganized or slow thinking.[12] About 75% of fibromyalgia patients report significant problems with concentration, memory, and multitasking.[33] A 2018 meta-analysis found that the largest differences between fibromyalgia patients and healthy subjects were for inhibitory control, memory, and processing speed.[33] It is hypothesized that the increased pain compromises attention systems, resulting in cognitive problems.[33]

Hypersensitivity edit

In addition to a hypersensitivity to pain, patients with fibromyalgia show hypersensitivity to other stimuli,[11] such as bright lights, loud noises, perfumes and cold.[12] A review article found that they have a lower cold pain threshold.[34] Other studies documented an acoustic hypersensitivity.[35]

Comorbidity edit

Fibromyalgia as a stand-alone diagnosis is uncommon, as most fibromyalgia patients often have other chronic overlapping pain problems or mental disorders.[11] Fibromyalgia is associated with mental health issues like anxiety,[36] posttraumatic stress disorder,[4][36] bipolar disorder,[36] alexithymia,[37] and depression.[36][38][39] Patients with fibromyalgia are five times more likely to have major depression than the general population.[40]

Fibromyalgia and numerous chronic pain conditions frequently coexist.[38] These include chronic tension headaches,[36] myofascial pain syndrome,[36] and temporomandibular disorders.[36] Multiple sclerosis, post-polio syndrome, neuropathic pain, and Parkinson's disease are four neurological disorders that have been linked to pain or fibromyalgia.[38] Fibromyalgia largely overlaps with chronic fatigue syndrome[41][42] and may share the same pathogenetic mechanisms.[42]

Comorbid fibromyalgia has been reported to occur in 20–30% of individuals with rheumatic diseases.[38] It has been reported in people with noninflammatory musculoskeletal diseases.[38]

The prevalence of fibromyalgia in gastrointestinal disease has been described mostly for celiac disease[38] and irritable bowel syndrome (IBS).[38][36] IBS and fibromyalgia share similar pathogenic mechanisms, involving immune system mast cells, inflammatory biomarkers, hormones, and neurotransmitters such as serotonin. Changes in the gut biome alter serotonin levels, leading to autonomic nervous system hyperstimulation.[43]

Fibromyalgia has also been linked with obesity.[44] Other conditions that are associated with fibromyalgia include connective tissue disorders,[45] cardiovascular autonomic abnormalities,[46] restless leg syndrome[47] and an overactive bladder.[48]

Risk factors edit

The cause of fibromyalgia is unknown. However, several risk factors, genetic and environmental, have been identified.

Genetics edit

Genetics play a major role in fibromyalgia, and may explain up to 50% of the disease susceptibility.[49] Fibromyalgia is potentially associated with polymorphisms of genes in the serotoninergic,[50] dopaminergic[50] and catecholaminergic systems.[50] Several genes have been suggested as candidates for susceptibility to fibromyalgia. These include SLC6A4,[49] TRPV2,[49] MYT1L,[49] NRXN3,[49] and the 5-HT2A receptor 102T/C polymorphism.[51] The heritability of fibromyalgia is estimated to be higher in patients younger than 50.[52]

Nearly all the genes suggested as potential risk factors for fibromyalgia are associated with neurotransmitters and their receptors.[53] Neuropathic pain and major depressive disorder often co-occur with fibromyalgia — the reason for this comorbidity appears to be due to shared genetic abnormalities, which leads to impairments in monoaminergic, glutamatergic, neurotrophic, opioid and proinflammatory cytokine signaling. In these vulnerable individuals, psychological stress or illness can cause abnormalities in inflammatory and stress pathways that regulate mood and pain. Eventually, a sensitization and kindling effect occurs in certain neurons leading to the establishment of fibromyalgia and sometimes a mood disorder.[54]

Stress edit

Stress may be an important precipitating factor in the development of fibromyalgia.[55] A 2021 meta-analysis found psychological trauma to be strongly associated with fibromyalgia.[56][57] People who suffered abuse in their lifetime were three times more likely to have fibromyalgia, people who suffered medical trauma or other stressors in their lifetime were about twice as likely.[56]

Some authors have proposed that, because exposure to stressful conditions can alter the function of the hypothalamic-pituitary-adrenal (HPA) axis, the development of fibromyalgia may stem from stress-induced disruption of the HPA axis.[58][59]

Personality edit

Although some have suggested that fibromyalgia patients are more likely to have specific personality traits, when depression is statistically controlled for, it appears that their personality is no different than that of people in the general population.[60]

Other risk markers edit

Other risk markers for fibromyalgia include premature birth, female sex, cognitive influences, primary pain disorders, multiregional pain, infectious illness, hypermobility of joints, iron deficiency and small-fiber polyneuropathy.[61] Metal-induced allergic inflammation has also been linked with fibromyalgia, especially in response to nickel but also inorganic mercury, cadmium, and lead.[62] Following the COVID-19 pandemic, some have suggested that the SARS-CoV-2 virus may trigger fibromyalgia.[63]

Pathophysiology edit

As of 2022, the pathophysiology of fibromyalgia has not yet been elucidated[64] and several theories have been suggested. The prevailing perspective considers fibromyalgia as a condition resulting from an amplification of pain by the central nervous system.[53] Substantial biological evidence backs up this notion, leading to the term of nociplastic pain.[53]

Nervous system edit

Pain processing abnormalities edit

Chronic pain can be divided into three categories. Nociceptive pain is pain caused by inflammation or damage to tissues. Neuropathic pain is pain caused by nerve damage. Nociplastic pain (or central sensitization) is less understood and is the common explanation of the pain experienced in fibromyalgia.[13][20][65] Because the three forms of pain can overlap, fibromyalgia patients may experience nociceptive (e.g., rheumatic illnesses) and neuropathic (e.g., small fiber neuropathy) pain, in addition to nociplastic pain.[20]

Nociplastic pain (central sensitization) edit

Main article: Nociplastic pain

Fibromyalgia can be viewed as a condition of nociplastic pain.[66] Nociplastic pain is caused by an altered function of pain-related sensory pathways in the periphery and the central nervous system, resulting in hypersensitivity.[67]

Nociplastic pain is commonly referred to as "Nociplastic pain syndrome" because it is coupled with other symptoms.[20] These include fatigue, sleep disturbance, cognitive disturbance, hypersensitivity to environmental stimuli, anxiety, and depression.[20] Nociplastic pain is caused by either (1) increased processing of pain stimuli or (2) decreased suppression of pain stimuli at several levels in the nervous system, or both.[20]

Neuropathic pain edit

An alternative hypothesis to nociplastic pain views fibromyalgia as a stress-related dysautonomia with neuropathic pain features.[68] This view highlights the role of autonomic and peripheral nociceptive nervous systems in the generation of widespread pain, fatigue, and insomnia.[69] The description of small fiber neuropathy in a subgroup of fibromyalgia patients supports the disease neuropathic-autonomic underpinning.[68] However, others claim that small fiber neuropathy occurs only in small groups of those with fibromyalgia.[16]

Autonomic nervous system edit

Some suggest that fibromyalgia is caused or maintained by a decreased vagal tone, which is indicated by low levels of heart rate variability,[55] signaling a heightened sympathetic response.[70] Accordingly, several studies show that clinical improvement is associated with an increase in heart rate variability.[71][70][72] Some examples of interventions that increase the heart rate variability and vagal tone are meditation, yoga, mindfulness and exercise.[55] In 2023 the Fibromyalgia: Imbalance of Threat and Soothing Systems (FITSS) model was suggested as a working hypothesis.[73] According to the FITSS model, the salience network (also known as the midcingulo-insular network) may remain continuously hyperactive due to an imbalance in emotion regulation, which is reflected by an overactive "threat" system and an underactive "soothing" system. This hyperactivation, along with other mechanisms, may contribute to fibromyalgia.[73]

Neurotransmitters edit

Some neurochemical abnormalities that occur in fibromyalgia also regulate mood, sleep, and energy, thus explaining why mood, sleep, and fatigue problems are commonly co-morbid with fibromyalgia.[23] Serotonin is the most widely studied neurotransmitter in fibromyalgia. It is hypothesized that an imbalance in the serotoninergic system may lead to the development of fibromyalgia.[74] There is also some data that suggests altered dopaminergic and noradrenergic signaling in fibromyalgia.[75] Supporting the monoamine related theories is the efficacy of monoaminergic antidepressants in fibromyalgia.[17] Glutamate/creatine ratios within the bilateral ventrolateral prefrontal cortex were found to be significantly higher in fibromyalgia patients than in controls, and may disrupt glutamate neurotransmission.[57][76]

Neurophysiology edit

Neuroimaging studies have observed that fibromyalgia patients have increased grey matter in the right postcentral gyrus and left angular gyrus, and decreased grey matter in the right cingulate gyrus, right paracingulate gyrus, left cerebellum, and left gyrus rectus.[77] These regions are associated with affective and cognitive functions and with motor adaptations to pain processing.[77] Other studies have documented decreased grey matter of the default mode network in people with fibromyalgia.[78] These deficits are associated with pain processing.[78]

Neuroendocrine system edit

Studies on the neuroendocrine system and HPA axis in fibromyalgia have been inconsistent. Depressed function of the HPA axis results in adrenal insufficiency and potentially chronic fatigue.[79]

One study found fibromyalgia patients exhibited higher plasma cortisol, more extreme peaks and troughs, and higher rates of dexamethasone non-suppression. However, other studies have only found correlations between a higher cortisol awakening response and pain, and not any other abnormalities in cortisol.[31] Increased baseline ACTH and increase in response to stress have been observed, hypothesized to be a result of decreased negative feedback.[75]

Oxidative stress edit

Pro-oxidative processes correlate with pain in fibromyalgia patients.[79] Decreased mitochondrial membrane potential, increased superoxide activity, and increased lipid peroxidation production are observed.[79] The high proportion of lipids in the central nervous system (CNS) makes the CNS especially vulnerable to free radical damage. Levels of lipid peroxidation products correlate with fibromyalgia symptoms.[79]

Immune system edit

Inflammation has been suggested to have a role in the pathogenesis of fibromyalgia.[80] People with fibromyalgia tend to have higher levels of inflammatory cytokines IL-6,[74][81][82] and IL-8.[74][81][82] There are also increased levels of the pro-inflammatory cytokines IL-1 receptor antagonist.[81][82] Increased levels of pro-inflammatory cytokines may increase sensitivity to pain, and contribute to mood problems.[83] Anti-inflammatory interleukins such as IL-10 have also been associated with fibromyalgia.[74]

A repeated observation shows that autoimmunity triggers such as traumas and infections are among the most frequent events preceding the onset of fibromyalgia.[84] Neurogenic inflammation has been proposed as a contributing factor to fibromyalgia.[85]

Digestive system edit

Gut microbiome edit

Though there is a lack of evidence in this area, it is hypothesized that gut bacteria may play a role in fibromyalgia.[86] People with fibromyalgia are more likely to show dysbiosis, a decrease in microbiota diversity.[87] There is a bidirectional interplay between the gut and the nervous system. Therefore, the gut can affect the nervous system, but the nervous system can also affect the gut. Neurological effects mediated via the autonomic nervous system as well as the hypothalamic pituitary adrenal axis are directed to intestinal functional effector cells, which in turn are under the influence of the gut microbiota.[88]

Gut-brain axis edit

The gut-brain axis, which connects the gut microbiome to the brain via the enteric nervous system, is another area of research. Fibromyalgia patients have less varied gut flora and altered serum metabolome levels of glutamate and serine,[89] implying abnormalities in neurotransmitter metabolism.[84]

Energy metabolism edit

Low ATP in skeletal muscle edit

Patients with fibromyalgia experience exercise intolerance. Primary fibromyalgia is idiopathic (cause unknown), whereas secondary fibromyalgia is in association with a known underlying disorder (such as Ankylosing spondylitis).[90][non-primary source needed] In patients with primary fibromyalgia, studies have found disruptions in energy metabolism within skeletal muscle, including: decreased levels of ATP, ADP, and phosphocreatine, and increased levels of AMP and creatine (use of creatine kinase and myokinase in the phosphagen system due to low ATP);[91][non-primary source needed] increased pyruvate;[92][non-primary source needed] as well as reduced capillary density impairing oxygen delivery to the muscle cells for oxidative phosphorylation.[93][94][non-primary source needed]

Low ATP in brain edit

Despite being a small percentage of the body's total mass, the brain consumes approximately 20% of the energy produced by the body.[57][non-primary source needed] Parts of the brain—the anterior cingulate cortex (ACC), thalamus, and insula—were studied using proton magnetic resonance spectroscopy (MRS) in patients with fibromyalgia and compared to healthy controls. The fibromyalgia patients were found to have lower phosphocreatine (PCr) and lower creatine (Cr) than the control group. Phosphocreatine is used in the phosphagen system to produce ATP. The study found that low creatine and low phosphocreatine were associated with high pain, and that high stress, including PTSD, may contribute to these low levels.[57][non-primary source needed]

Low phosphocreatine levels may disrupt glutamate neurotransmission within the brains of those with fibromyalgia. Glutamate/creatine ratios within the bilateral ventrolateral prefrontal cortex were found to be significantly higher than in controls.[57][76][non-primary source needed]

Diagnosis edit

 
The location of the nine paired tender points that comprise the 1990 American College of Rheumatology criteria for fibromyalgia

There is no single pathological feature, laboratory finding, or biomarker that can diagnose fibromyalgia and there is debate over what should be considered diagnostic criteria and whether an objective diagnosis is possible.[61] In most cases, people with fibromyalgia symptoms may have laboratory test results that appear normal and many of their symptoms may mimic those of other rheumatic conditions such as arthritis or osteoporosis. The specific diagnostic criteria for fibromyalgia have evolved over time.[95]

American College of Rheumatology 1990 edit

The first widely accepted set of classification criteria for research purposes was elaborated in 1990 by the Multicenter Criteria Committee of the American College of Rheumatology. These criteria, which are known informally as "the ACR 1990", defined fibromyalgia according to the presence of the following criteria:

  • A history of widespread pain lasting more than three months – affecting all four quadrants of the body, i.e., both sides, and above and below the waist.
  • Tender points – there are 18 designated possible tender points (although a person with the disorder may feel pain in other areas as well).

The ACR criteria for the classification of patients were originally established as inclusion criteria for research purposes and were not intended for clinical diagnosis but have later become the de facto diagnostic criteria in the clinical setting. A controversial study was done by a legal team looking to prove their client's disability based primarily on tender points and their widespread presence in non-litigious communities prompted the lead author of the ACR criteria to question now the useful validity of tender points in diagnosis.[96] Use of control points has been used to cast doubt on whether a person has fibromyalgia, and to claim the person is malingering.[97]

American College of Rheumatology 2010 provisional criteria edit

 
Widespread pain index (WPI) areas

In 2010, the American College of Rheumatology approved provisional revised diagnostic criteria for fibromyalgia that eliminated the 1990 criteria's reliance on tender point testing.[98] The revised criteria used a widespread pain index (WPI) and symptom severity scale (SSS) in place of tender point testing under the 1990 criteria. The WPI counts up to 19 general body areas[a] in which the person has experienced pain in the preceding week.[9] The SSS rates the severity of the person's fatigue, unrefreshed waking, cognitive symptoms, and general somatic symptoms,[b] each on a scale from 0 to 3, for a composite score ranging from 0 to 12.[9] The revised criteria for diagnosis were:

  • WPI ≥ 7 and SSS ≥ 5 OR WPI 3–6 and SSS ≥ 9,
  • Symptoms have been present at a similar level for at least three months, and
  • No other diagnosable disorder otherwise explains the pain.[98]: 607 

American College of Rheumatology 2016 revisions edit

In 2016, the provisional criteria of the American College of Rheumatology from 2010 were revised.[9] The new diagnosis required all of the following criteria:

  1. "Generalized pain, defined as pain in at least 4 of 5 regions, is present."
  2. "Symptoms have been present at a similar level for at least 3 months."
  3. "Widespread pain index (WPI) ≥ 7 and symptom severity scale (SSS) score ≥ 5 OR WPI of 4–6 and SSS score ≥ 9."
  4. "A diagnosis of fibromyalgia is valid irrespective of other diagnoses. A diagnosis of fibromyalgia does not exclude the presence of other clinically important illnesses."[9]

American Pain Society 2019 edit

 
Multisite pain is defined as six or more pain sites from a total of nine possible sites (head, arms, chest, abdomen, upper back, lower back, and legs), for at least three months.

In 2019, the American Pain Society in collaboration with the U.S. Food and Drug Administration developed a new diagnostic system using two dimensions.[12] The first dimension included core diagnostic criteria and the second included common features. In accordance to the 2016 diagnosis guidelines, the presence of another medical condition or pain disorder does not rule out the diagnosis of fibromyalgia. Nonetheless, other conditions should be ruled out as the main explaining reason for the patient's symptoms. The core diagnostic criteria are:[99]

  1. Multisite pain defined as six or more pain sites from a total of nine possible sites (head, arms, chest, abdomen, upper back, lower back, and legs), for at least three months
  2. Moderate to severe sleep problems or fatigue, for at least three months

Common features found in fibromyalgia patients can assist the diagnosis process. These are tenderness (sensitivity to light pressure), dyscognition (difficulty to think), musculoskeletal stiffness, and environmental sensitivity or hypervigilance.[12]

Self-report questionnaires edit

Some research has suggested using a multidimensional approach taking into consideration somatic symptoms, psychological factors, psychosocial stressors and subjective belief regarding fibromyalgia.[100] These symptoms can be assessed by several self-report questionnaires.[9]

Widespread Pain Index (WPI) edit

The Widespread Pain Index (WPI) measures the number of painful body regions.[98]

Symptom Severity Scale (SSS) edit

The Symptom Severity Scale (SSS) assesses the severity of the fibromyalgia symptoms.

Fibromyalgia Impact Questionnaire (FIQ) edit

The Fibromyalgia Impact Questionnaire (FIQ)[101] and the Revised Fibromyalgia Impact Questionnaire (FIQR)[102] assess three domains: function, overall impact and symptoms.[102] It is considered a useful measure of disease impact.[103]

Other questionnaires edit

Other measures include the Hospital Anxiety and Depression Scale, Multiple Ability Self-Report Questionnaire,[104] Multidimensional Fatigue Inventory, and Medical Outcomes Study Sleep Scale.

Differential diagnosis edit

As of 2009, as many as two out of every three people who are told that they have fibromyalgia by a rheumatologist may have some other medical condition instead.[105] Fibromyalgia could be misdiagnosed in cases of early undiagnosed rheumatic diseases such as preclinical rheumatoid arthritis, early stages of inflammatory spondyloarthritis, polymyalgia rheumatica, myofascial pain syndromes and hypermobility syndrome.[11][106] Neurological diseases with an important pain component include multiple sclerosis, Parkinson's disease and peripheral neuropathy.[11][106] Other medical illnesses that should be ruled out are endocrine disease or metabolic disorder (hypothyroidism, hyperparathyroidism, acromegaly, vitamin D deficiency), gastro-intestinal disease (celiac and non-celiac gluten sensitivity), infectious diseases (Lyme disease, hepatitis C and immunodeficiency disease) and the early stages of a malignancy such as multiple myeloma, metastatic cancer and leukemia/lymphoma.[11][106] Other systemic, inflammatory, endocrine, rheumatic, infectious, and neurologic disorders may cause fibromyalgia-like symptoms, such as systemic lupus erythematosus, Sjögren syndrome, ankylosing spondylitis, Ehlers-Danlos syndromes, psoriatic-related polyenthesitis, a nerve compression syndrome (such as carpal tunnel syndrome), and myasthenia gravis.[107][105][108][109] In addition, several medications can also evoke pain (statins, aromatase inhibitors, bisphosphonates, and opioids).[12]

The differential diagnosis is made during the evaluation on the basis of the person's medical history, physical examination, and laboratory investigations.[107][105][108][109] The patient's history can provide some hints to a fibromyalgia diagnosis. A family history of early chronic pain, a childhood history of pain, an emergence of broad pain following physical and/or psychosocial stress, a general hypersensitivity to touch, smell, noise, taste, hypervigilance, and various somatic symptoms (gastrointestinal, urology, gynecology, neurology), are all examples of these signals [11]

Extensive laboratory tests are usually unnecessary in the differential diagnosis of fibromyalgia.[12] Common tests that are conducted include complete blood count, comprehensive metabolic panel, erythrocyte sedimentation rate, C-reactive protein, and thyroid function test.[12]

Diagnostic criteria based on the biopsychosocial model edit

In 2024, a Brazilian researcher (Dr. André Pontes-Silva) proposed new criteria for the diagnosis of fibromyalgia using the biopsychosocial model. According to these criteria, patients with fibromyalgia must be diagnosed in two main categories: patients with fibromyalgia and affected social component; patients with fibromyalgia and unaffected social component. The article was published by the Oxford group in the official journal of the British Society for Rheumatology.[110]

Management edit

As with many other medically unexplained syndromes, there is no universally accepted treatment or cure for fibromyalgia, and treatment typically consists of symptom management and improving patient quality of life.[14] A personalized, multidisciplinary approach to treatment that includes both non-pharmacologic and pharmacologic therapy and begins with effective patient education is most beneficial.[14] Developments in the understanding of the pathophysiology of the disorder have led to improvements in treatment, which include prescription medication, behavioral intervention, and exercise.

A number of associations have published guidelines for the diagnosis and management of fibromyalgia. The European League Against Rheumatism (EULAR; 2017)[15] recommends a multidisciplinary approach, allowing a quick diagnosis and patient education. The recommended initial management should be non-pharmacological, later pharmacological treatment can be added. The European League Against Rheumatism gave the strongest recommendation for aerobic and strengthening exercise. Weak recommendations were given to a number of treatments, based on their outcomes. Qigong, yoga, and tai chi were weakly recommended for improving sleep and quality of life. Mindfulness was weakly recommended for improving pain and quality of life. Acupuncture and hydrotherapy were weakly recommended for improving pain. A weak recommendation was also given to psychotherapy. It was more suitable for patients with mood disorders or unhelpful coping strategies. Chiropractic was strongly recommended against, due to safety concerns. Some medications were weakly recommended for severe pain (duloxetine, pregabalin, tramadol) or sleep disturbance (amitriptyline, cyclobenzaprine, pregabalin). Others were not recommended due to a lack of efficacy (nonsteroidal anti-inflammatory drugs, monoamine oxidase inhibitors and selective serotonin reuptake inhibitors). Growth hormone, sodium oxybate, opioids and steroids were strongly recommended against due to lack of efficacy and side effects.

The guidelines published by the Association of the Scientific Medical Societies in Germany[111] inform patients that self-management strategies are an important component in managing the disease.[112] The Canadian Pain Society[113] also published guidelines for the diagnosis and management of fibromyalgia.

Exercise edit

Exercise is the only fibromyalgia treatment which has been given a strong recommendation by the European Alliance of Associations for Rheumatology (EULAR). There is strong evidence indicating that exercise improves fitness, sleep and quality of life and may reduce pain and fatigue for people with fibromyalgia.[114][19][115] Exercise has an added benefit in that it does not cause any serious adverse effects.[115]

Exercise may diminish fibromyalgia symptoms through a number of hypothesized biological mechanisms.[116] Exercise may improve pain modulation[117][118] through serotoninergic pathways.[118] It may reduce pain by altering the hypothalamic-pituitary-adrenal axis and reducing cortisol levels.[119] It also has anti-inflammatory effects that may improve fibromyalgia symptoms.[120][121] Aerobic exercise can improve muscle metabolism and pain through mitochondrial pathways.[120]

When comparing different exercise programs, aerobic exercise is capable of modulating the autonomic nervous function of fibromyalgia patients, whereas resistance exercise does not show such effects.[122] A 2022 meta-analysis found that aerobic training showed a high effect size while strength interventions showed moderate effects.[123] Meditative exercise seems preferable for improving sleep,[124][125] with no differences between resistance, flexibility and aquatic exercise in their favorable effects on fatigue.[124]

Despite its benefits, exercise is a challenge for patients with fibromyalgia, due to the chronic fatigue and pain they experience.[126] They perceive it as more effortful than healthy adults.[127] Exercise may intimidate them, in fear that they will be asked to do more than they are capable of.[128] They may also feel that those who recommend or deliver exercise interventions do not fully understand the possible negative impact of exercise on fatigue and pain.[128] This is especially true for non-personalized exercise programs.[128] Adherence is higher when the exercise program is recommended by doctors or supervised by nurses.[129] Depression and higher pain intensity serve as barriers to physical activity.[130] A recommended approach to a graded exercise program begins with small, frequent exercise periods and builds up from there.[123][131] In order to reduce pain, it is recommended to use an exercise program of 13 to 24 weeks, with each session lasting 30 to 60 minutes.[123]

Aerobic edit

Aerobic exercise for fibromyalgia patients is the most investigated type of exercise.[115] It includes activities such as walking, jogging, spinning, cycling, dancing and exercising in water,[120][122] with walking being named as one of the best methods.[132] A 2017 cochrane summary concluded that aerobic exercise probably improves quality of life, slightly decreases pain and improves physical function and makes no difference in fatigue and stiffness.[133] A 2019 meta-analysis showed that exercising aerobically can reduce autonomic dysfunction and increase heart rate variability.[122] This happens when patients exercise at least twice a week, for 45–60 minutes at about 60%-80% of the maximum heart rate.[122] Aerobic exercise also decreases anxiety and depression and improves the quality of life.[122]

Flexibility edit

Combinations of different exercises such as flexibility and aerobic training may improve stiffness.[134] However, the evidence is of low-quality.[134] It is not clear if flexibility training alone compared to aerobic training is effective at reducing symptoms or has any adverse effects.[135]

Resistance edit

In resistance exercise, participants apply a load to their body using weights, elastic band, body weight or other measures.

Two meta-analyses on fibromyalgia have shown that resistance training can reduce anxiety and depression,[122][136] one found that it decreases pain and disease severity[137] and one found that it improves quality of life.[122] Resistance training may also improve sleep, with a greater effect than that of flexibility training and a similar effect to that of aerobic exercise.[138]

The dosage of resistance exercise for women with fibromyalgia was studied in a 2022 meta-analysis.[139] Effective dosages were found when exercising twice a week, for at least eight weeks. Symptom improvement was found for even low dosages such as 1–2 sets of 4–20 repetitions.[139] Most studies use moderate exercise intensity of 40% to 85% one-repetition maximum. This level of intensity was effective in reducing pain.[139] Some treatment regimes increase the intensity over time (from 40% to 80%), whereas others increase it when the participant is able to perform 12 repetitions.[139] High-intensity exercises may cause lower treatment adherence.

Meditative edit

A 2021 meta-analysis found that meditative exercise programs (tai chi, yoga, qigong) were superior to other forms of exercise (aerobic, flexibility, resistance) in improving sleep quality.[124] Other meta-analyses also found positive effects of tai chi for sleep,[140] fibromyalgia symptoms,[141] and pain, fatigue, depression and quality of life.[142] These tai chi interventions frequently included 1-hour sessions practiced 1-3 times a week for 12 weeks. Meditative exercises, as a whole, may achieve desired outcomes through biological mechanisms such as antioxidation, anti-inflammation, reduction in sympathetic activity and modulation of glucocorticoid receptor sensitivity.[120]

Aquatic edit

Several reviews and meta-analyses suggest that aquatic training can improve symptoms and wellness in people with fibromyalgia.[143][144][145][146][147][148] It is recommended to practice aquatic therapy at least twice a week using a low to moderate intensity.[147] However, aquatic therapy does not appear to be superior to other types of exercise.[149]

Other edit

Limited evidence suggests vibration training in combination with exercise may improve pain, fatigue, and stiffness.[150]

Medications edit

A few countries have published guidelines for the management and treatment of fibromyalgia. As of 2018, all of them emphasize that medications are not required. However, medications, though imperfect, continue to be a component of treatment strategy for fibromyalgia patients. The German guidelines outlined parameters for drug therapy termination and recommended considering drug holidays after six months.[16]

Health Canada and the US Food and Drug Administration (FDA) have approved pregabalin[151] (an anticonvulsant) and duloxetine (a serotonin–norepinephrine reuptake inhibitor) for the management of fibromyalgia. The FDA also approved milnacipran (another serotonin–norepinephrine reuptake inhibitor), but the European Medicines Agency refused marketing authority.[152]

Antidepressants edit

Antidepressants are one of the common drugs for fibromyalgia. A 2021 meta-analysis concluded that antidepressants can improve the quality of life for fibromyalgia patients in the medium-term.[17] For most people with fibromyalgia, the potential benefits of treatment with the serotonin and norepinephrine reuptake inhibitors duloxetine and milnacipran and the tricyclic antidepressants, such as amitriptyline, are outweighed by significant adverse effects (more adverse effects than benefits), however, a small number of people may experience relief from symptoms with these medications.[153][154][155]

The length of time that antidepressant medications take to be effective at reducing symptoms can vary. Any potential benefits from the antidepressant amitriptyline may take up to three months to take effect and it may take between three and six months for duloxetine, milnacipran, and pregabalin to be effective at improving symptoms.[156] Some medications have the potential to cause withdrawal symptoms when stopping so gradual discontinuation may be warranted particularly for antidepressants and pregabalin.[97]

Serotonin and norepinephrine reuptake inhibitors edit

A 2023 meta analysis found that duloxetine improved fibromyalgia symptoms, regardless of the dosage.[157] SSRIs may be also be used to treat depression in people diagnosed with fibromyalgia.[158]

Tricyclic antidepressants edit

While amitriptyline has been used as a first line treatment, the quality of evidence to support this use and comparison between different medications is poor.[159][155] Very weak evidence indicates that a very small number of people may benefit from treatment with the tetracyclic antidepressant mirtazapine, however, for most, the potential benefits are not great and the risk of adverse effects and potential harm outweighs any potential for benefit.[160] As of 2018, the only tricyclic antidepressant that has sufficient evidence is amitriptyline.[16][159]

Monoamine oxidase inhibitors edit

Tentative evidence suggests that monoamine oxidase inhibitors (MAOIs) such as pirlindole and moclobemide are moderately effective for reducing pain.[161] Very low-quality evidence suggests pirlindole as more effective at treating pain than moclobemide.[161] Side effects of MAOIs may include nausea and vomiting.[161]

Central nervous system depressants edit

Central nervous system depressants include drug categories such as sedatives, tranquilizers, and hypnotics. A 2021 meta-analysis concluded that such drugs can improve the quality of life for fibromyalgia patients in the medium-term.[17]

Anti-seizure medication edit

The anti-convulsant medications gabapentin and pregabalin may be used to reduce pain.[8] There is tentative evidence that gabapentin may be of benefit for pain in about 18% of people with fibromyalgia.[8] It is not possible to predict who will benefit, and a short trial may be recommended to test the effectiveness of this type of medication. Approximately 6/10 people who take gabapentin to treat pain related to fibromyalgia experience unpleasant side effects such as dizziness, abnormal walking, or swelling from fluid accumulation.[162] Pregabalin demonstrates a benefit in about 9% of people.[163] Pregabalin reduced time off work by 0.2 days per week.[164]

Cannabinoids edit

Cannabinoids may have some benefits for people with fibromyalgia. However, as of 2022, the data on the topic is still limited.[165][166][167] Cannabinoids may also have adverse effects and may negatively interact with common rheumatological drugs.[168]

Opioids edit

The use of opioids is controversial. As of 2015, no opioid is approved for use in this condition by the FDA.[169] A 2016 Cochrane review concluded that there is no good evidence to support or refute the suggestion that oxycodone, alone or in combination with naloxone, reduces pain in fibromyalgia.[170] The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) in 2014 stated that there was a lack of evidence for opioids for most people.[5] The Association of the Scientific Medical Societies in Germany in 2012 made no recommendation either for or against the use of weak opioids because of the limited amount of scientific research addressing their use in the treatment of fibromyalgia. They strongly advise against using strong opioids.[111] The Canadian Pain Society in 2012 said that opioids, starting with a weak opioid like tramadol, can be tried but only for people with moderate to severe pain that is not well-controlled by non-opioid painkillers. They discourage the use of strong opioids and only recommend using them while they continue to provide improved pain and functioning. Healthcare providers should monitor people on opioids for ongoing effectiveness, side effects, and possible unwanted drug behaviors.[113]

A 2015 review found fair evidence to support tramadol use if other medications do not work.[169] A 2018 review found little evidence to support the combination of paracetamol (acetaminophen) and tramadol over a single medication.[171] Goldenberg et al suggest that tramadol works via its serotonin and norepinephrine reuptake inhibition, rather than via its action as a weak opioid receptor agonist.[172]

A large study of US people with fibromyalgia found that between 2005 and 2007 37.4% were prescribed short-acting opioids and 8.3% were prescribed long-acting opioids,[3] with around 10% of those prescribed short-acting opioids using tramadol;[173] and a 2011 Canadian study of 457 people with fibromyalgia found 32% used opioids and two-thirds of those used strong opioids.[113]

Topical treatment edit

Capsaicin has been suggested as a topical pain reliever. Preliminary results suggest that it may improve sleep quality and fatigue, but there are not enough studies to support this claim.[174]

Unapproved or unfounded edit

Sodium oxybate increases growth hormone production levels through increased slow-wave sleep patterns. However, this medication was not approved by the FDA for the indication for use in people with fibromyalgia due to the concern for abuse.[175]

The muscle relaxants cyclobenzaprine, carisoprodol with acetaminophen and caffeine, and tizanidine are sometimes used to treat fibromyalgia; however, as of 2015 they are not approved for this use in the United States.[176][177] The use of nonsteroidal anti-inflammatory drugs is not recommended as first-line therapy.[178] Moreover, nonsteroidal anti-inflammatory drugs cannot be considered as useful in the management of fibromyalgia.[179]

Very low-quality evidence suggests quetiapine may be effective in fibromyalgia.[180]

No high-quality evidence exists that suggests synthetic THC (nabilone) helps with fibromyalgia.[181]

Nutrition and dietary supplements edit

Nutrition is related to fibromyalgia in several ways. Some nutritional risk factors for fibromyalgia complications are obesity, nutritional deficiencies, food allergies and consuming food additives.[182] The consumption of fruits and vegetables, low-processed foods, high-quality proteins, and healthy fats may have some benefits.[182] Low-quality evidence found some benefits of a vegetarian or vegan diet.[183]

Although dietary supplements have been widely investigated in relation to fibromyalgia, most of the evidence, as of 2021, is of poor quality. It is therefore difficult to reach conclusive recommendations.[184] It appears that Q10 coenzyme and vitamin D supplements can reduce pain and improve quality of life for fibromyalgia patients.[19][185] Q10 coenzyme has beneficial effects on fatigue in fibromyalgia patients, with most studies using doses of 300 mg per day for three months.[186] Q10 coenzyme is hypothesized to improve mitochondrial activity and decrease inflammation.[187] Vitamin D has been shown to improve some fibromyalgia measures, but not others.[185][188]

Two review articles found that melatonin treatment has several positive effects on fibromyalgia patients, including the improvement of sleep quality, pain, and disease impact.[189][190] No major adverse events were reported.[189]

Psychotherapy edit

Due to the uncertainty about the pathogenesis of fibromyalgia, current treatment approaches focus on management of symptoms to improve quality of life,[191] using integrated pharmacological and non-pharmacological approaches.[4] There is no single intervention shown to be effective for all patients.[192] In a 2020 Cochrane review, cognitive behavioral therapy was found to have a small but beneficial effect for reducing pain and distress but adverse events were not well evaluated.[193] Cognitive behavioral therapy and related psychological and behavioural therapies have a small to moderate effect in reducing symptoms of fibromyalgia.[194][195] Effect sizes tend to be small when cognitive behavioral therapy is used as a stand-alone treatment for patients with fibromyalgia, but these improve significantly when it is part of a wider multidisciplinary treatment program.[195]

A 2010 systematic review of 14 studies reported that cognitive behavioral therapy improves self-efficacy or coping with pain and reduces the number of physician visits at post-treatment, but has no significant effect on pain, fatigue, sleep, or health-related quality of life at post-treatment or follow-up. Depressed mood was also improved but this could not be distinguished from some risks of bias.[196] A 2022 meta-analysis found that cognitive behavioral therapy reduces insomnia in people with chronic pain, including people with fibromyalgia.[197] Acceptance and commitment therapy, a type of cognitive behavioral therapy, has also proven effective.[198]

Patient education edit

Patient education is recommended by the European League Against Rheumatism (EULAR) as an important treatment component.[15] As of 2022, there is only low-quality evidence showing that patient education can decrease pain and fibromyalgia impact.[199][200]

Sleep hygiene interventions show low effectiveness in improving insomnia in people with chronic pain.[197]

Manual therapy edit

A 2021 meta-analysis concluded that massage and myofascial release diminish pain in the medium-term.[17] As of 2015, there was no good evidence for the benefit of other mind-body therapies.[201]

Acupuncture edit

A 2013 review found moderate-level evidence on the usage of acupuncture with electrical stimulation for improvement of the overall well-being. Acupuncture alone will not have the same effects, but will enhance the influence of exercise and medication in pain and stiffness.[202]

Electrical neuromodulation edit

Several forms of electrical neuromodulation, including transcutaneous electrical nerve stimulation (TENS) and transcranial direct current stimulation (tDCS), have been used to treat fibromyalgia. In general, they have been found to be helpful in reducing pain and depression and improving functioning.[203][204]

Transcutaneous electrical nerve stimulation (TENS) edit

Transcutaneous electrical nerve stimulation (TENS) is the delivery of pulsed electrical currents to the skin to stimulate peripheral nerves. TENS is widely used to treat pain and is considered to be a low-cost, safe, and self-administered treatment.[205] As such, it is commonly recommended by clinicians to people suffering from pain.[206] On 2019, an overview of eight Cochrane reviews was conducted, covering 51 TENS-related randomized controlled trials.[206] The review concluded that the quality of the available evidence was insufficient to make any recommendations.[206] A later review concluded that transcutaneous electrical nerve stimulation may diminish pain in the short-term, but there was uncertainty about the relevance of the results.[17]

Preliminary findings suggest that electrically stimulating the vagus nerve through an implanted device can potentially reduce fibromyalgia symptoms.[207] However, there may be adverse reactions to the procedure.[207]

Noninvasive brain stimulation edit

Noninvasive brain stimulation includes methods such as transcranial direct current stimulation and high-frequency repetitive transcranial magnetic stimulation (TMS). Both methods have been found to improve pain scores in neuropathic pain and fibromyalgia.[208]

A 2023 meta analysis of 16 RCTs found that transcranial direct current stimulation (tDCS) of over 4 weeks can decrease pain in patients with fibromyalgia.[209]

A 2021 meta-analysis of multiple intervention types concluded that magnetic field therapy and transcranial magnetic stimulation may diminish pain in the short-term, but conveyed an uncertainty about the relevance of the result.[17] Several 2022 meta-analyses focusing on transcranial magnetic stimulation found positive effects on fibromyalgia.[210][211][212] Repetitive transcranial magnetic stimulation improved pain in the short-term[211][212] and quality of life after 5–12 weeks.[211][212] Repetitive transcranial magnetic stimulation did not improve anxiety, depression, and fatigue.[212] Transcranial magnetic stimulation to the left dorsolateral prefrontal cortex was also ineffective.[211]

EEG neurofeedback edit

A systematic review of EEG neurofeedback for treatment of fibromyalgia found most treatments showed significant improvements of the main symptoms of the disease.[213] However, the protocols were so different, and the lack of controls or randomization impede drawing conclusive results.[213]

Hyperbaric oxygen therapy edit

Hyperbaric oxygen therapy (HBOT) has shown beneficial effects in treating chronic pain by reducing inflammation and oxidative stress.[79] However, treating fibromyalgia with hyperbaric oxygen therapy is still controversial, in light of the scarcity of large-scale clinical trials.[120] In addition, hyperbaric oxygen therapy raises safety concerns due to the oxidative damage that may follow it.[120] An evaluation of nine trials with 288 patients in total found that HBOT was more effective at relieving fibromyalgia patients' pain than the control intervention. In most of the trials HBOT improved sleep disturbance, multidimensional function, patient satisfaction, and tender spots. 24% of the patients experienced negative outcomes.[214]

Prognosis edit

Although in itself fibromyalgia is neither degenerative nor fatal, the chronic pain of fibromyalgia is pervasive and persistent. Most people with fibromyalgia report that their symptoms do not improve over time. However, most patients learn to adapt to the symptoms over time. The German guidelines for patients explain that:

  1. The symptoms of fibromyalgia are persistent in nearly all patients.
  2. Total relief of symptoms is seldom achieved.
  3. The symptoms do not lead to disablement and do not shorten life expectancy.[112]

An 11-year follow-up study on 1,555 patients found that most remained with high levels of self-reported symptoms and distress.[non-primary source needed][215] However, there was a great deal of patient heterogeneity accounting for almost half of the variance. At the final observation, 10% of the patients showed substantial improvement with minimal symptoms. An additional 15% had moderate improvement. This state, though, may be transient, given the fluctuations in symptom severity.[non-primary source needed][215]

A study of 97 adolescents diagnosed with fibromyalgia followed them for eight years.[non-primary source needed] After eight years, the majority of youth still experienced pain and disability in physical, social, and psychological areas. At the last follow-up, all participants reported experiencing one or more fibromyalgia symptoms such as pain, fatigue, and/or sleep problems, with 58% matching the complete ACR 2010 criteria for fibromyalgia. Based on the WPI and SS score cut-points, the remaining 42% exhibited subclinical symptoms. Pain and emotional symptom trajectories, on the other hand, displayed a variety of longitudinal patterns. The study concluded that while most patient's fibromyalgia symptoms endure, the severity of their pain tends to reduce over time.[216]

Baseline depressive symptoms in adolescents appear to predict worse pain at follow-up periods.[217][218]

A meta-analysis based on close to 200,000 fibromyalgia patients found that they were at a higher risk for all-cause mortality. Specific mortality causes that were suggested were accidents, infections and suicide.[219]

Epidemiology edit

Fibromyalgia is estimated to affect 1.8% of the population.[220]

Despite the fact that more than 90% of fibromyalgia patients are women, only 60% of people with fibromyalgia symptoms are female in the general population.[221]

History edit

Chronic widespread pain had already been described in the literature in the 19th century but the term fibromyalgia was not used until 1976 when Dr P.K. Hench used it to describe these symptoms.[97] Many names, including "muscular rheumatism", "fibrositis", "psychogenic rheumatism", and "neurasthenia" were applied historically to symptoms resembling those of fibromyalgia.[222] The term fibromyalgia was coined by researcher Mohammed Yunus as a synonym for fibrositis and was first used in a scientific publication in 1981.[223] Fibromyalgia is from the Latin fibra (fiber)[224] and the Greek words myo (muscle)[225] and algos (pain).[226]

Historical perspectives on the development of the fibromyalgia concept note the "central importance" of a 1977 paper by Smythe and Moldofsky on fibrositis.[227][228] The first clinical, controlled study of the characteristics of fibromyalgia syndrome was published in 1981,[229] providing support for symptom associations. In 1984, an interconnection between fibromyalgia syndrome and other similar conditions was proposed,[230] and in 1986, trials of the first proposed medications for fibromyalgia were published.[230]

A 1987 article in the Journal of the American Medical Association used the term "fibromyalgia syndrome" while saying it was a "controversial condition".[231] The American College of Rheumatology (ACR) published its first classification criteria for fibromyalgia in 1990.[232] Later revisions were made in 2010,[98] 2016,[9] and 2019.[12]

Society and culture edit

Economics edit

People with fibromyalgia generally have higher healthcare costs and utilization rates. A review of 36 studies found that fibromyalgia causes a significant economic burden on health care systems.[233] Annual costs per patient were estimated to be up to $35,920 in the US and $8,504 in Europe.[233]

Controversies edit

Fibromyalgia was defined relatively recently. In the past, it was a disputed diagnosis. Frederick Wolfe, lead author of the 1990 paper that first defined the diagnostic guidelines for fibromyalgia, stated in 2008 that he believed it "clearly" not to be a disease but instead a physical response to depression and stress.[234] In 2013, Wolfe added that its causes "are controversial in a sense" and "there are many factors that produce these symptoms – some are psychological and some are physical and it does exist on a continuum".[235] Some members of the medical community do not consider fibromyalgia a disease because of a lack of abnormalities on physical examination and the absence of objective diagnostic tests.[227][236]

In the past, some psychiatrists have viewed fibromyalgia as a type of affective disorder, or a somatic symptom disorder. These controversies do not engage healthcare specialists alone; some patients object to fibromyalgia being described in purely somatic terms.[237]

As of 2022, neurologists and pain specialists tend to view fibromyalgia as a pathology due to dysfunction of muscles and connective tissue as well as functional abnormalities in the central nervous system. Rheumatologists define the syndrome in the context of "central sensitization" – heightened brain response to normal stimuli in the absence of disorders of the muscles, joints, or connective tissues. Because of this symptomatic overlap, some researchers have proposed that fibromyalgia and other analogous syndromes be classified together as central sensitivity syndromes.[238][13]

Notes edit

  1. ^ Shoulder girdle (left & right), upper arm (left & right), lower arm (left & right), hip/buttock/trochanter (left & right), upper leg (left & right), lower leg (left & right), jaw (left & right), chest, abdomen, back (upper & lower), and neck.[98]: 607 
  2. ^ Somatic symptoms include, but are not limited to: muscle pain, irritable bowel syndrome, fatigue or tiredness, problems thinking or remembering, muscle weakness, headache, pain or cramps in the abdomen, numbness or tingling, dizziness, insomnia, depression, constipation, pain in the upper abdomen, nausea, nervousness, chest pain, blurred vision, fever, diarrhea, dry mouth, itching, wheezing, Raynaud's phenomenon, hives or welts, ringing in the ears, vomiting, heartburn, oral ulcers, loss of or changes in taste, seizures, dry eyes, shortness of breath, loss of appetite, rash, sun sensitivity, hearing difficulties, easy bruising, hair loss, frequent or painful urination, and bladder spasms.[98]: 607 

References edit

  1. ^ "fibromyalgia". Collins Dictionaries. from the original on 4 October 2015. Retrieved 16 March 2016.
  2. ^ "Neurology Now: Fibromyalgia: Is Fibromyalgia Real? | American Academy of Neurology". tools.aan.com. October 2009. Retrieved 1 June 2018.[permanent dead link]
  3. ^ a b c Ngian GS, Guymer EK, Littlejohn GO (February 2011). "The use of opioids in fibromyalgia". International Journal of Rheumatic Diseases. 14 (1): 6–11. doi:10.1111/j.1756-185X.2010.01567.x. PMID 21303476. S2CID 29000267.
  4. ^ a b c d e f g h i j k l Clauw DJ (April 2014). "Fibromyalgia: a clinical review". JAMA. 311 (15): 1547–1555. doi:10.1001/jama.2014.3266. PMID 24737367. S2CID 43693607.
  5. ^ a b c d e f g . NIAMS. July 2014. Archived from the original on 15 March 2016. Retrieved 15 March 2016.
  6. ^ Ferri FF (2010). "Chapter F". Ferri's differential diagnosis: a practical guide to the differential diagnosis of symptoms, signs, and clinical disorders (2nd ed.). Philadelphia, PA: Elsevier/Mosby. ISBN 978-0323076999.
  7. ^ Schneider MJ, Brady DM, Perle SM (2006). "Commentary: differential diagnosis of fibromyalgia syndrome: proposal of a model and algorithm for patients presenting with the primary symptom of chronic widespread pain". Journal of Manipulative and Physiological Therapeutics. 29 (6): 493–501. doi:10.1016/j.jmpt.2006.06.010. PMID 16904498.
  8. ^ a b c Cooper TE, Derry S, Wiffen PJ, Moore RA (January 2017). "Gabapentin for fibromyalgia pain in adults". The Cochrane Database of Systematic Reviews. 1 (1): CD012188. doi:10.1002/14651858.CD012188.pub2. PMC 6465053. PMID 28045473.
  9. ^ a b c d e f g h Wolfe F, Clauw DJ, Fitzcharles MA, Goldenberg DL, Häuser W, Katz RL, et al. (December 2016). "2016 Revisions to the 2010/2011 fibromyalgia diagnostic criteria". Seminars in Arthritis and Rheumatism. 46 (3): 319–329. doi:10.1016/j.semarthrit.2016.08.012. PMID 27916278.
  10. ^ a b Wu YL, Chang LY, Lee HC, Fang SC, Tsai PS (May 2017). "Sleep disturbances in fibromyalgia: A meta-analysis of case-control studies". Journal of Psychosomatic Research. 96: 89–97. doi:10.1016/j.jpsychores.2017.03.011. PMID 28545798.
  11. ^ a b c d e f g Häuser W, Sarzi-Puttini P, Fitzcharles MA (2019). "Fibromyalgia syndrome: under-, over- and misdiagnosis". Clinical and Experimental Rheumatology. 37 (1 Suppl 116): 90–97. PMID 30747096.
  12. ^ a b c d e f g h i j k l m n o p q r s t u Arnold LM, Bennett RM, Crofford LJ, Dean LE, Clauw DJ, Goldenberg DL, et al. (June 2019). "AAPT Diagnostic Criteria for Fibromyalgia". The Journal of Pain. 20 (6): 611–628. doi:10.1016/j.jpain.2018.10.008. hdl:2434/632765. PMID 30453109. S2CID 53872511.
  13. ^ a b c Mezhov V, Guymer E, Littlejohn G (December 2021). "Central sensitivity and fibromyalgia". Internal Medicine Journal. 51 (12): 1990–1998. doi:10.1111/imj.15430. PMID 34139045. S2CID 235471910.
  14. ^ a b c Prabhakar A, Kaiser JM, Novitch MB, Cornett EM, Urman RD, Kaye AD (March 2019). "The Role of Complementary and Alternative Medicine Treatments in Fibromyalgia: a Comprehensive Review". Current Rheumatology Reports. 21 (5): 14. doi:10.1007/s11926-019-0814-0. PMID 30830504. S2CID 73482737.
  15. ^ a b c d e f Macfarlane GJ, Kronisch C, Atzeni F, Häuser W, Choy EH, Amris K, et al. (December 2017). "EULAR recommendations for management of fibromyalgia" (PDF). Annals of the Rheumatic Diseases. 76 (12): e54. doi:10.1136/annrheumdis-2017-211587. PMID 28476880. S2CID 26251476.
  16. ^ a b c d e Häuser W, Fitzcharles MA (March 2018). "Facts and myths pertaining to fibromyalgia". Dialogues in Clinical Neuroscience. 20 (1): 53–62. doi:10.31887/dcns.2018.20.1/whauser. PMC 6016048. PMID 29946212.
  17. ^ a b c d e f g Mascarenhas RO, Souza MB, Oliveira MX, Lacerda AC, Mendonça VA, Henschke N, Oliveira VC (January 2021). "Association of Therapies With Reduced Pain and Improved Quality of Life in Patients With Fibromyalgia: A Systematic Review and Meta-analysis". JAMA Internal Medicine. 181 (1): 104–112. doi:10.1001/jamainternmed.2020.5651. PMC 7589080. PMID 33104162.
  18. ^ Kia S, Choy E (May 2017). "Update on Treatment Guideline in Fibromyalgia Syndrome with Focus on Pharmacology". Biomedicines. 5 (2): 20. doi:10.3390/biomedicines5020020. PMC 5489806. PMID 28536363.
  19. ^ a b c Ibáñez-Vera AJ, Alvero-Cruz JR, García-Romero JC (2018). "Therapeutic physical exercise and supplements to treat fibromyalgia". Apunts. Medicina de l'Esport. 53 (197): 33–41. doi:10.1016/j.apunts.2017.07.001.
  20. ^ a b c d e f g Fitzcharles MA, Cohen SP, Clauw DJ, Littlejohn G, Usui C, Häuser W (May 2021). "Nociplastic pain: towards an understanding of prevalent pain conditions". Lancet. 397 (10289): 2098–2110. doi:10.1016/s0140-6736(21)00392-5. PMID 34062144. S2CID 235245552.
  21. ^ Pontes-Silva A (3 February 2024). "Fibromyalgia: a new set of diagnostic criteria based on the biopsychosocial model". Rheumatology. doi:10.1093/rheumatology/keae074. ISSN 1462-0324. PMID 38310344.
  22. ^ Bergmann U (2012). Neurobiological foundations for EMDR practice. New York: Springer Pub. Co. p. 165. ISBN 978-0826109385.
  23. ^ a b Clauw DJ, Arnold LM, McCarberg BH (September 2011). "The science of fibromyalgia". Mayo Clinic Proceedings. 86 (9): 907–911. doi:10.4065/mcp.2011.0206. PMC 3258006. PMID 21878603.
  24. ^ "ICD-11 for Mortality and Morbidity Statistics". icd.who.int. Retrieved 9 April 2022.
  25. ^ Besiroglu MD, Dursun MD (July 2019). "The association between fibromyalgia and female sexual dysfunction: a systematic review and meta-analysis of observational studies". International Journal of Impotence Research. 31 (4): 288–297. doi:10.1038/s41443-018-0098-3. PMID 30467351. S2CID 53717513.
  26. ^ Zdebik N, Zdebik A, Bogusławska J, Przeździecka-Dołyk J, Turno-Kręcicka A (January 2021). "Fibromyalgia syndrome and the eye – A review". Survey of Ophthalmology. 66 (1): 132–137. doi:10.1016/j.survophthal.2020.05.006. PMID 32512032. S2CID 219548664.
  27. ^ academic.oup.com https://academic.oup.com/painmedicine/article/23/6/1144/6404604. Retrieved 11 February 2024. {{cite web}}: Missing or empty |title= (help)
  28. ^ "Fibromyalgia – Symptoms". nhs.uk. 20 October 2017. Retrieved 21 October 2020.
  29. ^ Kimura S, Toyoura M, Toyota Y, Takaoka Y (December 2020). "Serum concentrations of insulin-like growth factor-1 as a biomarker of improved circadian rhythm sleep-wake disorder in school-aged children". Journal of Clinical Sleep Medicine. 16 (12): 2073–2078. doi:10.5664/jcsm.8778. PMC 7848940. PMID 32876042.
  30. ^ Spaeth M, Rizzi M, Sarzi-Puttini P (April 2011). "Fibromyalgia and sleep". Best Practice & Research. Clinical Rheumatology. 25 (2): 227–239. doi:10.1016/j.berh.2011.03.004. PMID 22094198.
  31. ^ a b Bradley LA (December 2009). "Pathophysiology of fibromyalgia". The American Journal of Medicine. 122 (12 Suppl): S22–S30. doi:10.1016/j.amjmed.2009.09.008. PMC 2821819. PMID 19962493.
  32. ^ Wolfe F, Rasker JJ, Ten Klooster P, Häuser W (December 2021). "Subjective Cognitive Dysfunction in Patients With and Without Fibromyalgia: Prevalence, Predictors, Correlates, and Consequences". Cureus. 13 (12): e20351. doi:10.7759/cureus.20351. PMC 8752385. PMID 35036191.
  33. ^ a b c Bell T, Trost Z, Buelow MT, Clay O, Younger J, Moore D, Crowe M (September 2018). "Meta-analysis of cognitive performance in fibromyalgia". Journal of Clinical and Experimental Neuropsychology. 40 (7): 698–714. doi:10.1080/13803395.2017.1422699. PMC 6151134. PMID 29388512.
  34. ^ Berwick RJ, Siew S, Andersson DA, Marshall A, Goebel A (May 2021). "A Systematic Review Into the Influence of Temperature on Fibromyalgia Pain: Meteorological Studies and Quantitative Sensory Testing". The Journal of Pain. 22 (5): 473–486. doi:10.1016/j.jpain.2020.12.005. PMID 33421589. S2CID 231437516.
  35. ^ Staud R, Godfrey MM, Robinson ME (August 2021). "Fibromyalgia Patients Are Not Only Hypersensitive to Painful Stimuli But Also to Acoustic Stimuli". The Journal of Pain. 22 (8): 914–925. doi:10.1016/j.jpain.2021.02.009. PMID 33636370. S2CID 232066286.
  36. ^ a b c d e f g h Kleykamp BA, Ferguson MC, McNicol E, Bixho I, Arnold LM, Edwards RR, et al. (February 2021). "The Prevalence of Psychiatric and Chronic Pain Comorbidities in Fibromyalgia: an ACTTION systematic review". Seminars in Arthritis and Rheumatism. 51 (1): 166–174. doi:10.1016/j.semarthrit.2020.10.006. PMID 33383293. S2CID 229948862.
  37. ^ Habibi Asgarabad M, Salehi Yegaei P, Jafari F, Azami-Aghdash S, Lumley MA (March 2023). "The relationship of alexithymia to pain and other symptoms in fibromyalgia: A systematic review and meta-analysis". European Journal of Pain. 27 (3): 321–337. doi:10.1002/ejp.2064. PMID 36471652. S2CID 254273680.
  38. ^ a b c d e f g Fitzcharles MA, Perrot S, Häuser W (October 2018). "Comorbid fibromyalgia: A qualitative review of prevalence and importance". European Journal of Pain. 22 (9): 1565–1576. doi:10.1002/ejp.1252. PMID 29802812. S2CID 44068037.
  39. ^ Yepez D, Grandes XA, Talanki Manjunatha R, Habib S, Sangaraju SL (May 2022). "Fibromyalgia and Depression: A Literature Review of Their Shared Aspects". Cureus. 14 (5): e24909. doi:10.7759/cureus.24909. PMC 9187156. PMID 35698706.
  40. ^ Løge-Hagen JS, Sæle A, Juhl C, Bech P, Stenager E, Mellentin AI (February 2019). "Prevalence of depressive disorder among patients with fibromyalgia: Systematic review and meta-analysis". Journal of Affective Disorders. 245: 1098–1105. doi:10.1016/j.jad.2018.12.001. PMID 30699852. S2CID 73411416.
  41. ^ Anderson G, Maes M (December 2020). "Mitochondria and immunity in chronic fatigue syndrome". Progress in Neuro-Psychopharmacology & Biological Psychiatry. 103: 109976. doi:10.1016/j.pnpbp.2020.109976. PMID 32470498. S2CID 219104988.
  42. ^ a b Ramírez-Morales R, Bermúdez-Benítez E, Martínez-Martínez LA, Martínez-Lavín M (August 2022). "Clinical overlap between fibromyalgia and myalgic encephalomyelitis. A systematic review and meta-analysis". Autoimmunity Reviews. 21 (8): 103129. doi:10.1016/j.autrev.2022.103129. PMID 35690247.
  43. ^ Valencia C, Fatima H, Nwankwo I, Anam M, Maharjan S, Amjad Z, et al. (October 2022). "A Correlation Between the Pathogenic Processes of Fibromyalgia and Irritable Bowel Syndrome in the Middle-Aged Population: A Systematic Review". Cureus. 14 (10): e29923. doi:10.7759/cureus.29923. PMC 9635936. PMID 36381861.
  44. ^ D'Onghia M, Ciaffi J, Lisi L, Mancarella L, Ricci S, Stefanelli N, et al. (April 2021). "Fibromyalgia and obesity: A comprehensive systematic review and meta-analysis". Seminars in Arthritis and Rheumatism. 51 (2): 409–424. doi:10.1016/j.semarthrit.2021.02.007. PMID 33676126. S2CID 232136088.
  45. ^ Alsiri N, Alhadhoud M, Alkatefi T, Palmer S (February 2023). "The concomitant diagnosis of fibromyalgia and connective tissue disorders: A systematic review" (PDF). Seminars in Arthritis and Rheumatism. 58: 152127. doi:10.1016/j.semarthrit.2022.152127. PMID 36462303. S2CID 253650110.
  46. ^ Kocyigit BF, Akyol A (March 2023). "Coexistence of fibromyalgia syndrome and inflammatory rheumatic diseases, and autonomic cardiovascular system involvement in fibromyalgia syndrome". Clinical Rheumatology. 42 (3): 645–652. doi:10.1007/s10067-022-06385-8. PMID 36151442. S2CID 252496799.
  47. ^ Padhan P, Maikap D, Pathak M (2023). "Restless leg syndrome in rheumatic conditions: Its prevalence and risk factors, a meta-analysis". International Journal of Rheumatic Diseases. 26 (6): 1111–1119. doi:10.1111/1756-185X.14710. ISSN 1756-1841. PMID 37137528. S2CID 258484602.
  48. ^ Goldberg N, Tamam S, Weintraub AY (December 2022). "The association between overactive bladder and fibromyalgia: A systematic review and meta-analysis". International Journal of Gynaecology and Obstetrics. 159 (3): 630–641. doi:10.1002/ijgo.14290. PMID 35641437. S2CID 249236213.
  49. ^ a b c d e D'Agnelli S, Arendt-Nielsen L, Gerra MC, Zatorri K, Boggiani L, Baciarello M, Bignami E (January 2019). "Fibromyalgia: Genetics and epigenetics insights may provide the basis for the development of diagnostic biomarkers". Molecular Pain. 15: 1744806918819944. doi:10.1177/1744806918819944. PMC 6322092. PMID 30486733.
  50. ^ a b c Ablin JN, Buskila D (February 2015). "Update on the genetics of the fibromyalgia syndrome". Best Practice & Research. Clinical Rheumatology. 29 (1): 20–28. doi:10.1016/j.berh.2015.04.018. PMID 26266996.
  51. ^ Lee YH, Choi SJ, Ji JD, Song GG (February 2012). "Candidate gene studies of fibromyalgia: a systematic review and meta-analysis". Rheumatology International. 32 (2): 417–426. doi:10.1007/s00296-010-1678-9. PMID 21120487. S2CID 6239018.
  52. ^ Dutta D, Brummett CM, Moser SE, Fritsche LG, Tsodikov A, Lee S, et al. (May 2020). "Heritability of the Fibromyalgia Phenotype Varies by Age". Arthritis & Rheumatology. 72 (5): 815–823. doi:10.1002/art.41171. PMC 8372844. PMID 31736264.
  53. ^ a b c Pinto AM, Luís M, Geenen R, Palavra F, Lumley MA, Ablin JN, Amris K, Branco J, Buskila D, Castelhano J, Castelo-Branco M, Crofford LJ, Fitzcharles M, Häuser W, Kosek E (2023). "Neurophysiological and psychosocial mechanisms of fibromyalgia: A comprehensive review and call for an integrative model". Neuroscience & Biobehavioral Reviews. 151: 105235. doi:10.1016/j.neubiorev.2023.105235. ISSN 0149-7634. PMID 37207842. S2CID 258745974.
  54. ^ Maletic V, Raison CL (June 2009). "Neurobiology of depression, fibromyalgia and neuropathic pain". Frontiers in Bioscience. 14 (14): 5291–5338. doi:10.2741/3598. PMID 19482616.
  55. ^ a b c Martins DF, Viseux FJ, Salm DC, Ribeiro AC, da Silva HK, Seim LA, et al. (December 2021). "The role of the vagus nerve in fibromyalgia syndrome". Neuroscience and Biobehavioral Reviews. 131: 1136–1149. doi:10.1016/j.neubiorev.2021.10.021. PMID 34710514. S2CID 239772451.
  56. ^ a b Kaleycheva N, Cullen AE, Evans R, Harris T, Nicholson T, Chalder T (January 2021). "The role of lifetime stressors in adult fibromyalgia: systematic review and meta-analysis of case-control studies". Psychological Medicine. 51 (2): 177–193. doi:10.1017/S0033291720004547. PMID 33602373. S2CID 231955641.
  57. ^ a b c d e Jung YH, Kim H, Lee D, Lee JY, Moon JY, Choi SH, Kang DH (January 2021). "Dysfunctional energy metabolisms in fibromyalgia compared with healthy subjects". Molecular Pain. 17: 17448069211012833. doi:10.1177/17448069211012833. PMC 8113919. PMID 33940974.
  58. ^ Schmidt-Wilcke T, Clauw DJ (July 2011). "Fibromyalgia: from pathophysiology to therapy". Nature Reviews. Rheumatology. 7 (9): 518–527. doi:10.1038/nrrheum.2011.98. PMID 21769128. S2CID 20678671.
  59. ^ Casale R, Sarzi-Puttini P, Botto R, Alciati A, Batticciotto A, Marotto D, Torta R (January 2019). "Fibromyalgia and the concept of resilience". Clinical and Experimental Rheumatology. 37 (1): 105–113. PMID 30747098.
  60. ^ Conversano C, Marchi L, Rebecca C, Carmassi C, Contena B, Bazzichi LM, Gemignani A (28 September 2018). "Personality Traits in Fibromyalgia (FM): Does FM Personality Exists? A Systematic Review". Clinical Practice and Epidemiology in Mental Health. 14 (1): 223–232. doi:10.2174/1745017901814010223. PMC 6166394. PMID 30294356.
  61. ^ a b Tan AC, Jaaniste T, Champion D (5 May 2019). "Chronic Widespread Pain and Fibromyalgia Syndrome: Life-Course Risk Markers in Young People". Pain Research & Management. 2019: 6584753. doi:10.1155/2019/6584753. PMC 6525804. PMID 31191788.
  62. ^ Roach K, Roberts J (August 2022). "A comprehensive summary of disease variants implicated in metal allergy". Journal of Toxicology and Environmental Health Part B: Critical Reviews. 25 (6): 279–341. Bibcode:2022JTEHB..25..279R. doi:10.1080/10937404.2022.2104981. PMC 9968405. PMID 35975293. S2CID 251623384.
  63. ^ Fialho MF, Brum ES, Oliveira SM (2023). "Could the fibromyalgia syndrome be triggered or enhanced by COVID-19?". Inflammopharmacology. 31 (2): 633–651. doi:10.1007/s10787-023-01160-w. ISSN 0925-4692. PMC 9970139. PMID 36849853.
  64. ^ de Tommaso M, Vecchio E, Nolano M (March 2022). "The puzzle of fibromyalgia between central sensitization syndrome and small fiber neuropathy: a narrative review on neurophysiological and morphological evidence". Neurological Sciences. 43 (3): 1667–1684. doi:10.1007/s10072-021-05806-x. PMID 35028777. S2CID 245909381.
  65. ^ den Boer C, Dries L, Terluin B, van der Wouden JC, Blankenstein AH, van Wilgen CP, et al. (February 2019). "Central sensitization in chronic pain and medically unexplained symptom research: A systematic review of definitions, operationalizations and measurement instruments". Journal of Psychosomatic Research. 117: 32–40. doi:10.1016/j.jpsychores.2018.12.010. PMID 30665594. S2CID 58565532.
  66. ^ Bidari A, Ghavidel-Parsa B (October 2022). "Nociplastic pain concept, a mechanistic basis for pragmatic approach to fibromyalgia". Clinical Rheumatology. 41 (10): 2939–2947. doi:10.1007/s10067-022-06229-5. PMID 35701625. S2CID 249650477.
  67. ^ Nijs J, Lahousse A, Kapreli E, Bilika P, Saraçoğlu İ, Malfliet A, et al. (July 2021). "Nociplastic Pain Criteria or Recognition of Central Sensitization? Pain Phenotyping in the Past, Present and Future". Journal of Clinical Medicine. 10 (15): 3203. doi:10.3390/jcm10153203. PMC 8347369. PMID 34361986.
  68. ^ a b Martínez-Lavín M (December 2018). "Fibromyalgia and small fiber neuropathy: the plot thickens!". Clinical Rheumatology. 37 (12): 3167–3171. doi:10.1007/s10067-018-4300-2. PMID 30238382. S2CID 52306843.
  69. ^ Martínez-Lavín M (February 2021). "Dorsal root ganglia: fibromyalgia pain factory?". Clinical Rheumatology. 40 (2): 783–787. doi:10.1007/s10067-020-05528-z. PMC 7787228. PMID 33409721.
  70. ^ a b Martinez-Lavin M, Holman AJ (2021). "Heart rate variability analysis in rheumatology: past, present… and future?". Clinical and Experimental Rheumatology. 39 (5): 927–930. doi:10.55563/clinexprheumatol/nmvth1. PMID 34464245. S2CID 237375381.
  71. ^ Figueroa A, Kingsley JD, McMillan V, Panton LB (January 2008). "Resistance exercise training improves heart rate variability in women with fibromyalgia". Clinical Physiology and Functional Imaging. 28 (1): 49–54. doi:10.1111/j.1475-097X.2007.00776.x. PMID 18005081. S2CID 40592827.
  72. ^ Park HY, Jung WS, Kim J, Hwang H, Lim K (March 2020). "Twelve Weeks of Aerobic Exercise at the Lactate Threshold Improves Autonomic Nervous System Function, Body Composition, and Aerobic Performance in Women with Obesity". Journal of Obesity & Metabolic Syndrome. 29 (1): 67–75. doi:10.7570/jomes19063. PMC 7118007. PMID 32045515.
  73. ^ a b Pinto AM, Geenen R, Wager TD, Lumley MA, Häuser W, Kosek E, et al. (January 2023). "Emotion regulation and the salience network: a hypothetical integrative model of fibromyalgia". Nature Reviews. Rheumatology. 19 (1): 44–60. doi:10.1038/s41584-022-00873-6. PMID 36471023. S2CID 254273384.
  74. ^ a b c d Singh L, Kaur A, Bhatti MS, Bhatti R (July 2019). "Possible Molecular Mediators Involved and Mechanistic Insight into Fibromyalgia and Associated Co-morbidities". Neurochemical Research. 44 (7): 1517–1532. doi:10.1007/s11064-019-02805-5. PMID 31004261. S2CID 123945497.
  75. ^ a b Bellato E, Marini E, Castoldi F, Barbasetti N, Mattei L, Bonasia DE, Blonna D (1 January 2012). "Fibromyalgia syndrome: etiology, pathogenesis, diagnosis, and treatment". Pain Research and Treatment. 2012: 426130. doi:10.1155/2012/426130. PMC 3503476. PMID 23213512.
  76. ^ a b Feraco P, Bacci A, Pedrabissi F, Passamonti L, Zampogna G, Pedrabissi F, et al. (October 2011). "Metabolic abnormalities in pain-processing regions of patients with fibromyalgia: a 3T MR spectroscopy study". AJNR. American Journal of Neuroradiology. 32 (9): 1585–1590. doi:10.3174/ajnr.A2550. PMC 7965402. PMID 21799042.
  77. ^ a b Xin M, Qu Y, Peng X, Zhu D, Cheng S (9 May 2023). "A systematic review and meta-analysis of voxel-based morphometric studies of fibromyalgia". Frontiers in Neuroscience. 17. doi:10.3389/fnins.2023.1164145. ISSN 1662-453X. PMC 10203234. PMID 37229427.
  78. ^ a b Lin C, Lee SH, Weng HH (1 January 2016). "Gray Matter Atrophy within the Default Mode Network of Fibromyalgia: A Meta-Analysis of Voxel-Based Morphometry Studies". BioMed Research International. 2016: 7296125. doi:10.1155/2016/7296125. PMC 5220433. PMID 28105430.
  79. ^ a b c d e Assavarittirong C, Samborski W, Grygiel-Górniak B (2022). "Oxidative Stress in Fibromyalgia: From Pathology to Treatment". Oxidative Medicine and Cellular Longevity. 2022: 1582432. doi:10.1155/2022/1582432. PMC 9556195. PMID 36246401.
  80. ^ Coskun Benlidayi I (May 2019). "Role of inflammation in the pathogenesis and treatment of fibromyalgia". Rheumatology International. 39 (5): 781–791. doi:10.1007/s00296-019-04251-6. PMID 30756137. S2CID 131775636.
  81. ^ a b c Uçeyler N, Häuser W, Sommer C (October 2011). "Systematic review with meta-analysis: cytokines in fibromyalgia syndrome". BMC Musculoskeletal Disorders. 12: 245. doi:10.1186/1471-2474-12-245. PMC 3234198. PMID 22034969.
  82. ^ a b c Rodriguez-Pintó I, Agmon-Levin N, Howard A, Shoenfeld Y (October 2014). "Fibromyalgia and cytokines". Immunology Letters. 161 (2): 200–203. doi:10.1016/j.imlet.2014.01.009. PMID 24462815.
  83. ^ Dell'Osso L, Bazzichi L, Baroni S, Falaschi V, Conversano C, Carmassi C, Marazziti D (1 January 2015). "The inflammatory hypothesis of mood spectrum broadened to fibromyalgia and chronic fatigue syndrome". Clinical and Experimental Rheumatology. 33 (1 Suppl 88): S109–S116. PMID 25786052.
  84. ^ a b Bazzichi L, Giacomelli C, Consensi A, Giorgi V, Batticciotto A, Di Franco M, Sarzi-Puttini P (2020). "One year in review 2020: fibromyalgia". Clinical and Experimental Rheumatology. 38 (1): 3–8. PMID 32116216.
  85. ^ Littlejohn G (November 2015). "Neurogenic neuroinflammation in fibromyalgia and complex regional pain syndrome". Nature Reviews. Rheumatology. 11 (11): 639–648. doi:10.1038/nrrheum.2015.100. PMID 26241184. S2CID 4368913.
  86. ^ Erdrich S, Hawrelak JA, Myers SP, Harnett JE (March 2020). "Determining the association between fibromyalgia, the gut microbiome and its biomarkers: A systematic review". BMC Musculoskeletal Disorders. 21 (1): 181. doi:10.1186/s12891-020-03201-9. PMC 7083062. PMID 32192466.
  87. ^ Wang Y, Wei J, Zhang W, Doherty M, Zhang Y, Xie H, et al. (June 2022). "Gut dysbiosis in rheumatic diseases: A systematic review and meta-analysis of 92 observational studies". eBioMedicine. 80: 104055. doi:10.1016/j.ebiom.2022.104055. PMC 9120231. PMID 35594658.
  88. ^ Minerbi A, Fitzcharles MA (January 2020). "Gut microbiome: pertinence in fibromyalgia". Clinical and Experimental Rheumatology. 38 (1): 99–104. PMID 32116215.
  89. ^ Clos-Garcia M, Andrés-Marin N, Fernández-Eulate G, Abecia L, Lavín JL, van Liempd S, et al. (August 2019). "Gut microbiome and serum metabolome analyses identify molecular biomarkers and altered glutamate metabolism in fibromyalgia". eBioMedicine. 46: 499–511. doi:10.1016/j.ebiom.2019.07.031. PMC 6710987. PMID 31327695.
  90. ^ Borenstein D (April 1995). "Prevalence and treatment outcome of primary and secondary fibromyalgia in patients with spinal pain". Spine. 20 (7): 796–800. doi:10.1097/00007632-199504000-00011. PMID 7701393. S2CID 30837539.
  91. ^ Bengtsson A, Henriksson KG, Larsson J (July 1986). "Reduced high-energy phosphate levels in the painful muscles of patients with primary fibromyalgia". Arthritis and Rheumatism. 29 (7): 817–821. doi:10.1002/art.1780290701. PMID 3741498.
  92. ^ Gerdle B, Ghafouri B, Lund E, Bengtsson A, Lundberg P, Ettinger-Veenstra HV, et al. (October 2020). "Evidence of Mitochondrial Dysfunction in Fibromyalgia: Deviating Muscle Energy Metabolism Detected Using Microdialysis and Magnetic Resonance". Journal of Clinical Medicine. 9 (11): 3527. doi:10.3390/jcm9113527. PMC 7693920. PMID 33142767.
  93. ^ Srikuea R, Symons TB, Long DE, Lee JD, Shang Y, Chomentowski PJ, et al. (February 2013). "Association of fibromyalgia with altered skeletal muscle characteristics which may contribute to postexertional fatigue in postmenopausal women". Arthritis and Rheumatism. 65 (2): 519–528. doi:10.1002/art.37763. PMC 3558634. PMID 23124535.
  94. ^ Shang Y, Gurley K, Symons B, Long D, Srikuea R, Crofford LJ, et al. (November 2012). "Noninvasive optical characterization of muscle blood flow, oxygenation, and metabolism in women with fibromyalgia". Arthritis Research & Therapy. 14 (6): R236. doi:10.1186/ar4079. PMC 3674608. PMID 23116302.
  95. ^ Häuser W, Fitzcharles MA (March 2018). "Facts and myths pertaining to fibromyalgia". Dialogues in Clinical Neuroscience. 20 (1): 53–62. doi:10.31887/DCNS.2018.20.1/whauser. PMC 6016048. PMID 29946212.
  96. ^ Wolfe F (August 2003). "Stop using the American College of Rheumatology criteria in the clinic". The Journal of Rheumatology. 30 (8): 1671–1672. PMID 12913920. from the original on 14 October 2011.
  97. ^ a b c Häuser W, Eich W, Herrmann M, Nutzinger DO, Schiltenwolf M, Henningsen P (June 2009). "Fibromyalgia syndrome: classification, diagnosis, and treatment". Deutsches Ärzteblatt International. 106 (23): 383–391. doi:10.3238/arztebl.2009.0383. PMC 2712241. PMID 19623319.
  98. ^ a b c d e f Wolfe F, Clauw DJ, Fitzcharles MA, Goldenberg DL, Katz RS, Mease P, et al. (May 2010). "The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity". Arthritis Care & Research. 62 (5): 600–610. doi:10.1002/acr.20140. hdl:2027.42/75772. PMID 20461783. S2CID 17154205.
  99. ^ Galvez-Sánchez CM, Reyes Del Paso GA (April 2020). "Diagnostic Criteria for Fibromyalgia: Critical Review and Future Perspectives". Journal of Clinical Medicine. 9 (4): 1219. doi:10.3390/jcm9041219. PMC 7230253. PMID 32340369.
  100. ^ Wang SM, Han C, Lee SJ, Patkar AA, Masand PS, Pae CU (June 2015). "Fibromyalgia diagnosis: a review of the past, present and future". Expert Review of Neurotherapeutics. 15 (6): 667–679. doi:10.1586/14737175.2015.1046841. PMID 26035624. S2CID 2412984.
  101. ^ Burckhardt CS, Clark SR, Bennett RM (May 1991). "The fibromyalgia impact questionnaire: development and validation". The Journal of Rheumatology. 18 (5): 728–733. PMID 1865419.
  102. ^ a b Bennett RM, Friend R, Jones KD, Ward R, Han BK, Ross RL (1 January 2009). "The Revised Fibromyalgia Impact Questionnaire (FIQR): validation and psychometric properties". Arthritis Research & Therapy. 11 (4): R120. doi:10.1186/ar2783. PMC 2745803. PMID 19664287.
  103. ^ "Fibromyalgia Impact Questionnaire (FIQ)". American College of Rheumatology.
  104. ^ Seidenberg M, Haltiner A, Taylor MA, Hermann BB, Wyler A (February 1994). "Development and validation of a Multiple Ability Self-Report Questionnaire". Journal of Clinical and Experimental Neuropsychology. 16 (1): 93–104. doi:10.1080/01688639408402620. PMID 8150893.
  105. ^ a b c Goldenberg DL (December 2009). "Diagnosis and differential diagnosis of fibromyalgia". The American Journal of Medicine (Review). 122 (12 Suppl): S14–S21. doi:10.1016/j.amjmed.2009.09.007. PMID 19962492.
  106. ^ a b c Häuser W, Perrot S, Sommer C, Shir Y, Fitzcharles MA (May 2017). "Diagnostic confounders of chronic widespread pain: not always fibromyalgia". Pain Reports. 2 (3): e598. doi:10.1097/PR9.0000000000000598. PMC 5741304. PMID 29392213.
  107. ^ a b Rossi A, Di Lollo AC, Guzzo MP, Giacomelli C, Atzeni F, Bazzichi L, Di Franco M (2015). "Fibromyalgia and nutrition: what news?". Clinical and Experimental Rheumatology. 33 (1 Suppl 88): S117–S125. PMID 25786053.
  108. ^ a b Marchesoni A, De Marco G, Merashli M, McKenna F, Tinazzi I, Marzo-Ortega H, McGonagle DG (January 2018). "The problem in differentiation between psoriatic-related polyenthesitis and fibromyalgia". Rheumatology (Review). 57 (1): 32–40. doi:10.1093/rheumatology/kex079. PMID 28387854. S2CID 205309871.
  109. ^ a b Palazzi C, D'Amico E, D'Angelo S, Gilio M, Olivieri I (January 2016). "Rheumatic manifestations of hepatitis C virus chronic infection: Indications for a correct diagnosis". World Journal of Gastroenterology (Review). 22 (4): 1405–1410. doi:10.3748/wjg.v22.i4.1405. PMC 4721975. PMID 26819509.
  110. ^ Pontes-Silva A (3 February 2024). "Fibromyalgia: a new set of diagnostic criteria based on the biopsychosocial model". Rheumatology. doi:10.1093/rheumatology/keae074. ISSN 1462-0324. PMID 38310344.
  111. ^ a b Sommer C, Häuser W, Alten R, Petzke F, Späth M, Tölle T, et al. (June 2012). (PDF). Schmerz. 26 (3): 297–310. doi:10.1007/s00482-012-1172-2. PMID 22760463. S2CID 1348989. Archived from the original (PDF) on 16 February 2013.
  112. ^ a b Fitzcharles MA, Shir Y, Ablin JN, Buskila D, Amital H, Henningsen P, Häuser W (2013). "Classification and clinical diagnosis of fibromyalgia syndrome: recommendations of recent evidence-based interdisciplinary guidelines". Evidence-Based Complementary and Alternative Medicine. 2013: 528952. doi:10.1155/2013/528952. PMC 3860136. PMID 24379886.
  113. ^ a b c . Archived from the original on 11 June 2013.
  114. ^ Busch AJ, Barber KA, Overend TJ, Peloso PM, Schachter CL (October 2007). "Exercise for treating fibromyalgia syndrome". The Cochrane Database of Systematic Reviews (4): CD003786. doi:10.1002/14651858.CD003786.pub2. PMID 17943797.
  115. ^ a b c Andrade A, Dominski FH, Sieczkowska SM (December 2020). "What we already know about the effects of exercise in patients with fibromyalgia: An umbrella review". Seminars in Arthritis and Rheumatism. 50 (6): 1465–1480. doi:10.1016/j.semarthrit.2020.02.003. PMID 32147091. S2CID 212638860.
  116. ^ [unreliable medical source?] Masquelier E, D'haeyere J (October 2021). "Physical activity in the treatment of fibromyalgia". Joint Bone Spine. 88 (5): 105202. doi:10.1016/j.jbspin.2021.105202. PMID 33962033.
  117. ^ McLoughlin MJ, Stegner AJ, Cook DB (June 2011). "The relationship between physical activity and brain responses to pain in fibromyalgia". The Journal of Pain. 12 (6): 640–651. doi:10.1016/j.jpain.2010.12.004. PMC 3111901. PMID 21330218.
  118. ^ a b Valim V, Natour J, Xiao Y, Pereira AF, Lopes BB, Pollak DF, et al. (November 2013). "Effects of physical exercise on serum levels of serotonin and its metabolite in fibromyalgia: a randomized pilot study". Revista Brasileira de Reumatologia (in Spanish). 53 (6): 538–541. doi:10.1016/j.rbr.2013.02.001. PMID 24477734.
  119. ^ Genc A, Tur BS, Aytur YK, Oztuna D, Erdogan MF (July 2015). "Does aerobic exercise affect the hypothalamic-pituitary-adrenal hormonal response in patients with fibromyalgia syndrome?". Journal of Physical Therapy Science. 27 (7): 2225–2231. doi:10.1589/jpts.27.2225. PMC 4540854. PMID 26311959.
  120. ^ a b c d e f El-Shewy KM, Kunbaz A, Gad MM, Al-Husseini MJ, Saad AM, Sammour YM, Abdel-Daim MM (January 2019). "Hyperbaric oxygen and aerobic exercise in the long-term treatment of fibromyalgia: A narrative review". Biomedicine & Pharmacotherapy. 109: 629–638. doi:10.1016/j.biopha.2018.10.157. PMID 30399600. S2CID 53240356.
  121. ^ Andrade A, Vilarino GT, Sieczkowska SM, Coimbra DR, Steffens RA, Vietta GG (March 2018). "Acute effects of physical exercises on the inflammatory markers of patients with fibromyalgia syndrome: A systematic review". Journal of Neuroimmunology. 316: 40–49. doi:10.1016/j.jneuroim.2017.12.007. PMID 29254627. S2CID 46879701.
  122. ^ a b c d e f g Andrade A, Vilarino GT, Serafim TT, Pereira Júnior AA, de Souza CA, Sieczkowska SM (October 2019). "Modulation of Autonomic Function by Physical Exercise in Patients with Fibromyalgia Syndrome: A Systematic Review". PM&R. 11 (10): 1121–1131. doi:10.1002/pmrj.12158. PMID 30900831. S2CID 85448644.
  123. ^ a b c Albuquerque ML, Monteiro D, Marinho DA, Vilarino GT, Andrade A, Neiva HP (November 2022). "Effects of different protocols of physical exercise on fibromyalgia syndrome treatment: systematic review and meta-analysis of randomized controlled trials". Rheumatology International. 42 (11): 1893–1908. doi:10.1007/s00296-022-05140-1. hdl:10400.8/7188. PMID 35604435. S2CID 248970279.
  124. ^ a b c Estévez-López F, Maestre-Cascales C, Russell D, Álvarez-Gallardo IC, Rodriguez-Ayllon M, Hughes CM, et al. (April 2021). "Effectiveness of Exercise on Fatigue and Sleep Quality in Fibromyalgia: A Systematic Review and Meta-analysis of Randomized Trials". Archives of Physical Medicine and Rehabilitation. 102 (4): 752–761. doi:10.1016/j.apmr.2020.06.019. hdl:10481/68683. PMID 32721388. S2CID 220847961.
  125. ^ Cuenca-Martínez F, Suso-Martí L, Fernández-Carnero J, Muñoz-Alarcos V, Sempere-Rubio N (2023). "Exercise-based interventions on sleep quality in patients with fibromyalgia syndrome: An umbrella and mapping review with meta-analysis". Seminars in Arthritis and Rheumatism. 61: 152216. doi:10.1016/j.semarthrit.2023.152216. PMID 37229847. S2CID 258597720.
  126. ^ McVeigh JG, Lucas A, Hurley DA, Basford JR, Baxter GD (September 2003). "Patients' perceptions of exercise therapy in the treatment of fibromyalgia syndrome: a survey". Musculoskeletal Care. 1 (2): 98–107. doi:10.1002/msc.45. PMID 20217670.
  127. ^ Barhorst EE, Andrae WE, Rayne TJ, Falvo MJ, Cook DB, Lindheimer JB (December 2020). "Elevated Perceived Exertion in People with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome and Fibromyalgia: A Meta-analysis". Medicine and Science in Sports and Exercise. 52 (12): 2615–2627. doi:10.1249/MSS.0000000000002421. PMC 10200687. PMID 32555018. S2CID 219918068.
  128. ^ a b c Russell D, Álvarez Gallardo IC, Wilson I, Hughes CM, Davison GW, Sañudo B, McVeigh JG (March 2018). "'Exercise to me is a scary word': perceptions of fatigue, sleep dysfunction, and exercise in people with fibromyalgia syndrome-a focus group study". Rheumatology International. 38 (3): 507–515. doi:10.1007/s00296-018-3932-5. PMID 29340774. S2CID 3395036.
  129. ^ Sanz-Baños Y, Pastor-Mira MÁ, Lledó A, López-Roig S, Peñacoba C, Sánchez-Meca J (October 2018). "Do women with fibromyalgia adhere to walking for exercise programs to improve their health? Systematic review and meta-analysis". Disability and Rehabilitation. 40 (21): 2475–2487. doi:10.1080/09638288.2017.1347722. PMID 28687050. S2CID 9032840.
  130. ^ Vancampfort D, McGrath RL, Hemmings L, Gillis V, Bernar K, Van Damme T (November 2022). "Physical activity correlates in people with fibromyalgia: a systematic review". Disability and Rehabilitation. 45 (25): 4165–4174. doi:10.1080/09638288.2022.2146911. PMID 36398698. S2CID 253627372.
  131. ^ Ryan S (2013). "Care of patients with fibromyalgia: assessment and management". Nursing Standard. 28 (13): 37–43. doi:10.7748/ns2013.11.28.13.37.e7722. PMID 24279570.
  132. ^ Majdoub F, Ben Nessib D, Ferjani HL, Kaffel D, Triki W, Maatallah K, Hamdi W (February 2023). "Non-pharmacological therapies in Fibromyalgia: New horizons for physicians, new hopes for patients". Musculoskeletal Care. 21 (3): 603–610. doi:10.1002/msc.1741. PMID 36757930. S2CID 256696861.
  133. ^ Bidonde J, Busch AJ, Schachter CL, Overend TJ, Kim SY, Góes SM, et al. (June 2017). "Aerobic exercise training for adults with fibromyalgia". The Cochrane Database of Systematic Reviews. 2017 (6): CD012700. doi:10.1002/14651858.cd012700. PMC 6481524. PMID 28636204.
  134. ^ a b Bidonde J, Busch AJ, Schachter CL, Webber SC, Musselman KE, Overend TJ, et al. (May 2019). "Mixed exercise training for adults with fibromyalgia". The Cochrane Database of Systematic Reviews. 2019 (5): CD013340. doi:10.1002/14651858.cd013340. PMC 6931522. PMID 31124142.
  135. ^ Kim SY, Busch AJ, Overend TJ, Schachter CL, van der Spuy I, Boden C, et al. (September 2019). "Flexibility exercise training for adults with fibromyalgia". The Cochrane Database of Systematic Reviews. 2019 (9): CD013419. doi:10.1002/14651858.CD013419. PMC 6718217. PMID 31476271.
  136. ^ Vilarino GT, Andreato LV, de Souza LC, Branco JH, Andrade A (November 2021). "Effects of resistance training on the mental health of patients with fibromyalgia: a systematic review". Clinical Rheumatology. 40 (11): 4417–4425. doi:10.1007/s10067-021-05738-z. PMID 33987785. S2CID 234489153.
  137. ^ Rodríguez-Domínguez Á, Rebollo-Salas M, Chillón-Martínez R, Rosales-Tristancho A, Jiménez-Rejano J (17 July 2023). "Clinical relevance of resistance training in women with fibromyalgia: A systematic review and meta-analysis". European Journal of Pain. 28 (1): 21–36. doi:10.1002/ejp.2161. ISSN 1090-3801. PMID 37458315. S2CID 259949000.
  138. ^ Bastos AC, Vilarino GT, de Souza LC, Dominski FH, Branco JH, Andrade A (15 May 2023). "Effects of resistance training on sleep of patients with fibromyalgia: A systematic review". Journal of Health Psychology. 28 (11): 1072–1084. doi:10.1177/13591053231172288. ISSN 1359-1053. PMID 37183814. S2CID 258687258.
  139. ^ a b c d da Silva JM, de Barros BS, Almeida GJ, O'Neil J, Imoto AM (March 2022). "Dosage of resistance exercises in fibromyalgia: evidence synthesis for a systematic literature review up-date and meta-analysis". Rheumatology International. 42 (3): 413–429. doi:10.1007/s00296-021-05025-9. PMID 34652480. S2CID 238991065.
  140. ^ Li H, Chen J, Xu G, Duan Y, Huang D, Tang C, Liu J (September 2020). "The Effect of Tai Chi for Improving Sleep Quality: A Systematic Review and Meta-analysis". Journal of Affective Disorders. 274: 1102–1112. doi:10.1016/j.jad.2020.05.076. PMID 32663938. S2CID 219743962.
  141. ^ Vasileios P, Styliani P, Nifon G, Pavlos S, Aris F, Ioannis P (November 2022). "Managing fibromyalgia with complementary and alternative medical exercise: a systematic review and meta-analysis of clinical trials". Rheumatology International. 42 (11): 1909–1923. doi:10.1007/s00296-022-05151-y. PMID 35796820. S2CID 250317143.
  142. ^ Cheng CA, Chiu YW, Wu D, Kuan YC, Chen SN, Tam KW (October 2019). "Effectiveness of Tai Chi on fibromyalgia patients: A meta-analysis of randomized controlled trials". Complementary Therapies in Medicine. 46: 1–8. doi:10.1016/j.ctim.2019.07.007. PMID 31519264. S2CID 199039433.
  143. ^ Bidonde J, Busch AJ, Webber SC, Schachter CL, Danyliw A, Overend TJ, et al. (October 2014). "Aquatic exercise training for fibromyalgia". The Cochrane Database of Systematic Reviews. 2014 (10): CD011336. doi:10.1002/14651858.cd011336. PMC 10638613. PMID 25350761.
  144. ^ Lima TB, Dias JM, Mazuquin BF, da Silva CT, Nogueira RM, Marques AP, et al. (October 2013). "The effectiveness of aquatic physical therapy in the treatment of fibromyalgia: a systematic review with meta-analysis". Clinical Rehabilitation. 27 (10): 892–908. doi:10.1177/0269215513484772. PMID 23818412. S2CID 25701866.
  145. ^ Perraton L, Machotka Z, Kumar S (November 2009). "Components of effective randomized controlled trials of hydrotherapy programs for fibromyalgia syndrome: A systematic review". Journal of Pain Research. 2: 165–173. doi:10.2147/JPR.S8052. PMC 3004626. PMID 21197303.
  146. ^ Galvão-Moreira LV, de Castro LO, Moura EC, de Oliveira CM, Nogueira Neto J, Gomes LM, Leal PD (July 2021). "Pool-based exercise for amelioration of pain in adults with fibromyalgia syndrome: A systematic review and meta-analysis". Modern Rheumatology. 31 (4): 904–911. doi:10.1080/14397595.2020.1829339. PMID 32990113. S2CID 222167851.
  147. ^ a b Calles Plata I, Ortiz-Rubio A, Torres Sánchez I, Cabrera Martos I, Calvache Mateo A, Heredia-Ciuró A, Valenza MC (February 2023). "Effectiveness of aquatic therapy on sleep in persons with fibromyalgia. A meta-analysis". Sleep Medicine. 102: 76–83. doi:10.1016/j.sleep.2022.12.016. PMID 36603514. S2CID 255217819.
  148. ^ Ma J, Zhang T, Li X, Chen X, Zhao Q (September 2022). "Effects of aquatic physical therapy on clinical symptoms, physical function, and quality of life in patients with fibromyalgia: A systematic review and meta-analysis". Physiotherapy Theory and Practice. 40 (2): 205–223. doi:10.1080/09593985.2022.2119906. PMID 36062580. S2CID 252079586.
  149. ^ Correyero-León M, Medrano-de-la-Fuente R, Hernando-Garijo I, Jiménez-Del-Barrio S, Hernández-Lázaro H, Ceballos-Laita L, Mingo-Gómez MT (July 2023). "Effectiveness of aquatic training based on aerobic and strengthening exercises in patients with fibromyalgia: systematic review with meta-analysis". Explore. doi:10.1016/j.explore.2023.07.003. PMID 37460329. S2CID 259580881.
  150. ^ Bidonde J, Busch AJ, van der Spuy I, Tupper S, Kim SY, Boden C (September 2017). "Whole body vibration exercise training for fibromyalgia". The Cochrane Database of Systematic Reviews. 2017 (9): CD011755. doi:10.1002/14651858.cd011755.pub2. PMC 6483692. PMID 28950401.
  151. ^ "FDA Approves First Drug for Treating Fibromyalgia" (Press release). U.S. Food and Drug Administration. 21 June 2007. from the original on 21 February 2008. Retrieved 14 January 2008.
  152. ^ European Medicines Agency. "Questions and answers on the recommendati on for the refusal of the marketing authorisation for Milnacipran Pierre Fabre Médicament/Impulsor" (PDF). European Medicines Agency. (PDF) from the original on 22 February 2014. Retrieved 30 May 2013.
  153. ^ Häuser W, Wolfe F, Tölle T, Uçeyler N, Sommer C (April 2012). "The role of antidepressants in the management of fibromyalgia syndrome: a systematic review and meta-analysis". CNS Drugs. 26 (4): 297–307. doi:10.2165/11598970-000000000-00000. PMID 22452526. S2CID 207301478.
  154. ^ Cording M, Derry S, Phillips T, Moore RA, Wiffen PJ (October 2015). "Milnacipran for pain in fibromyalgia in adults". The Cochrane Database of Systematic Reviews. 2015 (10): CD008244. doi:10.1002/14651858.CD008244.pub3. PMC 6481368. PMID 26482422.
  155. ^ a b Welsch P, Üçeyler N, Klose P, Walitt B, Häuser W (February 2018). "Serotonin and noradrenaline reuptake inhibitors (SNRIs) for fibromyalgia". The Cochrane Database of Systematic Reviews. 2 (2): CD010292. doi:10.1002/14651858.CD010292.pub2. PMC 5846183. PMID 29489029.
  156. ^ Moore RA, Derry S, Aldington D, Cole P, Wiffen PJ (May 2019). "Amitriptyline for fibromyalgia in adults". The Cochrane Database of Systematic Reviews. 5 (7): CD011824. doi:10.1002/14651858.CD011824. PMC 6485478. PMID 35658166.
  157. ^ Migliorini F, Maffulli N, Eschweiler J, Baroncini A, Bell A, Colarossi G (17 July 2023). "Duloxetine for fibromyalgia syndrome: a systematic review and meta-analysis". Journal of Orthopaedic Surgery and Research. 18 (1): 504. doi:10.1186/s13018-023-03995-z. ISSN 1749-799X. PMC 10351165. PMID 37461044.
  158. ^ Walitt B, Urrútia G, Nishishinya MB, Cantrell SE, Häuser W (June 2015). "Selective serotonin reuptake inhibitors for fibromyalgia syndrome". The Cochrane Database of Systematic Reviews. 2015 (6): CD011735. doi:10.1002/14651858.cd011735. PMC 4755337. PMID 26046493.
  159. ^ a b Moore RA, Derry S, Aldington D, Cole P, Wiffen PJ (July 2015). "Amitriptyline for neuropathic pain in adults". The Cochrane Database of Systematic Reviews. 2015 (7): CD008242. doi:10.1002/14651858.CD011824. PMC 6485478. PMID 26146793.
  160. ^ Welsch P, Bernardy K, Derry S, Moore RA, Häuser W (August 2018). "Mirtazapine for fibromyalgia in adults". The Cochrane Database of Systematic Reviews. 8 (8): CD012708. doi:10.1002/14651858.CD012708.pub2. PMC 6513659. PMID 30080242.
  161. ^ a b c Tort S, Urrútia G, Nishishinya MB, Walitt B (April 2012). "Monoamine oxidase inhibitors (MAOIs) for fibromyalgia syndrome". The Cochrane Database of Systematic Reviews (4): CD009807. doi:10.1002/14651858.cd009807. PMID 22513976.
  162. ^ Wiffen PJ, Derry S, Bell RF, Rice AS, Tölle TR, Phillips T, Moore RA (June 2017). "Gabapentin for chronic neuropathic pain in adults". The Cochrane Database of Systematic Reviews. 6 (6): CD007938. doi:10.1002/14651858.CD007938.pub4. PMC 6452908. PMID 28597471.
  163. ^ Derry S, Cording M, Wiffen PJ, Law S, Phillips T, Moore RA (September 2016). "Pregabalin for pain in fibromyalgia in adults". The Cochrane Database of Systematic Reviews. 9 (9): CD011790. doi:10.1002/14651858.CD011790.pub2. PMC 6457745. PMID 27684492.
  164. ^ Straube S, Moore RA, Paine J, Derry S, Phillips CJ, Hallier E, McQuay HJ (June 2011). "Interference with work in fibromyalgia: effect of treatment with pregabalin and relation to pain response". BMC Musculoskeletal Disorders. 12: 125. doi:10.1186/1471-2474-12-125. PMC 3118156. PMID 21639874.
  165. ^ Nowell WB, Gavigan K, L Silverman S (May 2022). "Cannabis for Rheumatic Disease Pain: a Review of Current Literature". Current Rheumatology Reports. 24 (5): 119–131. doi:10.1007/s11926-022-01065-7. PMID 35486218. S2CID 248423563.
  166. ^ Boehnke KF, Häuser W, Fitzcharles MA (July 2022). "Cannabidiol (CBD) in Rheumatic Diseases (Musculoskeletal Pain)". Current Rheumatology Reports. 24 (7): 238–246. doi:10.1007/s11926-022-01077-3. PMC 9062628. PMID 35503198.
  167. ^ Bourke SL, Schlag AK, O'Sullivan SE, Nutt DJ, Finn DP (December 2022). "Cannabinoids and the endocannabinoid system in fibromyalgia: A review of preclinical and clinical research". Pharmacology & Therapeutics. 240: 108216. doi:10.1016/j.pharmthera.2022.108216. PMID 35609718. S2CID 248973512.
  168. ^ Jain N, Moorthy A (June 2022). "Cannabinoids in rheumatology: Friend, foe or a bystander?". Musculoskeletal Care. 20 (2): 416–428. doi:10.1002/msc.1636. PMC 9322323. PMID 35476898.
  169. ^ a b MacLean AJ, Schwartz TL (May 2015). "Tramadol for the treatment of fibromyalgia". Expert Review of Neurotherapeutics. 15 (5): 469–475. doi:10.1586/14737175.2015.1034693. PMID 25896486. S2CID 26613022.
  170. ^ Gaskell H, Moore RA, Derry S, Stannard C, et al. (Cochrane Pain, Palliative and Supportive Care Group) (September 2016). "Oxycodone for pain in fibromyalgia in adults". The Cochrane Database of Systematic Reviews. 2016 (9): CD012329. doi:10.1002/14651858.CD012329. PMC 6457853. PMID 27582266.
  171. ^ Thorpe J, Shum B, Moore RA, Wiffen PJ, Gilron I (February 2018). "Combination pharmacotherapy for the treatment of fibromyalgia in adults". The Cochrane Database of Systematic Reviews. 2 (2): CD010585. doi:10.1002/14651858.CD010585.pub2. PMC 6491103. PMID 29457627.
  172. ^ Goldenberg DL, Clauw DJ, Palmer RE, Clair AG (May 2016). "Opioid Use in Fibromyalgia: A Cautionary Tale". Mayo Clinic Proceedings (Review). 91 (5): 640–648. doi:10.1016/j.mayocp.2016.02.002. PMID 26975749. S2CID 20228209.
  173. ^ Berger A. In: EULAR; 2009:SAT0461
  174. ^ Elijah J, Powell K, Smith MA (June 2022). "The Efficacy of Capsaicin on Sleep Quality and Fatigue in Fibromyalgia". Journal of Pain & Palliative Care Pharmacotherapy. 36 (2): 112–116. doi:10.1080/15360288.2022.2063468. PMID 35471125. S2CID 248389141.
  175. ^ Staud R (August 2011). "Sodium oxybate for the treatment of fibromyalgia". Expert Opinion on Pharmacotherapy. 12 (11): 1789–1798. doi:10.1517/14656566.2011.589836. PMID 21679091. S2CID 33026097.
  176. ^ See S, Ginzburg R (August 2008). "Choosing a skeletal muscle relaxant". American Family Physician. 78 (3): 365–370. PMID 18711953. from the original on 1 April 2016.
  177. ^ Kaltsas G, Tsiveriotis K (2000). "Fibromyalgia". Endotext. MDText.com, Inc. PMID 25905317.
  178. ^ Heymann RE, Paiva ED, Helfenstein M, Pollak DF, Martinez JE, Provenza JR, et al. (2010). "Brazilian consensus on the treatment of fibromyalgia". Revista Brasileira de Reumatologia. 50 (1): 56–66. doi:10.1590/S0482-50042010000100006. PMID 21125141.
  179. ^ Derry S, Wiffen PJ, Häuser W, Mücke M, Tölle TR, Bell RF, Moore RA (March 2017). "Oral nonsteroidal anti-inflammatory drugs for fibromyalgia in adults". The Cochrane Database of Systematic Reviews. 3 (3): CD012332. doi:10.1002/14651858.CD012332.pub2. PMC 6464559. PMID 28349517.
  180. ^ Walitt B, Klose P, Üçeyler N, Phillips T, Häuser W (June 2016). "Antipsychotics for fibromyalgia in adults". The Cochrane Database of Systematic Reviews. 2016 (6): CD011804. doi:10.1002/14651858.cd011804.pub2. PMC 6457603. PMID 27251337.
  181. ^ Walitt B, Klose P, Fitzcharles MA, Phillips T, Häuser W (July 2016). "Cannabinoids for fibromyalgia". The Cochrane Database of Systematic Reviews. 7 (7): CD011694. doi:10.1002/14651858.cd011694.pub2. PMC 6457965. PMID 27428009.
  182. ^ a b Kadayifci FZ, Bradley MJ, Onat AM, Shi HN, Zheng S (November 2022). "Review of nutritional approaches to fibromyalgia". Nutrition Reviews. 80 (12): 2260–2274. doi:10.1093/nutrit/nuac036. PMID 35674686.
  183. ^ Nadal-Nicolás Y, Miralles-Amorós L, Martínez-Olcina M, Sánchez-Ortega M, Mora J, Martínez-Rodríguez A (May 2021). "Vegetarian and Vegan Diet in Fibromyalgia: A Systematic Review". International Journal of Environmental Research and Public Health. 18 (9): 4955. doi:10.3390/ijerph18094955. PMC 8125538. PMID 34066603.
  184. ^ Haddad HW, Mallepalli NR, Scheinuk JE, Bhargava P, Cornett EM, Urits I, Kaye AD (December 2021). "The Role of Nutrient Supplementation in the Management of Chronic Pain in Fibromyalgia: A Narrative Review". Pain and Therapy. 10 (2): 827–848. doi:10.1007/s40122-021-00266-9. PMC 8586285. PMID 33909266.
  185. ^ a b Qu K, Li MX, Zhou YL, Yu P, Dong M (April 2022). "The efficacy of vitamin D in treatment of fibromyalgia: a meta-analysis of randomized controlled studies and systematic review". Expert Review of Clinical Pharmacology. 15 (4): 433–442. doi:10.1080/17512433.2022.2081151. PMID 35596576. S2CID 248948241.
  186. ^ Mehrabani S, Askari G, Miraghajani M, Tavakoly R, Arab A (April 2019). "Effect of coenzyme Q10 supplementation on fatigue: A systematic review of interventional studies". Complementary Therapies in Medicine. 43: 181–187. doi:10.1016/j.ctim.2019.01.022. PMID 30935528. S2CID 86467031.
  187. ^ Hargreaves IP, Mantle D (2021). "Targeted Treatment of Age-Related Fibromyalgia with Supplemental Coenzyme Q10" (PDF). In Guest PC (ed.). Reviews on New Drug Targets in Age-Related Disorders. Advances in Experimental Medicine and Biology. Vol. 1286. Cham: Springer International Publishing. pp. 77–85. doi:10.1007/978-3-030-55035-6_5. ISBN 978-3-030-55034-9. PMID 33725346. S2CID 232261388.
  188. ^ Erkilic B, Dalgic GS (January 2023). "The preventive role of vitamin D in the prevention and management of Fibromyalgia syndrome". Nutrition and Health. 29 (2): 223–229. doi:10.1177/02601060221144801.
February 15, 2024
fibromyalgia, confused, with, myalgic, encephalomyelitis, chronic, fatigue, syndrome, with, myelofibrosis, medical, condition, defined, presence, chronic, widespread, pain, fatigue, waking, unrefreshed, cognitive, symptoms, lower, abdominal, pain, cramps, depr. Not to be confused with myalgic encephalomyelitis chronic fatigue syndrome nor with myelofibrosis Fibromyalgia is a medical condition defined by the presence of chronic widespread pain fatigue waking unrefreshed cognitive symptoms lower abdominal pain or cramps and depression 9 Other symptoms include insomnia 10 and a general hypersensitivity 11 12 FibromyalgiaOther namesFibromyalgia syndromeThe nine possible pain sites of fibromyalgia according to the American Pain Society Pronunciation ˌ f aɪ b r oʊ m aɪ ˈ ae l dʒ e 1 SpecialtyRheumatology neurology 2 SymptomsWidespread pain feeling tired sleep problems 3 4 Usual onsetMiddle age 5 DurationLong term 3 CausesUnknown 4 5 Diagnostic methodBased on symptoms after ruling out other potential causes 4 5 Differential diagnosisAnemia autoimmune disorders such as ankylosing spondylitis polymyalgia rheumatica rheumatoid arthritis scleroderma or multiple sclerosis Lyme disease osteoarthritis thyroid disease 6 7 TreatmentSufficient sleep and exercise 5 MedicationDuloxetine milnacipran pregabalin gabapentin 5 8 PrognosisNormal life expectancy 5 Frequency2 4 The cause of fibromyalgia is unknown but is believed to involve a combination of genetic and environmental factors 4 Environmental factors may include psychological stress trauma and certain infections 4 The pain appears to result from processes in the central nervous system and the condition is referred to as a central sensitization syndrome 4 13 The treatment of fibromyalgia is symptomatic 14 and multidisciplinary 15 The European Alliance of Associations for Rheumatology strongly recommends aerobic and strengthening exercise 15 Weak recommendations are given to mindfulness psychotherapy acupuncture hydrotherapy and meditative exercise such as qigong yoga and tai chi 15 The use of medication in the treatment of fibromyalgia is debated 15 16 although antidepressants can improve quality of life 17 The medications duloxetine milnacipran or pregabalin have been approved by the US Food and Drug Administration FDA for the management of fibromyalgia Other common helpful medications include serotonin noradrenaline reuptake inhibitors nonsteroidal anti inflammatory drugs and muscle relaxants 18 Q10 coenzyme and vitamin D supplements may reduce pain and improve quality of life 19 While fibromyalgia is persistent in nearly all patients it does not result in death or tissue damage 16 Fibromyalgia is estimated to affect 2 4 of the population 20 Women are affected about twice as often as men 4 20 Rates appear similar in different areas of the world and among different cultures 4 Fibromyalgia was first defined in 1990 with updated criteria in 2011 4 2016 9 2019 12 and 2024 21 The term fibromyalgia is from Neo Latin fibro meaning fibrous tissues Greek myo myo muscle and Greek algos algos pain thus the term literally means muscle and fibrous connective tissue pain 22 Contents 1 Classification 2 Signs and symptoms 2 1 Pain 2 2 Fatigue 2 3 Sleep problems 2 4 Cognitive problems 2 5 Hypersensitivity 3 Comorbidity 4 Risk factors 4 1 Genetics 4 2 Stress 4 3 Personality 4 4 Other risk markers 5 Pathophysiology 5 1 Nervous system 5 1 1 Pain processing abnormalities 5 1 2 Nociplastic pain central sensitization 5 1 3 Neuropathic pain 5 1 4 Autonomic nervous system 5 1 5 Neurotransmitters 5 1 6 Neurophysiology 5 1 7 Neuroendocrine system 5 1 8 Oxidative stress 5 2 Immune system 5 3 Digestive system 5 3 1 Gut microbiome 5 3 2 Gut brain axis 5 4 Energy metabolism 5 4 1 Low ATP in skeletal muscle 5 4 2 Low ATP in brain 6 Diagnosis 6 1 American College of Rheumatology 1990 6 2 American College of Rheumatology 2010 provisional criteria 6 3 American College of Rheumatology 2016 revisions 6 4 American Pain Society 2019 6 5 Self report questionnaires 6 5 1 Widespread Pain Index WPI 6 5 2 Symptom Severity Scale SSS 6 5 3 Fibromyalgia Impact Questionnaire FIQ 6 5 4 Other questionnaires 6 6 Differential diagnosis 6 7 Diagnostic criteria based on the biopsychosocial model 7 Management 7 1 Exercise 7 1 1 Aerobic 7 1 2 Flexibility 7 1 3 Resistance 7 1 4 Meditative 7 1 5 Aquatic 7 1 6 Other 7 2 Medications 7 2 1 Antidepressants 7 2 1 1 Serotonin and norepinephrine reuptake inhibitors 7 2 1 2 Tricyclic antidepressants 7 2 1 3 Monoamine oxidase inhibitors 7 2 2 Central nervous system depressants 7 2 3 Anti seizure medication 7 2 4 Cannabinoids 7 2 5 Opioids 7 2 6 Topical treatment 7 2 7 Unapproved or unfounded 7 3 Nutrition and dietary supplements 7 4 Psychotherapy 7 5 Patient education 7 6 Manual therapy 7 6 1 Acupuncture 7 7 Electrical neuromodulation 7 7 1 Transcutaneous electrical nerve stimulation TENS 7 7 2 Noninvasive brain stimulation 7 7 3 EEG neurofeedback 7 8 Hyperbaric oxygen therapy 8 Prognosis 9 Epidemiology 10 History 11 Society and culture 11 1 Economics 11 2 Controversies 12 Notes 13 References 14 External linksClassification editFibromyalgia is classed as a disorder of pain processing due to abnormalities in how pain signals are processed in the central nervous system 23 The International Classification of Diseases ICD 11 includes fibromyalgia in the category of Chronic widespread pain code MG30 01 24 Signs and symptoms editThe defining symptoms of fibromyalgia are chronic widespread pain fatigue and sleep disturbance 12 Other symptoms may include heightened pain in response to tactile pressure allodynia 12 cognitive problems 12 musculoskeletal stiffness 12 environmental sensitivity 12 hypervigilance 12 sexual dysfunction 25 and visual symptoms 26 Post Exertional Malaise PEM is also recognised as a symptom of Fibromyalgia 27 Pain edit Fibromyalgia is predominantly a chronic pain disorder 12 According to the NHS widespread pain is one major symptom which could feel like an ache a burning sensation or a sharp stabbing pain 28 Fatigue edit Fatigue is one of the defining symptoms of fibromyalgia 12 Patients may experience physical or mental fatigue Physical fatigue can be demonstrated by a feeling of exhaustion after exercise or by a limitation in daily activities 12 Sleep problems edit Sleep problems are a core symptom in fibromyalgia 12 These include difficulty falling asleep or staying asleep awakening while sleeping and waking up feeling unrefreshed 12 A meta analysis compared objective and subjective sleep metrics in people with fibromyalgia and healthy people Individuals with fibromyalgia had lower sleep quality and efficiency as well as longer wake time after sleep start shorter sleep duration lighter sleep and greater trouble initiating sleep when objectively assessed and more difficulty initiating sleep when subjectively assessed 10 Sleep problems may contribute to pain by decreased release of IGF 1 and human growth hormone leading to decreased tissue repair 29 Improving sleep quality can help people with fibromyalgia minimize pain 30 31 Cognitive problems edit Many people with fibromyalgia experience cognitive problems known as fibrofog or brainfog One study found that approximately 50 of fibromyalgia patients had subjective cognitive dysfunction and that it was associated with higher levels of pain and other fibromyalgia symptoms 32 The American Pain Society recognizes these problems as a major feature of fibromyalgia characterized by trouble concentrating forgetfulness and disorganized or slow thinking 12 About 75 of fibromyalgia patients report significant problems with concentration memory and multitasking 33 A 2018 meta analysis found that the largest differences between fibromyalgia patients and healthy subjects were for inhibitory control memory and processing speed 33 It is hypothesized that the increased pain compromises attention systems resulting in cognitive problems 33 Hypersensitivity edit In addition to a hypersensitivity to pain patients with fibromyalgia show hypersensitivity to other stimuli 11 such as bright lights loud noises perfumes and cold 12 A review article found that they have a lower cold pain threshold 34 Other studies documented an acoustic hypersensitivity 35 Comorbidity editFibromyalgia as a stand alone diagnosis is uncommon as most fibromyalgia patients often have other chronic overlapping pain problems or mental disorders 11 Fibromyalgia is associated with mental health issues like anxiety 36 posttraumatic stress disorder 4 36 bipolar disorder 36 alexithymia 37 and depression 36 38 39 Patients with fibromyalgia are five times more likely to have major depression than the general population 40 Fibromyalgia and numerous chronic pain conditions frequently coexist 38 These include chronic tension headaches 36 myofascial pain syndrome 36 and temporomandibular disorders 36 Multiple sclerosis post polio syndrome neuropathic pain and Parkinson s disease are four neurological disorders that have been linked to pain or fibromyalgia 38 Fibromyalgia largely overlaps with chronic fatigue syndrome 41 42 and may share the same pathogenetic mechanisms 42 Comorbid fibromyalgia has been reported to occur in 20 30 of individuals with rheumatic diseases 38 It has been reported in people with noninflammatory musculoskeletal diseases 38 The prevalence of fibromyalgia in gastrointestinal disease has been described mostly for celiac disease 38 and irritable bowel syndrome IBS 38 36 IBS and fibromyalgia share similar pathogenic mechanisms involving immune system mast cells inflammatory biomarkers hormones and neurotransmitters such as serotonin Changes in the gut biome alter serotonin levels leading to autonomic nervous system hyperstimulation 43 Fibromyalgia has also been linked with obesity 44 Other conditions that are associated with fibromyalgia include connective tissue disorders 45 cardiovascular autonomic abnormalities 46 restless leg syndrome 47 and an overactive bladder 48 Risk factors editThe cause of fibromyalgia is unknown However several risk factors genetic and environmental have been identified Genetics edit Genetics play a major role in fibromyalgia and may explain up to 50 of the disease susceptibility 49 Fibromyalgia is potentially associated with polymorphisms of genes in the serotoninergic 50 dopaminergic 50 and catecholaminergic systems 50 Several genes have been suggested as candidates for susceptibility to fibromyalgia These include SLC6A4 49 TRPV2 49 MYT1L 49 NRXN3 49 and the 5 HT2A receptor 102T C polymorphism 51 The heritability of fibromyalgia is estimated to be higher in patients younger than 50 52 Nearly all the genes suggested as potential risk factors for fibromyalgia are associated with neurotransmitters and their receptors 53 Neuropathic pain and major depressive disorder often co occur with fibromyalgia the reason for this comorbidity appears to be due to shared genetic abnormalities which leads to impairments in monoaminergic glutamatergic neurotrophic opioid and proinflammatory cytokine signaling In these vulnerable individuals psychological stress or illness can cause abnormalities in inflammatory and stress pathways that regulate mood and pain Eventually a sensitization and kindling effect occurs in certain neurons leading to the establishment of fibromyalgia and sometimes a mood disorder 54 Stress edit Stress may be an important precipitating factor in the development of fibromyalgia 55 A 2021 meta analysis found psychological trauma to be strongly associated with fibromyalgia 56 57 People who suffered abuse in their lifetime were three times more likely to have fibromyalgia people who suffered medical trauma or other stressors in their lifetime were about twice as likely 56 Some authors have proposed that because exposure to stressful conditions can alter the function of the hypothalamic pituitary adrenal HPA axis the development of fibromyalgia may stem from stress induced disruption of the HPA axis 58 59 Personality edit Although some have suggested that fibromyalgia patients are more likely to have specific personality traits when depression is statistically controlled for it appears that their personality is no different than that of people in the general population 60 Other risk markers edit Other risk markers for fibromyalgia include premature birth female sex cognitive influences primary pain disorders multiregional pain infectious illness hypermobility of joints iron deficiency and small fiber polyneuropathy 61 Metal induced allergic inflammation has also been linked with fibromyalgia especially in response to nickel but also inorganic mercury cadmium and lead 62 Following the COVID 19 pandemic some have suggested that the SARS CoV 2 virus may trigger fibromyalgia 63 Pathophysiology editAs of 2022 the pathophysiology of fibromyalgia has not yet been elucidated 64 and several theories have been suggested The prevailing perspective considers fibromyalgia as a condition resulting from an amplification of pain by the central nervous system 53 Substantial biological evidence backs up this notion leading to the term of nociplastic pain 53 Nervous system edit Pain processing abnormalities edit Chronic pain can be divided into three categories Nociceptive pain is pain caused by inflammation or damage to tissues Neuropathic pain is pain caused by nerve damage Nociplastic pain or central sensitization is less understood and is the common explanation of the pain experienced in fibromyalgia 13 20 65 Because the three forms of pain can overlap fibromyalgia patients may experience nociceptive e g rheumatic illnesses and neuropathic e g small fiber neuropathy pain in addition to nociplastic pain 20 Nociplastic pain central sensitization edit Main article Nociplastic pain Fibromyalgia can be viewed as a condition of nociplastic pain 66 Nociplastic pain is caused by an altered function of pain related sensory pathways in the periphery and the central nervous system resulting in hypersensitivity 67 Nociplastic pain is commonly referred to as Nociplastic pain syndrome because it is coupled with other symptoms 20 These include fatigue sleep disturbance cognitive disturbance hypersensitivity to environmental stimuli anxiety and depression 20 Nociplastic pain is caused by either 1 increased processing of pain stimuli or 2 decreased suppression of pain stimuli at several levels in the nervous system or both 20 Neuropathic pain edit An alternative hypothesis to nociplastic pain views fibromyalgia as a stress related dysautonomia with neuropathic pain features 68 This view highlights the role of autonomic and peripheral nociceptive nervous systems in the generation of widespread pain fatigue and insomnia 69 The description of small fiber neuropathy in a subgroup of fibromyalgia patients supports the disease neuropathic autonomic underpinning 68 However others claim that small fiber neuropathy occurs only in small groups of those with fibromyalgia 16 Autonomic nervous system edit Some suggest that fibromyalgia is caused or maintained by a decreased vagal tone which is indicated by low levels of heart rate variability 55 signaling a heightened sympathetic response 70 Accordingly several studies show that clinical improvement is associated with an increase in heart rate variability 71 70 72 Some examples of interventions that increase the heart rate variability and vagal tone are meditation yoga mindfulness and exercise 55 In 2023 the Fibromyalgia Imbalance of Threat and Soothing Systems FITSS model was suggested as a working hypothesis 73 According to the FITSS model the salience network also known as the midcingulo insular network may remain continuously hyperactive due to an imbalance in emotion regulation which is reflected by an overactive threat system and an underactive soothing system This hyperactivation along with other mechanisms may contribute to fibromyalgia 73 Neurotransmitters edit Some neurochemical abnormalities that occur in fibromyalgia also regulate mood sleep and energy thus explaining why mood sleep and fatigue problems are commonly co morbid with fibromyalgia 23 Serotonin is the most widely studied neurotransmitter in fibromyalgia It is hypothesized that an imbalance in the serotoninergic system may lead to the development of fibromyalgia 74 There is also some data that suggests altered dopaminergic and noradrenergic signaling in fibromyalgia 75 Supporting the monoamine related theories is the efficacy of monoaminergic antidepressants in fibromyalgia 17 Glutamate creatine ratios within the bilateral ventrolateral prefrontal cortex were found to be significantly higher in fibromyalgia patients than in controls and may disrupt glutamate neurotransmission 57 76 Neurophysiology edit Neuroimaging studies have observed that fibromyalgia patients have increased grey matter in the right postcentral gyrus and left angular gyrus and decreased grey matter in the right cingulate gyrus right paracingulate gyrus left cerebellum and left gyrus rectus 77 These regions are associated with affective and cognitive functions and with motor adaptations to pain processing 77 Other studies have documented decreased grey matter of the default mode network in people with fibromyalgia 78 These deficits are associated with pain processing 78 Neuroendocrine system edit Studies on the neuroendocrine system and HPA axis in fibromyalgia have been inconsistent Depressed function of the HPA axis results in adrenal insufficiency and potentially chronic fatigue 79 One study found fibromyalgia patients exhibited higher plasma cortisol more extreme peaks and troughs and higher rates of dexamethasone non suppression However other studies have only found correlations between a higher cortisol awakening response and pain and not any other abnormalities in cortisol 31 Increased baseline ACTH and increase in response to stress have been observed hypothesized to be a result of decreased negative feedback 75 Oxidative stress edit Pro oxidative processes correlate with pain in fibromyalgia patients 79 Decreased mitochondrial membrane potential increased superoxide activity and increased lipid peroxidation production are observed 79 The high proportion of lipids in the central nervous system CNS makes the CNS especially vulnerable to free radical damage Levels of lipid peroxidation products correlate with fibromyalgia symptoms 79 Immune system edit Inflammation has been suggested to have a role in the pathogenesis of fibromyalgia 80 People with fibromyalgia tend to have higher levels of inflammatory cytokines IL 6 74 81 82 and IL 8 74 81 82 There are also increased levels of the pro inflammatory cytokines IL 1 receptor antagonist 81 82 Increased levels of pro inflammatory cytokines may increase sensitivity to pain and contribute to mood problems 83 Anti inflammatory interleukins such as IL 10 have also been associated with fibromyalgia 74 A repeated observation shows that autoimmunity triggers such as traumas and infections are among the most frequent events preceding the onset of fibromyalgia 84 Neurogenic inflammation has been proposed as a contributing factor to fibromyalgia 85 Digestive system edit Gut microbiome edit Though there is a lack of evidence in this area it is hypothesized that gut bacteria may play a role in fibromyalgia 86 People with fibromyalgia are more likely to show dysbiosis a decrease in microbiota diversity 87 There is a bidirectional interplay between the gut and the nervous system Therefore the gut can affect the nervous system but the nervous system can also affect the gut Neurological effects mediated via the autonomic nervous system as well as the hypothalamic pituitary adrenal axis are directed to intestinal functional effector cells which in turn are under the influence of the gut microbiota 88 Gut brain axis edit The gut brain axis which connects the gut microbiome to the brain via the enteric nervous system is another area of research Fibromyalgia patients have less varied gut flora and altered serum metabolome levels of glutamate and serine 89 implying abnormalities in neurotransmitter metabolism 84 Energy metabolism edit Low ATP in skeletal muscle edit Patients with fibromyalgia experience exercise intolerance Primary fibromyalgia is idiopathic cause unknown whereas secondary fibromyalgia is in association with a known underlying disorder such as Ankylosing spondylitis 90 non primary source needed In patients with primary fibromyalgia studies have found disruptions in energy metabolism within skeletal muscle including decreased levels of ATP ADP and phosphocreatine and increased levels of AMP and creatine use of creatine kinase and myokinase in the phosphagen system due to low ATP 91 non primary source needed increased pyruvate 92 non primary source needed as well as reduced capillary density impairing oxygen delivery to the muscle cells for oxidative phosphorylation 93 94 non primary source needed Low ATP in brain edit Despite being a small percentage of the body s total mass the brain consumes approximately 20 of the energy produced by the body 57 non primary source needed Parts of the brain the anterior cingulate cortex ACC thalamus and insula were studied using proton magnetic resonance spectroscopy MRS in patients with fibromyalgia and compared to healthy controls The fibromyalgia patients were found to have lower phosphocreatine PCr and lower creatine Cr than the control group Phosphocreatine is used in the phosphagen system to produce ATP The study found that low creatine and low phosphocreatine were associated with high pain and that high stress including PTSD may contribute to these low levels 57 non primary source needed Low phosphocreatine levels may disrupt glutamate neurotransmission within the brains of those with fibromyalgia Glutamate creatine ratios within the bilateral ventrolateral prefrontal cortex were found to be significantly higher than in controls 57 76 non primary source needed Diagnosis edit nbsp The location of the nine paired tender points that comprise the 1990 American College of Rheumatology criteria for fibromyalgiaThere is no single pathological feature laboratory finding or biomarker that can diagnose fibromyalgia and there is debate over what should be considered diagnostic criteria and whether an objective diagnosis is possible 61 In most cases people with fibromyalgia symptoms may have laboratory test results that appear normal and many of their symptoms may mimic those of other rheumatic conditions such as arthritis or osteoporosis The specific diagnostic criteria for fibromyalgia have evolved over time 95 American College of Rheumatology 1990 edit The first widely accepted set of classification criteria for research purposes was elaborated in 1990 by the Multicenter Criteria Committee of the American College of Rheumatology These criteria which are known informally as the ACR 1990 defined fibromyalgia according to the presence of the following criteria A history of widespread pain lasting more than three months affecting all four quadrants of the body i e both sides and above and below the waist Tender points there are 18 designated possible tender points although a person with the disorder may feel pain in other areas as well The ACR criteria for the classification of patients were originally established as inclusion criteria for research purposes and were not intended for clinical diagnosis but have later become the de facto diagnostic criteria in the clinical setting A controversial study was done by a legal team looking to prove their client s disability based primarily on tender points and their widespread presence in non litigious communities prompted the lead author of the ACR criteria to question now the useful validity of tender points in diagnosis 96 Use of control points has been used to cast doubt on whether a person has fibromyalgia and to claim the person is malingering 97 American College of Rheumatology 2010 provisional criteria edit nbsp Widespread pain index WPI areasIn 2010 the American College of Rheumatology approved provisional revised diagnostic criteria for fibromyalgia that eliminated the 1990 criteria s reliance on tender point testing 98 The revised criteria used a widespread pain index WPI and symptom severity scale SSS in place of tender point testing under the 1990 criteria The WPI counts up to 19 general body areas a in which the person has experienced pain in the preceding week 9 The SSS rates the severity of the person s fatigue unrefreshed waking cognitive symptoms and general somatic symptoms b each on a scale from 0 to 3 for a composite score ranging from 0 to 12 9 The revised criteria for diagnosis were WPI 7 and SSS 5 OR WPI 3 6 and SSS 9 Symptoms have been present at a similar level for at least three months and No other diagnosable disorder otherwise explains the pain 98 607 American College of Rheumatology 2016 revisions edit In 2016 the provisional criteria of the American College of Rheumatology from 2010 were revised 9 The new diagnosis required all of the following criteria Generalized pain defined as pain in at least 4 of 5 regions is present Symptoms have been present at a similar level for at least 3 months Widespread pain index WPI 7 and symptom severity scale SSS score 5 OR WPI of 4 6 and SSS score 9 A diagnosis of fibromyalgia is valid irrespective of other diagnoses A diagnosis of fibromyalgia does not exclude the presence of other clinically important illnesses 9 American Pain Society 2019 edit nbsp Multisite pain is defined as six or more pain sites from a total of nine possible sites head arms chest abdomen upper back lower back and legs for at least three months In 2019 the American Pain Society in collaboration with the U S Food and Drug Administration developed a new diagnostic system using two dimensions 12 The first dimension included core diagnostic criteria and the second included common features In accordance to the 2016 diagnosis guidelines the presence of another medical condition or pain disorder does not rule out the diagnosis of fibromyalgia Nonetheless other conditions should be ruled out as the main explaining reason for the patient s symptoms The core diagnostic criteria are 99 Multisite pain defined as six or more pain sites from a total of nine possible sites head arms chest abdomen upper back lower back and legs for at least three months Moderate to severe sleep problems or fatigue for at least three monthsCommon features found in fibromyalgia patients can assist the diagnosis process These are tenderness sensitivity to light pressure dyscognition difficulty to think musculoskeletal stiffness and environmental sensitivity or hypervigilance 12 Self report questionnaires edit Some research has suggested using a multidimensional approach taking into consideration somatic symptoms psychological factors psychosocial stressors and subjective belief regarding fibromyalgia 100 These symptoms can be assessed by several self report questionnaires 9 Widespread Pain Index WPI edit The Widespread Pain Index WPI measures the number of painful body regions 98 Symptom Severity Scale SSS edit The Symptom Severity Scale SSS assesses the severity of the fibromyalgia symptoms Fibromyalgia Impact Questionnaire FIQ edit The Fibromyalgia Impact Questionnaire FIQ 101 and the Revised Fibromyalgia Impact Questionnaire FIQR 102 assess three domains function overall impact and symptoms 102 It is considered a useful measure of disease impact 103 Other questionnaires edit Other measures include the Hospital Anxiety and Depression Scale Multiple Ability Self Report Questionnaire 104 Multidimensional Fatigue Inventory and Medical Outcomes Study Sleep Scale Differential diagnosis edit As of 2009 as many as two out of every three people who are told that they have fibromyalgia by a rheumatologist may have some other medical condition instead 105 Fibromyalgia could be misdiagnosed in cases of early undiagnosed rheumatic diseases such as preclinical rheumatoid arthritis early stages of inflammatory spondyloarthritis polymyalgia rheumatica myofascial pain syndromes and hypermobility syndrome 11 106 Neurological diseases with an important pain component include multiple sclerosis Parkinson s disease and peripheral neuropathy 11 106 Other medical illnesses that should be ruled out are endocrine disease or metabolic disorder hypothyroidism hyperparathyroidism acromegaly vitamin D deficiency gastro intestinal disease celiac and non celiac gluten sensitivity infectious diseases Lyme disease hepatitis C and immunodeficiency disease and the early stages of a malignancy such as multiple myeloma metastatic cancer and leukemia lymphoma 11 106 Other systemic inflammatory endocrine rheumatic infectious and neurologic disorders may cause fibromyalgia like symptoms such as systemic lupus erythematosus Sjogren syndrome ankylosing spondylitis Ehlers Danlos syndromes psoriatic related polyenthesitis a nerve compression syndrome such as carpal tunnel syndrome and myasthenia gravis 107 105 108 109 In addition several medications can also evoke pain statins aromatase inhibitors bisphosphonates and opioids 12 The differential diagnosis is made during the evaluation on the basis of the person s medical history physical examination and laboratory investigations 107 105 108 109 The patient s history can provide some hints to a fibromyalgia diagnosis A family history of early chronic pain a childhood history of pain an emergence of broad pain following physical and or psychosocial stress a general hypersensitivity to touch smell noise taste hypervigilance and various somatic symptoms gastrointestinal urology gynecology neurology are all examples of these signals 11 Extensive laboratory tests are usually unnecessary in the differential diagnosis of fibromyalgia 12 Common tests that are conducted include complete blood count comprehensive metabolic panel erythrocyte sedimentation rate C reactive protein and thyroid function test 12 Diagnostic criteria based on the biopsychosocial model edit In 2024 a Brazilian researcher Dr Andre Pontes Silva proposed new criteria for the diagnosis of fibromyalgia using the biopsychosocial model According to these criteria patients with fibromyalgia must be diagnosed in two main categories patients with fibromyalgia and affected social component patients with fibromyalgia and unaffected social component The article was published by the Oxford group in the official journal of the British Society for Rheumatology 110 Management editAs with many other medically unexplained syndromes there is no universally accepted treatment or cure for fibromyalgia and treatment typically consists of symptom management and improving patient quality of life 14 A personalized multidisciplinary approach to treatment that includes both non pharmacologic and pharmacologic therapy and begins with effective patient education is most beneficial 14 Developments in the understanding of the pathophysiology of the disorder have led to improvements in treatment which include prescription medication behavioral intervention and exercise A number of associations have published guidelines for the diagnosis and management of fibromyalgia The European League Against Rheumatism EULAR 2017 15 recommends a multidisciplinary approach allowing a quick diagnosis and patient education The recommended initial management should be non pharmacological later pharmacological treatment can be added The European League Against Rheumatism gave the strongest recommendation for aerobic and strengthening exercise Weak recommendations were given to a number of treatments based on their outcomes Qigong yoga and tai chi were weakly recommended for improving sleep and quality of life Mindfulness was weakly recommended for improving pain and quality of life Acupuncture and hydrotherapy were weakly recommended for improving pain A weak recommendation was also given to psychotherapy It was more suitable for patients with mood disorders or unhelpful coping strategies Chiropractic was strongly recommended against due to safety concerns Some medications were weakly recommended for severe pain duloxetine pregabalin tramadol or sleep disturbance amitriptyline cyclobenzaprine pregabalin Others were not recommended due to a lack of efficacy nonsteroidal anti inflammatory drugs monoamine oxidase inhibitors and selective serotonin reuptake inhibitors Growth hormone sodium oxybate opioids and steroids were strongly recommended against due to lack of efficacy and side effects The guidelines published by the Association of the Scientific Medical Societies in Germany 111 inform patients that self management strategies are an important component in managing the disease 112 The Canadian Pain Society 113 also published guidelines for the diagnosis and management of fibromyalgia Exercise edit Exercise is the only fibromyalgia treatment which has been given a strong recommendation by the European Alliance of Associations for Rheumatology EULAR There is strong evidence indicating that exercise improves fitness sleep and quality of life and may reduce pain and fatigue for people with fibromyalgia 114 19 115 Exercise has an added benefit in that it does not cause any serious adverse effects 115 Exercise may diminish fibromyalgia symptoms through a number of hypothesized biological mechanisms 116 Exercise may improve pain modulation 117 118 through serotoninergic pathways 118 It may reduce pain by altering the hypothalamic pituitary adrenal axis and reducing cortisol levels 119 It also has anti inflammatory effects that may improve fibromyalgia symptoms 120 121 Aerobic exercise can improve muscle metabolism and pain through mitochondrial pathways 120 When comparing different exercise programs aerobic exercise is capable of modulating the autonomic nervous function of fibromyalgia patients whereas resistance exercise does not show such effects 122 A 2022 meta analysis found that aerobic training showed a high effect size while strength interventions showed moderate effects 123 Meditative exercise seems preferable for improving sleep 124 125 with no differences between resistance flexibility and aquatic exercise in their favorable effects on fatigue 124 Despite its benefits exercise is a challenge for patients with fibromyalgia due to the chronic fatigue and pain they experience 126 They perceive it as more effortful than healthy adults 127 Exercise may intimidate them in fear that they will be asked to do more than they are capable of 128 They may also feel that those who recommend or deliver exercise interventions do not fully understand the possible negative impact of exercise on fatigue and pain 128 This is especially true for non personalized exercise programs 128 Adherence is higher when the exercise program is recommended by doctors or supervised by nurses 129 Depression and higher pain intensity serve as barriers to physical activity 130 A recommended approach to a graded exercise program begins with small frequent exercise periods and builds up from there 123 131 In order to reduce pain it is recommended to use an exercise program of 13 to 24 weeks with each session lasting 30 to 60 minutes 123 Aerobic edit Aerobic exercise for fibromyalgia patients is the most investigated type of exercise 115 It includes activities such as walking jogging spinning cycling dancing and exercising in water 120 122 with walking being named as one of the best methods 132 A 2017 cochrane summary concluded that aerobic exercise probably improves quality of life slightly decreases pain and improves physical function and makes no difference in fatigue and stiffness 133 A 2019 meta analysis showed that exercising aerobically can reduce autonomic dysfunction and increase heart rate variability 122 This happens when patients exercise at least twice a week for 45 60 minutes at about 60 80 of the maximum heart rate 122 Aerobic exercise also decreases anxiety and depression and improves the quality of life 122 Flexibility edit Combinations of different exercises such as flexibility and aerobic training may improve stiffness 134 However the evidence is of low quality 134 It is not clear if flexibility training alone compared to aerobic training is effective at reducing symptoms or has any adverse effects 135 Resistance edit In resistance exercise participants apply a load to their body using weights elastic band body weight or other measures Two meta analyses on fibromyalgia have shown that resistance training can reduce anxiety and depression 122 136 one found that it decreases pain and disease severity 137 and one found that it improves quality of life 122 Resistance training may also improve sleep with a greater effect than that of flexibility training and a similar effect to that of aerobic exercise 138 The dosage of resistance exercise for women with fibromyalgia was studied in a 2022 meta analysis 139 Effective dosages were found when exercising twice a week for at least eight weeks Symptom improvement was found for even low dosages such as 1 2 sets of 4 20 repetitions 139 Most studies use moderate exercise intensity of 40 to 85 one repetition maximum This level of intensity was effective in reducing pain 139 Some treatment regimes increase the intensity over time from 40 to 80 whereas others increase it when the participant is able to perform 12 repetitions 139 High intensity exercises may cause lower treatment adherence Meditative edit A 2021 meta analysis found that meditative exercise programs tai chi yoga qigong were superior to other forms of exercise aerobic flexibility resistance in improving sleep quality 124 Other meta analyses also found positive effects of tai chi for sleep 140 fibromyalgia symptoms 141 and pain fatigue depression and quality of life 142 These tai chi interventions frequently included 1 hour sessions practiced 1 3 times a week for 12 weeks Meditative exercises as a whole may achieve desired outcomes through biological mechanisms such as antioxidation anti inflammation reduction in sympathetic activity and modulation of glucocorticoid receptor sensitivity 120 Aquatic edit Several reviews and meta analyses suggest that aquatic training can improve symptoms and wellness in people with fibromyalgia 143 144 145 146 147 148 It is recommended to practice aquatic therapy at least twice a week using a low to moderate intensity 147 However aquatic therapy does not appear to be superior to other types of exercise 149 Other edit Limited evidence suggests vibration training in combination with exercise may improve pain fatigue and stiffness 150 Medications edit A few countries have published guidelines for the management and treatment of fibromyalgia As of 2018 all of them emphasize that medications are not required However medications though imperfect continue to be a component of treatment strategy for fibromyalgia patients The German guidelines outlined parameters for drug therapy termination and recommended considering drug holidays after six months 16 Health Canada and the US Food and Drug Administration FDA have approved pregabalin 151 an anticonvulsant and duloxetine a serotonin norepinephrine reuptake inhibitor for the management of fibromyalgia The FDA also approved milnacipran another serotonin norepinephrine reuptake inhibitor but the European Medicines Agency refused marketing authority 152 Antidepressants edit Antidepressants are one of the common drugs for fibromyalgia A 2021 meta analysis concluded that antidepressants can improve the quality of life for fibromyalgia patients in the medium term 17 For most people with fibromyalgia the potential benefits of treatment with the serotonin and norepinephrine reuptake inhibitors duloxetine and milnacipran and the tricyclic antidepressants such as amitriptyline are outweighed by significant adverse effects more adverse effects than benefits however a small number of people may experience relief from symptoms with these medications 153 154 155 The length of time that antidepressant medications take to be effective at reducing symptoms can vary Any potential benefits from the antidepressant amitriptyline may take up to three months to take effect and it may take between three and six months for duloxetine milnacipran and pregabalin to be effective at improving symptoms 156 Some medications have the potential to cause withdrawal symptoms when stopping so gradual discontinuation may be warranted particularly for antidepressants and pregabalin 97 Serotonin and norepinephrine reuptake inhibitors edit A 2023 meta analysis found that duloxetine improved fibromyalgia symptoms regardless of the dosage 157 SSRIs may be also be used to treat depression in people diagnosed with fibromyalgia 158 Tricyclic antidepressants edit While amitriptyline has been used as a first line treatment the quality of evidence to support this use and comparison between different medications is poor 159 155 Very weak evidence indicates that a very small number of people may benefit from treatment with the tetracyclic antidepressant mirtazapine however for most the potential benefits are not great and the risk of adverse effects and potential harm outweighs any potential for benefit 160 As of 2018 the only tricyclic antidepressant that has sufficient evidence is amitriptyline 16 159 Monoamine oxidase inhibitors edit Tentative evidence suggests that monoamine oxidase inhibitors MAOIs such as pirlindole and moclobemide are moderately effective for reducing pain 161 Very low quality evidence suggests pirlindole as more effective at treating pain than moclobemide 161 Side effects of MAOIs may include nausea and vomiting 161 Central nervous system depressants edit Central nervous system depressants include drug categories such as sedatives tranquilizers and hypnotics A 2021 meta analysis concluded that such drugs can improve the quality of life for fibromyalgia patients in the medium term 17 Anti seizure medication edit The anti convulsant medications gabapentin and pregabalin may be used to reduce pain 8 There is tentative evidence that gabapentin may be of benefit for pain in about 18 of people with fibromyalgia 8 It is not possible to predict who will benefit and a short trial may be recommended to test the effectiveness of this type of medication Approximately 6 10 people who take gabapentin to treat pain related to fibromyalgia experience unpleasant side effects such as dizziness abnormal walking or swelling from fluid accumulation 162 Pregabalin demonstrates a benefit in about 9 of people 163 Pregabalin reduced time off work by 0 2 days per week 164 Cannabinoids edit Cannabinoids may have some benefits for people with fibromyalgia However as of 2022 the data on the topic is still limited 165 166 167 Cannabinoids may also have adverse effects and may negatively interact with common rheumatological drugs 168 Opioids edit The use of opioids is controversial As of 2015 no opioid is approved for use in this condition by the FDA 169 A 2016 Cochrane review concluded that there is no good evidence to support or refute the suggestion that oxycodone alone or in combination with naloxone reduces pain in fibromyalgia 170 The National Institute of Arthritis and Musculoskeletal and Skin Diseases NIAMS in 2014 stated that there was a lack of evidence for opioids for most people 5 The Association of the Scientific Medical Societies in Germany in 2012 made no recommendation either for or against the use of weak opioids because of the limited amount of scientific research addressing their use in the treatment of fibromyalgia They strongly advise against using strong opioids 111 The Canadian Pain Society in 2012 said that opioids starting with a weak opioid like tramadol can be tried but only for people with moderate to severe pain that is not well controlled by non opioid painkillers They discourage the use of strong opioids and only recommend using them while they continue to provide improved pain and functioning Healthcare providers should monitor people on opioids for ongoing effectiveness side effects and possible unwanted drug behaviors 113 A 2015 review found fair evidence to support tramadol use if other medications do not work 169 A 2018 review found little evidence to support the combination of paracetamol acetaminophen and tramadol over a single medication 171 Goldenberg et al suggest that tramadol works via its serotonin and norepinephrine reuptake inhibition rather than via its action as a weak opioid receptor agonist 172 A large study of US people with fibromyalgia found that between 2005 and 2007 37 4 were prescribed short acting opioids and 8 3 were prescribed long acting opioids 3 with around 10 of those prescribed short acting opioids using tramadol 173 and a 2011 Canadian study of 457 people with fibromyalgia found 32 used opioids and two thirds of those used strong opioids 113 Topical treatment edit Capsaicin has been suggested as a topical pain reliever Preliminary results suggest that it may improve sleep quality and fatigue but there are not enough studies to support this claim 174 Unapproved or unfounded edit Sodium oxybate increases growth hormone production levels through increased slow wave sleep patterns However this medication was not approved by the FDA for the indication for use in people with fibromyalgia due to the concern for abuse 175 The muscle relaxants cyclobenzaprine carisoprodol with acetaminophen and caffeine and tizanidine are sometimes used to treat fibromyalgia however as of 2015 they are not approved for this use in the United States 176 177 The use of nonsteroidal anti inflammatory drugs is not recommended as first line therapy 178 Moreover nonsteroidal anti inflammatory drugs cannot be considered as useful in the management of fibromyalgia 179 Very low quality evidence suggests quetiapine may be effective in fibromyalgia 180 No high quality evidence exists that suggests synthetic THC nabilone helps with fibromyalgia 181 Nutrition and dietary supplements edit Nutrition is related to fibromyalgia in several ways Some nutritional risk factors for fibromyalgia complications are obesity nutritional deficiencies food allergies and consuming food additives 182 The consumption of fruits and vegetables low processed foods high quality proteins and healthy fats may have some benefits 182 Low quality evidence found some benefits of a vegetarian or vegan diet 183 Although dietary supplements have been widely investigated in relation to fibromyalgia most of the evidence as of 2021 is of poor quality It is therefore difficult to reach conclusive recommendations 184 It appears that Q10 coenzyme and vitamin D supplements can reduce pain and improve quality of life for fibromyalgia patients 19 185 Q10 coenzyme has beneficial effects on fatigue in fibromyalgia patients with most studies using doses of 300 mg per day for three months 186 Q10 coenzyme is hypothesized to improve mitochondrial activity and decrease inflammation 187 Vitamin D has been shown to improve some fibromyalgia measures but not others 185 188 Two review articles found that melatonin treatment has several positive effects on fibromyalgia patients including the improvement of sleep quality pain and disease impact 189 190 No major adverse events were reported 189 Psychotherapy edit Due to the uncertainty about the pathogenesis of fibromyalgia current treatment approaches focus on management of symptoms to improve quality of life 191 using integrated pharmacological and non pharmacological approaches 4 There is no single intervention shown to be effective for all patients 192 In a 2020 Cochrane review cognitive behavioral therapy was found to have a small but beneficial effect for reducing pain and distress but adverse events were not well evaluated 193 Cognitive behavioral therapy and related psychological and behavioural therapies have a small to moderate effect in reducing symptoms of fibromyalgia 194 195 Effect sizes tend to be small when cognitive behavioral therapy is used as a stand alone treatment for patients with fibromyalgia but these improve significantly when it is part of a wider multidisciplinary treatment program 195 A 2010 systematic review of 14 studies reported that cognitive behavioral therapy improves self efficacy or coping with pain and reduces the number of physician visits at post treatment but has no significant effect on pain fatigue sleep or health related quality of life at post treatment or follow up Depressed mood was also improved but this could not be distinguished from some risks of bias 196 A 2022 meta analysis found that cognitive behavioral therapy reduces insomnia in people with chronic pain including people with fibromyalgia 197 Acceptance and commitment therapy a type of cognitive behavioral therapy has also proven effective 198 Patient education edit Patient education is recommended by the European League Against Rheumatism EULAR as an important treatment component 15 As of 2022 there is only low quality evidence showing that patient education can decrease pain and fibromyalgia impact 199 200 Sleep hygiene interventions show low effectiveness in improving insomnia in people with chronic pain 197 Manual therapy edit A 2021 meta analysis concluded that massage and myofascial release diminish pain in the medium term 17 As of 2015 there was no good evidence for the benefit of other mind body therapies 201 Acupuncture edit A 2013 review found moderate level evidence on the usage of acupuncture with electrical stimulation for improvement of the overall well being Acupuncture alone will not have the same effects but will enhance the influence of exercise and medication in pain and stiffness 202 Electrical neuromodulation edit Several forms of electrical neuromodulation including transcutaneous electrical nerve stimulation TENS and transcranial direct current stimulation tDCS have been used to treat fibromyalgia In general they have been found to be helpful in reducing pain and depression and improving functioning 203 204 Transcutaneous electrical nerve stimulation TENS edit Transcutaneous electrical nerve stimulation TENS is the delivery of pulsed electrical currents to the skin to stimulate peripheral nerves TENS is widely used to treat pain and is considered to be a low cost safe and self administered treatment 205 As such it is commonly recommended by clinicians to people suffering from pain 206 On 2019 an overview of eight Cochrane reviews was conducted covering 51 TENS related randomized controlled trials 206 The review concluded that the quality of the available evidence was insufficient to make any recommendations 206 A later review concluded that transcutaneous electrical nerve stimulation may diminish pain in the short term but there was uncertainty about the relevance of the results 17 Preliminary findings suggest that electrically stimulating the vagus nerve through an implanted device can potentially reduce fibromyalgia symptoms 207 However there may be adverse reactions to the procedure 207 Noninvasive brain stimulation edit Noninvasive brain stimulation includes methods such as transcranial direct current stimulation and high frequency repetitive transcranial magnetic stimulation TMS Both methods have been found to improve pain scores in neuropathic pain and fibromyalgia 208 A 2023 meta analysis of 16 RCTs found that transcranial direct current stimulation tDCS of over 4 weeks can decrease pain in patients with fibromyalgia 209 A 2021 meta analysis of multiple intervention types concluded that magnetic field therapy and transcranial magnetic stimulation may diminish pain in the short term but conveyed an uncertainty about the relevance of the result 17 Several 2022 meta analyses focusing on transcranial magnetic stimulation found positive effects on fibromyalgia 210 211 212 Repetitive transcranial magnetic stimulation improved pain in the short term 211 212 and quality of life after 5 12 weeks 211 212 Repetitive transcranial magnetic stimulation did not improve anxiety depression and fatigue 212 Transcranial magnetic stimulation to the left dorsolateral prefrontal cortex was also ineffective 211 EEG neurofeedback edit A systematic review of EEG neurofeedback for treatment of fibromyalgia found most treatments showed significant improvements of the main symptoms of the disease 213 However the protocols were so different and the lack of controls or randomization impede drawing conclusive results 213 Hyperbaric oxygen therapy edit Hyperbaric oxygen therapy HBOT has shown beneficial effects in treating chronic pain by reducing inflammation and oxidative stress 79 However treating fibromyalgia with hyperbaric oxygen therapy is still controversial in light of the scarcity of large scale clinical trials 120 In addition hyperbaric oxygen therapy raises safety concerns due to the oxidative damage that may follow it 120 An evaluation of nine trials with 288 patients in total found that HBOT was more effective at relieving fibromyalgia patients pain than the control intervention In most of the trials HBOT improved sleep disturbance multidimensional function patient satisfaction and tender spots 24 of the patients experienced negative outcomes 214 Prognosis editAlthough in itself fibromyalgia is neither degenerative nor fatal the chronic pain of fibromyalgia is pervasive and persistent Most people with fibromyalgia report that their symptoms do not improve over time However most patients learn to adapt to the symptoms over time The German guidelines for patients explain that The symptoms of fibromyalgia are persistent in nearly all patients Total relief of symptoms is seldom achieved The symptoms do not lead to disablement and do not shorten life expectancy 112 An 11 year follow up study on 1 555 patients found that most remained with high levels of self reported symptoms and distress non primary source needed 215 However there was a great deal of patient heterogeneity accounting for almost half of the variance At the final observation 10 of the patients showed substantial improvement with minimal symptoms An additional 15 had moderate improvement This state though may be transient given the fluctuations in symptom severity non primary source needed 215 A study of 97 adolescents diagnosed with fibromyalgia followed them for eight years non primary source needed After eight years the majority of youth still experienced pain and disability in physical social and psychological areas At the last follow up all participants reported experiencing one or more fibromyalgia symptoms such as pain fatigue and or sleep problems with 58 matching the complete ACR 2010 criteria for fibromyalgia Based on the WPI and SS score cut points the remaining 42 exhibited subclinical symptoms Pain and emotional symptom trajectories on the other hand displayed a variety of longitudinal patterns The study concluded that while most patient s fibromyalgia symptoms endure the severity of their pain tends to reduce over time 216 Baseline depressive symptoms in adolescents appear to predict worse pain at follow up periods 217 218 A meta analysis based on close to 200 000 fibromyalgia patients found that they were at a higher risk for all cause mortality Specific mortality causes that were suggested were accidents infections and suicide 219 Epidemiology editFibromyalgia is estimated to affect 1 8 of the population 220 Despite the fact that more than 90 of fibromyalgia patients are women only 60 of people with fibromyalgia symptoms are female in the general population 221 History editChronic widespread pain had already been described in the literature in the 19th century but the term fibromyalgia was not used until 1976 when Dr P K Hench used it to describe these symptoms 97 Many names including muscular rheumatism fibrositis psychogenic rheumatism and neurasthenia were applied historically to symptoms resembling those of fibromyalgia 222 The term fibromyalgia was coined by researcher Mohammed Yunus as a synonym for fibrositis and was first used in a scientific publication in 1981 223 Fibromyalgia is from the Latin fibra fiber 224 and the Greek words myo muscle 225 and algos pain 226 Historical perspectives on the development of the fibromyalgia concept note the central importance of a 1977 paper by Smythe and Moldofsky on fibrositis 227 228 The first clinical controlled study of the characteristics of fibromyalgia syndrome was published in 1981 229 providing support for symptom associations In 1984 an interconnection between fibromyalgia syndrome and other similar conditions was proposed 230 and in 1986 trials of the first proposed medications for fibromyalgia were published 230 A 1987 article in the Journal of the American Medical Association used the term fibromyalgia syndrome while saying it was a controversial condition 231 The American College of Rheumatology ACR published its first classification criteria for fibromyalgia in 1990 232 Later revisions were made in 2010 98 2016 9 and 2019 12 Society and culture editEconomics edit People with fibromyalgia generally have higher healthcare costs and utilization rates A review of 36 studies found that fibromyalgia causes a significant economic burden on health care systems 233 Annual costs per patient were estimated to be up to 35 920 in the US and 8 504 in Europe 233 Controversies edit Fibromyalgia was defined relatively recently In the past it was a disputed diagnosis Frederick Wolfe lead author of the 1990 paper that first defined the diagnostic guidelines for fibromyalgia stated in 2008 that he believed it clearly not to be a disease but instead a physical response to depression and stress 234 In 2013 Wolfe added that its causes are controversial in a sense and there are many factors that produce these symptoms some are psychological and some are physical and it does exist on a continuum 235 Some members of the medical community do not consider fibromyalgia a disease because of a lack of abnormalities on physical examination and the absence of objective diagnostic tests 227 236 In the past some psychiatrists have viewed fibromyalgia as a type of affective disorder or a somatic symptom disorder These controversies do not engage healthcare specialists alone some patients object to fibromyalgia being described in purely somatic terms 237 As of 2022 neurologists and pain specialists tend to view fibromyalgia as a pathology due to dysfunction of muscles and connective tissue as well as functional abnormalities in the central nervous system Rheumatologists define the syndrome in the context of central sensitization heightened brain response to normal stimuli in the absence of disorders of the muscles joints or connective tissues Because of this symptomatic overlap some researchers have proposed that fibromyalgia and other analogous syndromes be classified together as central sensitivity syndromes 238 13 Notes edit Shoulder girdle left amp right upper arm left amp right lower arm left amp right hip buttock trochanter left amp right upper leg left amp right lower leg left amp right jaw left amp right chest abdomen back upper amp lower and neck 98 607 Somatic symptoms include but are not limited to muscle pain irritable bowel syndrome fatigue or tiredness problems thinking or remembering muscle weakness headache pain or cramps in the abdomen numbness or tingling dizziness insomnia depression constipation pain in the upper abdomen nausea nervousness chest pain blurred vision fever diarrhea dry mouth itching wheezing Raynaud s phenomenon hives or welts ringing in the ears vomiting heartburn oral ulcers loss of or changes in taste seizures dry eyes shortness of breath loss of appetite rash sun sensitivity hearing difficulties easy bruising hair loss frequent or painful urination and bladder spasms 98 607 References edit fibromyalgia Collins Dictionaries Archived from the original on 4 October 2015 Retrieved 16 March 2016 Neurology Now Fibromyalgia Is Fibromyalgia Real American Academy of Neurology tools aan com October 2009 Retrieved 1 June 2018 permanent dead link a b c Ngian GS Guymer EK Littlejohn GO February 2011 The use of opioids in fibromyalgia International Journal of Rheumatic Diseases 14 1 6 11 doi 10 1111 j 1756 185X 2010 01567 x PMID 21303476 S2CID 29000267 a b c d e f g h i j k l Clauw DJ April 2014 Fibromyalgia a clinical review JAMA 311 15 1547 1555 doi 10 1001 jama 2014 3266 PMID 24737367 S2CID 43693607 a b c d e f g Questions and Answers about Fibromyalgia NIAMS July 2014 Archived from the original on 15 March 2016 Retrieved 15 March 2016 Ferri FF 2010 Chapter F Ferri s differential diagnosis a practical guide to the differential diagnosis of symptoms signs and clinical disorders 2nd ed Philadelphia PA Elsevier Mosby ISBN 978 0323076999 Schneider MJ Brady DM Perle SM 2006 Commentary differential diagnosis of fibromyalgia syndrome proposal of a model and algorithm for patients presenting with the primary symptom of chronic widespread pain Journal of Manipulative and Physiological Therapeutics 29 6 493 501 doi 10 1016 j jmpt 2006 06 010 PMID 16904498 a b c Cooper TE Derry S Wiffen PJ Moore RA January 2017 Gabapentin for fibromyalgia pain in adults The Cochrane Database of Systematic Reviews 1 1 CD012188 doi 10 1002 14651858 CD012188 pub2 PMC 6465053 PMID 28045473 a b c d e f g h Wolfe F Clauw DJ Fitzcharles MA Goldenberg DL Hauser W Katz RL et al December 2016 2016 Revisions to the 2010 2011 fibromyalgia diagnostic criteria Seminars in Arthritis and Rheumatism 46 3 319 329 doi 10 1016 j semarthrit 2016 08 012 PMID 27916278 a b Wu YL Chang LY Lee HC Fang SC Tsai PS May 2017 Sleep disturbances in fibromyalgia A meta analysis of case control studies Journal of Psychosomatic Research 96 89 97 doi 10 1016 j jpsychores 2017 03 011 PMID 28545798 a b c d e f g Hauser W Sarzi Puttini P Fitzcharles MA 2019 Fibromyalgia syndrome under over and misdiagnosis Clinical and Experimental Rheumatology 37 1 Suppl 116 90 97 PMID 30747096 a b c d e f g h i j k l m n o p q r s t u Arnold LM Bennett RM Crofford LJ Dean LE Clauw DJ Goldenberg DL et al June 2019 AAPT Diagnostic Criteria for Fibromyalgia The Journal of Pain 20 6 611 628 doi 10 1016 j jpain 2018 10 008 hdl 2434 632765 PMID 30453109 S2CID 53872511 a b c Mezhov V Guymer E Littlejohn G December 2021 Central sensitivity and fibromyalgia Internal Medicine Journal 51 12 1990 1998 doi 10 1111 imj 15430 PMID 34139045 S2CID 235471910 a b c Prabhakar A Kaiser JM Novitch MB Cornett EM Urman RD Kaye AD March 2019 The Role of Complementary and Alternative Medicine Treatments in Fibromyalgia a Comprehensive Review Current Rheumatology Reports 21 5 14 doi 10 1007 s11926 019 0814 0 PMID 30830504 S2CID 73482737 a b c d e f Macfarlane GJ Kronisch C Atzeni F Hauser W Choy EH Amris K et al December 2017 EULAR recommendations for management of fibromyalgia PDF Annals of the Rheumatic Diseases 76 12 e54 doi 10 1136 annrheumdis 2017 211587 PMID 28476880 S2CID 26251476 a b c d e Hauser W Fitzcharles MA March 2018 Facts and myths pertaining to fibromyalgia Dialogues in Clinical Neuroscience 20 1 53 62 doi 10 31887 dcns 2018 20 1 whauser PMC 6016048 PMID 29946212 a b c d e f g Mascarenhas RO Souza MB Oliveira MX Lacerda AC Mendonca VA Henschke N Oliveira VC January 2021 Association of Therapies With Reduced Pain and Improved Quality of Life in Patients With Fibromyalgia A Systematic Review and Meta analysis JAMA Internal Medicine 181 1 104 112 doi 10 1001 jamainternmed 2020 5651 PMC 7589080 PMID 33104162 Kia S Choy E May 2017 Update on Treatment Guideline in Fibromyalgia Syndrome with Focus on Pharmacology Biomedicines 5 2 20 doi 10 3390 biomedicines5020020 PMC 5489806 PMID 28536363 a b c Ibanez Vera AJ Alvero Cruz JR Garcia Romero JC 2018 Therapeutic physical exercise and supplements to treat fibromyalgia Apunts Medicina de l Esport 53 197 33 41 doi 10 1016 j apunts 2017 07 001 a b c d e f g Fitzcharles MA Cohen SP Clauw DJ Littlejohn G Usui C Hauser W May 2021 Nociplastic pain towards an understanding of prevalent pain conditions Lancet 397 10289 2098 2110 doi 10 1016 s0140 6736 21 00392 5 PMID 34062144 S2CID 235245552 Pontes Silva A 3 February 2024 Fibromyalgia a new set of diagnostic criteria based on the biopsychosocial model Rheumatology doi 10 1093 rheumatology keae074 ISSN 1462 0324 PMID 38310344 Bergmann U 2012 Neurobiological foundations for EMDR practice New York Springer Pub Co p 165 ISBN 978 0826109385 a b Clauw DJ Arnold LM McCarberg BH September 2011 The science of fibromyalgia Mayo Clinic Proceedings 86 9 907 911 doi 10 4065 mcp 2011 0206 PMC 3258006 PMID 21878603 ICD 11 for Mortality and Morbidity Statistics icd who int Retrieved 9 April 2022 Besiroglu MD Dursun MD July 2019 The association between fibromyalgia and female sexual dysfunction a systematic review and meta analysis of observational studies International Journal of Impotence Research 31 4 288 297 doi 10 1038 s41443 018 0098 3 PMID 30467351 S2CID 53717513 Zdebik N Zdebik A Boguslawska J Przezdziecka Dolyk J Turno Krecicka A January 2021 Fibromyalgia syndrome and the eye A review Survey of Ophthalmology 66 1 132 137 doi 10 1016 j survophthal 2020 05 006 PMID 32512032 S2CID 219548664 academic oup com https academic oup com painmedicine article 23 6 1144 6404604 Retrieved 11 February 2024 a href Template Cite web html title Template Cite web cite web a Missing or empty title help Fibromyalgia Symptoms nhs uk 20 October 2017 Retrieved 21 October 2020 Kimura S Toyoura M Toyota Y Takaoka Y December 2020 Serum concentrations of insulin like growth factor 1 as a biomarker of improved circadian rhythm sleep wake disorder in school aged children Journal of Clinical Sleep Medicine 16 12 2073 2078 doi 10 5664 jcsm 8778 PMC 7848940 PMID 32876042 Spaeth M Rizzi M Sarzi Puttini P April 2011 Fibromyalgia and sleep Best Practice amp Research Clinical Rheumatology 25 2 227 239 doi 10 1016 j berh 2011 03 004 PMID 22094198 a b Bradley LA December 2009 Pathophysiology of fibromyalgia The American Journal of Medicine 122 12 Suppl S22 S30 doi 10 1016 j amjmed 2009 09 008 PMC 2821819 PMID 19962493 Wolfe F Rasker JJ Ten Klooster P Hauser W December 2021 Subjective Cognitive Dysfunction in Patients With and Without Fibromyalgia Prevalence Predictors Correlates and Consequences Cureus 13 12 e20351 doi 10 7759 cureus 20351 PMC 8752385 PMID 35036191 a b c Bell T Trost Z Buelow MT Clay O Younger J Moore D Crowe M September 2018 Meta analysis of cognitive performance in fibromyalgia Journal of Clinical and Experimental Neuropsychology 40 7 698 714 doi 10 1080 13803395 2017 1422699 PMC 6151134 PMID 29388512 Berwick RJ Siew S Andersson DA Marshall A Goebel A May 2021 A Systematic Review Into the Influence of Temperature on Fibromyalgia Pain Meteorological Studies and Quantitative Sensory Testing The Journal of Pain 22 5 473 486 doi 10 1016 j jpain 2020 12 005 PMID 33421589 S2CID 231437516 Staud R Godfrey MM Robinson ME August 2021 Fibromyalgia Patients Are Not Only Hypersensitive to Painful Stimuli But Also to Acoustic Stimuli The Journal of Pain 22 8 914 925 doi 10 1016 j jpain 2021 02 009 PMID 33636370 S2CID 232066286 a b c d e f g h Kleykamp BA Ferguson MC McNicol E Bixho I Arnold LM Edwards RR et al February 2021 The Prevalence of Psychiatric and Chronic Pain Comorbidities in Fibromyalgia an ACTTION systematic review Seminars in Arthritis and Rheumatism 51 1 166 174 doi 10 1016 j semarthrit 2020 10 006 PMID 33383293 S2CID 229948862 Habibi Asgarabad M Salehi Yegaei P Jafari F Azami Aghdash S Lumley MA March 2023 The relationship of alexithymia to pain and other symptoms in fibromyalgia A systematic review and meta analysis European Journal of Pain 27 3 321 337 doi 10 1002 ejp 2064 PMID 36471652 S2CID 254273680 a b c d e f g Fitzcharles MA Perrot S Hauser W October 2018 Comorbid fibromyalgia A qualitative review of prevalence and importance European Journal of Pain 22 9 1565 1576 doi 10 1002 ejp 1252 PMID 29802812 S2CID 44068037 Yepez D Grandes XA Talanki Manjunatha R Habib S Sangaraju SL May 2022 Fibromyalgia and Depression A Literature Review of Their Shared Aspects Cureus 14 5 e24909 doi 10 7759 cureus 24909 PMC 9187156 PMID 35698706 Loge Hagen JS Saele A Juhl C Bech P Stenager E Mellentin AI February 2019 Prevalence of depressive disorder among patients with fibromyalgia Systematic review and meta analysis Journal of Affective Disorders 245 1098 1105 doi 10 1016 j jad 2018 12 001 PMID 30699852 S2CID 73411416 Anderson G Maes M December 2020 Mitochondria and immunity in chronic fatigue syndrome Progress in Neuro Psychopharmacology amp Biological Psychiatry 103 109976 doi 10 1016 j pnpbp 2020 109976 PMID 32470498 S2CID 219104988 a b Ramirez Morales R Bermudez Benitez E Martinez Martinez LA Martinez Lavin M August 2022 Clinical overlap between fibromyalgia and myalgic encephalomyelitis A systematic review and meta analysis Autoimmunity Reviews 21 8 103129 doi 10 1016 j autrev 2022 103129 PMID 35690247 Valencia C Fatima H Nwankwo I Anam M Maharjan S Amjad Z et al October 2022 A Correlation Between the Pathogenic Processes of Fibromyalgia and Irritable Bowel Syndrome in the Middle Aged Population A Systematic Review Cureus 14 10 e29923 doi 10 7759 cureus 29923 PMC 9635936 PMID 36381861 D Onghia M Ciaffi J Lisi L Mancarella L Ricci S Stefanelli N et al April 2021 Fibromyalgia and obesity A comprehensive systematic review and meta analysis Seminars in Arthritis and Rheumatism 51 2 409 424 doi 10 1016 j semarthrit 2021 02 007 PMID 33676126 S2CID 232136088 Alsiri N Alhadhoud M Alkatefi T Palmer S February 2023 The concomitant diagnosis of fibromyalgia and connective tissue disorders A systematic review PDF Seminars in Arthritis and Rheumatism 58 152127 doi 10 1016 j semarthrit 2022 152127 PMID 36462303 S2CID 253650110 Kocyigit BF Akyol A March 2023 Coexistence of fibromyalgia syndrome and inflammatory rheumatic diseases and autonomic cardiovascular system involvement in fibromyalgia syndrome Clinical Rheumatology 42 3 645 652 doi 10 1007 s10067 022 06385 8 PMID 36151442 S2CID 252496799 Padhan P Maikap D Pathak M 2023 Restless leg syndrome in rheumatic conditions Its prevalence and risk factors a meta analysis International Journal of Rheumatic Diseases 26 6 1111 1119 doi 10 1111 1756 185X 14710 ISSN 1756 1841 PMID 37137528 S2CID 258484602 Goldberg N Tamam S Weintraub AY December 2022 The association between overactive bladder and fibromyalgia A systematic review and meta analysis International Journal of Gynaecology and Obstetrics 159 3 630 641 doi 10 1002 ijgo 14290 PMID 35641437 S2CID 249236213 a b c d e D Agnelli S Arendt Nielsen L Gerra MC Zatorri K Boggiani L Baciarello M Bignami E January 2019 Fibromyalgia Genetics and epigenetics insights may provide the basis for the development of diagnostic biomarkers Molecular Pain 15 1744806918819944 doi 10 1177 1744806918819944 PMC 6322092 PMID 30486733 a b c Ablin JN Buskila D February 2015 Update on the genetics of the fibromyalgia syndrome Best Practice amp Research Clinical Rheumatology 29 1 20 28 doi 10 1016 j berh 2015 04 018 PMID 26266996 Lee YH Choi SJ Ji JD Song GG February 2012 Candidate gene studies of fibromyalgia a systematic review and meta analysis Rheumatology International 32 2 417 426 doi 10 1007 s00296 010 1678 9 PMID 21120487 S2CID 6239018 Dutta D Brummett CM Moser SE Fritsche LG Tsodikov A Lee S et al May 2020 Heritability of the Fibromyalgia Phenotype Varies by Age Arthritis amp Rheumatology 72 5 815 823 doi 10 1002 art 41171 PMC 8372844 PMID 31736264 a b c Pinto AM Luis M Geenen R Palavra F Lumley MA Ablin JN Amris K Branco J Buskila D Castelhano J Castelo Branco M Crofford LJ Fitzcharles M Hauser W Kosek E 2023 Neurophysiological and psychosocial mechanisms of fibromyalgia A comprehensive review and call for an integrative model Neuroscience amp Biobehavioral Reviews 151 105235 doi 10 1016 j neubiorev 2023 105235 ISSN 0149 7634 PMID 37207842 S2CID 258745974 Maletic V Raison CL June 2009 Neurobiology of depression fibromyalgia and neuropathic pain Frontiers in Bioscience 14 14 5291 5338 doi 10 2741 3598 PMID 19482616 a b c Martins DF Viseux FJ Salm DC Ribeiro AC da Silva HK Seim LA et al December 2021 The role of the vagus nerve in fibromyalgia syndrome Neuroscience and Biobehavioral Reviews 131 1136 1149 doi 10 1016 j neubiorev 2021 10 021 PMID 34710514 S2CID 239772451 a b Kaleycheva N Cullen AE Evans R Harris T Nicholson T Chalder T January 2021 The role of lifetime stressors in adult fibromyalgia systematic review and meta analysis of case control studies Psychological Medicine 51 2 177 193 doi 10 1017 S0033291720004547 PMID 33602373 S2CID 231955641 a b c d e Jung YH Kim H Lee D Lee JY Moon JY Choi SH Kang DH January 2021 Dysfunctional energy metabolisms in fibromyalgia compared with healthy subjects Molecular Pain 17 17448069211012833 doi 10 1177 17448069211012833 PMC 8113919 PMID 33940974 Schmidt Wilcke T Clauw DJ July 2011 Fibromyalgia from pathophysiology to therapy Nature Reviews Rheumatology 7 9 518 527 doi 10 1038 nrrheum 2011 98 PMID 21769128 S2CID 20678671 Casale R Sarzi Puttini P Botto R Alciati A Batticciotto A Marotto D Torta R January 2019 Fibromyalgia and the concept of resilience Clinical and Experimental Rheumatology 37 1 105 113 PMID 30747098 Conversano C Marchi L Rebecca C Carmassi C Contena B Bazzichi LM Gemignani A 28 September 2018 Personality Traits in Fibromyalgia FM Does FM Personality Exists A Systematic Review Clinical Practice and Epidemiology in Mental Health 14 1 223 232 doi 10 2174 1745017901814010223 PMC 6166394 PMID 30294356 a b Tan AC Jaaniste T Champion D 5 May 2019 Chronic Widespread Pain and Fibromyalgia Syndrome Life Course Risk Markers in Young People Pain Research amp Management 2019 6584753 doi 10 1155 2019 6584753 PMC 6525804 PMID 31191788 Roach K Roberts J August 2022 A comprehensive summary of disease variants implicated in metal allergy Journal of Toxicology and Environmental Health Part B Critical Reviews 25 6 279 341 Bibcode 2022JTEHB 25 279R doi 10 1080 10937404 2022 2104981 PMC 9968405 PMID 35975293 S2CID 251623384 Fialho MF Brum ES Oliveira SM 2023 Could the fibromyalgia syndrome be triggered or enhanced by COVID 19 Inflammopharmacology 31 2 633 651 doi 10 1007 s10787 023 01160 w ISSN 0925 4692 PMC 9970139 PMID 36849853 de Tommaso M Vecchio E Nolano M March 2022 The puzzle of fibromyalgia between central sensitization syndrome and small fiber neuropathy a narrative review on neurophysiological and morphological evidence Neurological Sciences 43 3 1667 1684 doi 10 1007 s10072 021 05806 x PMID 35028777 S2CID 245909381 den Boer C Dries L Terluin B van der Wouden JC Blankenstein AH van Wilgen CP et al February 2019 Central sensitization in chronic pain and medically unexplained symptom research A systematic review of definitions operationalizations and measurement instruments Journal of Psychosomatic Research 117 32 40 doi 10 1016 j jpsychores 2018 12 010 PMID 30665594 S2CID 58565532 Bidari A Ghavidel Parsa B October 2022 Nociplastic pain concept a mechanistic basis for pragmatic approach to fibromyalgia Clinical Rheumatology 41 10 2939 2947 doi 10 1007 s10067 022 06229 5 PMID 35701625 S2CID 249650477 Nijs J Lahousse A Kapreli E Bilika P Saracoglu I Malfliet A et al July 2021 Nociplastic Pain Criteria or Recognition of Central Sensitization Pain Phenotyping in the Past Present and Future Journal of Clinical Medicine 10 15 3203 doi 10 3390 jcm10153203 PMC 8347369 PMID 34361986 a b Martinez Lavin M December 2018 Fibromyalgia and small fiber neuropathy the plot thickens Clinical Rheumatology 37 12 3167 3171 doi 10 1007 s10067 018 4300 2 PMID 30238382 S2CID 52306843 Martinez Lavin M February 2021 Dorsal root ganglia fibromyalgia pain factory Clinical Rheumatology 40 2 783 787 doi 10 1007 s10067 020 05528 z PMC 7787228 PMID 33409721 a b Martinez Lavin M Holman AJ 2021 Heart rate variability analysis in rheumatology past present and future Clinical and Experimental Rheumatology 39 5 927 930 doi 10 55563 clinexprheumatol nmvth1 PMID 34464245 S2CID 237375381 Figueroa A Kingsley JD McMillan V Panton LB January 2008 Resistance exercise training improves heart rate variability in women with fibromyalgia Clinical Physiology and Functional Imaging 28 1 49 54 doi 10 1111 j 1475 097X 2007 00776 x PMID 18005081 S2CID 40592827 Park HY Jung WS Kim J Hwang H Lim K March 2020 Twelve Weeks of Aerobic Exercise at the Lactate Threshold Improves Autonomic Nervous System Function Body Composition and Aerobic Performance in Women with Obesity Journal of Obesity amp Metabolic Syndrome 29 1 67 75 doi 10 7570 jomes19063 PMC 7118007 PMID 32045515 a b Pinto AM Geenen R Wager TD Lumley MA Hauser W Kosek E et al January 2023 Emotion regulation and the salience network a hypothetical integrative model of fibromyalgia Nature Reviews Rheumatology 19 1 44 60 doi 10 1038 s41584 022 00873 6 PMID 36471023 S2CID 254273384 a b c d Singh L Kaur A Bhatti MS Bhatti R July 2019 Possible Molecular Mediators Involved and Mechanistic Insight into Fibromyalgia and Associated Co morbidities Neurochemical Research 44 7 1517 1532 doi 10 1007 s11064 019 02805 5 PMID 31004261 S2CID 123945497 a b Bellato E Marini E Castoldi F Barbasetti N Mattei L Bonasia DE Blonna D 1 January 2012 Fibromyalgia syndrome etiology pathogenesis diagnosis and treatment Pain Research and Treatment 2012 426130 doi 10 1155 2012 426130 PMC 3503476 PMID 23213512 a b Feraco P Bacci A Pedrabissi F Passamonti L Zampogna G Pedrabissi F et al October 2011 Metabolic abnormalities in pain processing regions of patients with fibromyalgia a 3T MR spectroscopy study AJNR American Journal of Neuroradiology 32 9 1585 1590 doi 10 3174 ajnr A2550 PMC 7965402 PMID 21799042 a b Xin M Qu Y Peng X Zhu D Cheng S 9 May 2023 A systematic review and meta analysis of voxel based morphometric studies of fibromyalgia Frontiers in Neuroscience 17 doi 10 3389 fnins 2023 1164145 ISSN 1662 453X PMC 10203234 PMID 37229427 a b Lin C Lee SH Weng HH 1 January 2016 Gray Matter Atrophy within the Default Mode Network of Fibromyalgia A Meta Analysis of Voxel Based Morphometry Studies BioMed Research International 2016 7296125 doi 10 1155 2016 7296125 PMC 5220433 PMID 28105430 a b c d e Assavarittirong C Samborski W Grygiel Gorniak B 2022 Oxidative Stress in Fibromyalgia From Pathology to Treatment Oxidative Medicine and Cellular Longevity 2022 1582432 doi 10 1155 2022 1582432 PMC 9556195 PMID 36246401 Coskun Benlidayi I May 2019 Role of inflammation in the pathogenesis and treatment of fibromyalgia Rheumatology International 39 5 781 791 doi 10 1007 s00296 019 04251 6 PMID 30756137 S2CID 131775636 a b c Uceyler N Hauser W Sommer C October 2011 Systematic review with meta analysis cytokines in fibromyalgia syndrome BMC Musculoskeletal Disorders 12 245 doi 10 1186 1471 2474 12 245 PMC 3234198 PMID 22034969 a b c Rodriguez Pinto I Agmon Levin N Howard A Shoenfeld Y October 2014 Fibromyalgia and cytokines Immunology Letters 161 2 200 203 doi 10 1016 j imlet 2014 01 009 PMID 24462815 Dell Osso L Bazzichi L Baroni S Falaschi V Conversano C Carmassi C Marazziti D 1 January 2015 The inflammatory hypothesis of mood spectrum broadened to fibromyalgia and chronic fatigue syndrome Clinical and Experimental Rheumatology 33 1 Suppl 88 S109 S116 PMID 25786052 a b Bazzichi L Giacomelli C Consensi A Giorgi V Batticciotto A Di Franco M Sarzi Puttini P 2020 One year in review 2020 fibromyalgia Clinical and Experimental Rheumatology 38 1 3 8 PMID 32116216 Littlejohn G November 2015 Neurogenic neuroinflammation in fibromyalgia and complex regional pain syndrome Nature Reviews Rheumatology 11 11 639 648 doi 10 1038 nrrheum 2015 100 PMID 26241184 S2CID 4368913 Erdrich S Hawrelak JA Myers SP Harnett JE March 2020 Determining the association between fibromyalgia the gut microbiome and its biomarkers A systematic review BMC Musculoskeletal Disorders 21 1 181 doi 10 1186 s12891 020 03201 9 PMC 7083062 PMID 32192466 Wang Y Wei J Zhang W Doherty M Zhang Y Xie H et al June 2022 Gut dysbiosis in rheumatic diseases A systematic review and meta analysis of 92 observational studies eBioMedicine 80 104055 doi 10 1016 j ebiom 2022 104055 PMC 9120231 PMID 35594658 Minerbi A Fitzcharles MA January 2020 Gut microbiome pertinence in fibromyalgia Clinical and Experimental Rheumatology 38 1 99 104 PMID 32116215 Clos Garcia M Andres Marin N Fernandez Eulate G Abecia L Lavin JL van Liempd S et al August 2019 Gut microbiome and serum metabolome analyses identify molecular biomarkers and altered glutamate metabolism in fibromyalgia eBioMedicine 46 499 511 doi 10 1016 j ebiom 2019 07 031 PMC 6710987 PMID 31327695 Borenstein D April 1995 Prevalence and treatment outcome of primary and secondary fibromyalgia in patients with spinal pain Spine 20 7 796 800 doi 10 1097 00007632 199504000 00011 PMID 7701393 S2CID 30837539 Bengtsson A Henriksson KG Larsson J July 1986 Reduced high energy phosphate levels in the painful muscles of patients with primary fibromyalgia Arthritis and Rheumatism 29 7 817 821 doi 10 1002 art 1780290701 PMID 3741498 Gerdle B Ghafouri B Lund E Bengtsson A Lundberg P Ettinger Veenstra HV et al October 2020 Evidence of Mitochondrial Dysfunction in Fibromyalgia Deviating Muscle Energy Metabolism Detected Using Microdialysis and Magnetic Resonance Journal of Clinical Medicine 9 11 3527 doi 10 3390 jcm9113527 PMC 7693920 PMID 33142767 Srikuea R Symons TB Long DE Lee JD Shang Y Chomentowski PJ et al February 2013 Association of fibromyalgia with altered skeletal muscle characteristics which may contribute to postexertional fatigue in postmenopausal women Arthritis and Rheumatism 65 2 519 528 doi 10 1002 art 37763 PMC 3558634 PMID 23124535 Shang Y Gurley K Symons B Long D Srikuea R Crofford LJ et al November 2012 Noninvasive optical characterization of muscle blood flow oxygenation and metabolism in women with fibromyalgia Arthritis Research amp Therapy 14 6 R236 doi 10 1186 ar4079 PMC 3674608 PMID 23116302 Hauser W Fitzcharles MA March 2018 Facts and myths pertaining to fibromyalgia Dialogues in Clinical Neuroscience 20 1 53 62 doi 10 31887 DCNS 2018 20 1 whauser PMC 6016048 PMID 29946212 Wolfe F August 2003 Stop using the American College of Rheumatology criteria in the clinic The Journal of Rheumatology 30 8 1671 1672 PMID 12913920 Archived from the original on 14 October 2011 a b c Hauser W Eich W Herrmann M Nutzinger DO Schiltenwolf M Henningsen P June 2009 Fibromyalgia syndrome classification diagnosis and treatment Deutsches Arzteblatt International 106 23 383 391 doi 10 3238 arztebl 2009 0383 PMC 2712241 PMID 19623319 a b c d e f Wolfe F Clauw DJ Fitzcharles MA Goldenberg DL Katz RS Mease P et al May 2010 The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity Arthritis Care amp Research 62 5 600 610 doi 10 1002 acr 20140 hdl 2027 42 75772 PMID 20461783 S2CID 17154205 Galvez Sanchez CM Reyes Del Paso GA April 2020 Diagnostic Criteria for Fibromyalgia Critical Review and Future Perspectives Journal of Clinical Medicine 9 4 1219 doi 10 3390 jcm9041219 PMC 7230253 PMID 32340369 Wang SM Han C Lee SJ Patkar AA Masand PS Pae CU June 2015 Fibromyalgia diagnosis a review of the past present and future Expert Review of Neurotherapeutics 15 6 667 679 doi 10 1586 14737175 2015 1046841 PMID 26035624 S2CID 2412984 Burckhardt CS Clark SR Bennett RM May 1991 The fibromyalgia impact questionnaire development and validation The Journal of Rheumatology 18 5 728 733 PMID 1865419 a b Bennett RM Friend R Jones KD Ward R Han BK Ross RL 1 January 2009 The Revised Fibromyalgia Impact Questionnaire FIQR validation and psychometric properties Arthritis Research amp Therapy 11 4 R120 doi 10 1186 ar2783 PMC 2745803 PMID 19664287 Fibromyalgia Impact Questionnaire FIQ American College of Rheumatology Seidenberg M Haltiner A Taylor MA Hermann BB Wyler A February 1994 Development and validation of a Multiple Ability Self Report Questionnaire Journal of Clinical and Experimental Neuropsychology 16 1 93 104 doi 10 1080 01688639408402620 PMID 8150893 a b c Goldenberg DL December 2009 Diagnosis and differential diagnosis of fibromyalgia The American Journal of Medicine Review 122 12 Suppl S14 S21 doi 10 1016 j amjmed 2009 09 007 PMID 19962492 a b c Hauser W Perrot S Sommer C Shir Y Fitzcharles MA May 2017 Diagnostic confounders of chronic widespread pain not always fibromyalgia Pain Reports 2 3 e598 doi 10 1097 PR9 0000000000000598 PMC 5741304 PMID 29392213 a b Rossi A Di Lollo AC Guzzo MP Giacomelli C Atzeni F Bazzichi L Di Franco M 2015 Fibromyalgia and nutrition what news Clinical and Experimental Rheumatology 33 1 Suppl 88 S117 S125 PMID 25786053 a b Marchesoni A De Marco G Merashli M McKenna F Tinazzi I Marzo Ortega H McGonagle DG January 2018 The problem in differentiation between psoriatic related polyenthesitis and fibromyalgia Rheumatology Review 57 1 32 40 doi 10 1093 rheumatology kex079 PMID 28387854 S2CID 205309871 a b Palazzi C D Amico E D Angelo S Gilio M Olivieri I January 2016 Rheumatic manifestations of hepatitis C virus chronic infection Indications for a correct diagnosis World Journal of Gastroenterology Review 22 4 1405 1410 doi 10 3748 wjg v22 i4 1405 PMC 4721975 PMID 26819509 Pontes Silva A 3 February 2024 Fibromyalgia a new set of diagnostic criteria based on the biopsychosocial model Rheumatology doi 10 1093 rheumatology keae074 ISSN 1462 0324 PMID 38310344 a b Sommer C Hauser W Alten R Petzke F Spath M Tolle T et al June 2012 Drug therapy of fibromyalgia syndrome Systematic review meta analysis and guideline PDF Schmerz 26 3 297 310 doi 10 1007 s00482 012 1172 2 PMID 22760463 S2CID 1348989 Archived from the original PDF on 16 February 2013 a b Fitzcharles MA Shir Y Ablin JN Buskila D Amital H Henningsen P Hauser W 2013 Classification and clinical diagnosis of fibromyalgia syndrome recommendations of recent evidence based interdisciplinary guidelines Evidence Based Complementary and Alternative Medicine 2013 528952 doi 10 1155 2013 528952 PMC 3860136 PMID 24379886 a b c Management Canadian Guidelines for the Diagnosis and Management of Fibromyalgia Archived from the original on 11 June 2013 Busch AJ Barber KA Overend TJ Peloso PM Schachter CL October 2007 Exercise for treating fibromyalgia syndrome The Cochrane Database of Systematic Reviews 4 CD003786 doi 10 1002 14651858 CD003786 pub2 PMID 17943797 a b c Andrade A Dominski FH Sieczkowska SM December 2020 What we already know about the effects of exercise in patients with fibromyalgia An umbrella review Seminars in Arthritis and Rheumatism 50 6 1465 1480 doi 10 1016 j semarthrit 2020 02 003 PMID 32147091 S2CID 212638860 unreliable medical source Masquelier E D haeyere J October 2021 Physical activity in the treatment of fibromyalgia Joint Bone Spine 88 5 105202 doi 10 1016 j jbspin 2021 105202 PMID 33962033 McLoughlin MJ Stegner AJ Cook DB June 2011 The relationship between physical activity and brain responses to pain in fibromyalgia The Journal of Pain 12 6 640 651 doi 10 1016 j jpain 2010 12 004 PMC 3111901 PMID 21330218 a b Valim V Natour J Xiao Y Pereira AF Lopes BB Pollak DF et al November 2013 Effects of physical exercise on serum levels of serotonin and its metabolite in fibromyalgia a randomized pilot study Revista Brasileira de Reumatologia in Spanish 53 6 538 541 doi 10 1016 j rbr 2013 02 001 PMID 24477734 Genc A Tur BS Aytur YK Oztuna D Erdogan MF July 2015 Does aerobic exercise affect the hypothalamic pituitary adrenal hormonal response in patients with fibromyalgia syndrome Journal of Physical Therapy Science 27 7 2225 2231 doi 10 1589 jpts 27 2225 PMC 4540854 PMID 26311959 a b c d e f El Shewy KM Kunbaz A Gad MM Al Husseini MJ Saad AM Sammour YM Abdel Daim MM January 2019 Hyperbaric oxygen and aerobic exercise in the long term treatment of fibromyalgia A narrative review Biomedicine amp Pharmacotherapy 109 629 638 doi 10 1016 j biopha 2018 10 157 PMID 30399600 S2CID 53240356 Andrade A Vilarino GT Sieczkowska SM Coimbra DR Steffens RA Vietta GG March 2018 Acute effects of physical exercises on the inflammatory markers of patients with fibromyalgia syndrome A systematic review Journal of Neuroimmunology 316 40 49 doi 10 1016 j jneuroim 2017 12 007 PMID 29254627 S2CID 46879701 a b c d e f g Andrade A Vilarino GT Serafim TT Pereira Junior AA de Souza CA Sieczkowska SM October 2019 Modulation of Autonomic Function by Physical Exercise in Patients with Fibromyalgia Syndrome A Systematic Review PM amp R 11 10 1121 1131 doi 10 1002 pmrj 12158 PMID 30900831 S2CID 85448644 a b c Albuquerque ML Monteiro D Marinho DA Vilarino GT Andrade A Neiva HP November 2022 Effects of different protocols of physical exercise on fibromyalgia syndrome treatment systematic review and meta analysis of randomized controlled trials Rheumatology International 42 11 1893 1908 doi 10 1007 s00296 022 05140 1 hdl 10400 8 7188 PMID 35604435 S2CID 248970279 a b c Estevez Lopez F Maestre Cascales C Russell D Alvarez Gallardo IC Rodriguez Ayllon M Hughes CM et al April 2021 Effectiveness of Exercise on Fatigue and Sleep Quality in Fibromyalgia A Systematic Review and Meta analysis of Randomized Trials Archives of Physical Medicine and Rehabilitation 102 4 752 761 doi 10 1016 j apmr 2020 06 019 hdl 10481 68683 PMID 32721388 S2CID 220847961 Cuenca Martinez F Suso Marti L Fernandez Carnero J Munoz Alarcos V Sempere Rubio N 2023 Exercise based interventions on sleep quality in patients with fibromyalgia syndrome An umbrella and mapping review with meta analysis Seminars in Arthritis and Rheumatism 61 152216 doi 10 1016 j semarthrit 2023 152216 PMID 37229847 S2CID 258597720 McVeigh JG Lucas A Hurley DA Basford JR Baxter GD September 2003 Patients perceptions of exercise therapy in the treatment of fibromyalgia syndrome a survey Musculoskeletal Care 1 2 98 107 doi 10 1002 msc 45 PMID 20217670 Barhorst EE Andrae WE Rayne TJ Falvo MJ Cook DB Lindheimer JB December 2020 Elevated Perceived Exertion in People with Myalgic Encephalomyelitis Chronic Fatigue Syndrome and Fibromyalgia A Meta analysis Medicine and Science in Sports and Exercise 52 12 2615 2627 doi 10 1249 MSS 0000000000002421 PMC 10200687 PMID 32555018 S2CID 219918068 a b c Russell D Alvarez Gallardo IC Wilson I Hughes CM Davison GW Sanudo B McVeigh JG March 2018 Exercise to me is a scary word perceptions of fatigue sleep dysfunction and exercise in people with fibromyalgia syndrome a focus group study Rheumatology International 38 3 507 515 doi 10 1007 s00296 018 3932 5 PMID 29340774 S2CID 3395036 Sanz Banos Y Pastor Mira MA Lledo A Lopez Roig S Penacoba C Sanchez Meca J October 2018 Do women with fibromyalgia adhere to walking for exercise programs to improve their health Systematic review and meta analysis Disability and Rehabilitation 40 21 2475 2487 doi 10 1080 09638288 2017 1347722 PMID 28687050 S2CID 9032840 Vancampfort D McGrath RL Hemmings L Gillis V Bernar K Van Damme T November 2022 Physical activity correlates in people with fibromyalgia a systematic review Disability and Rehabilitation 45 25 4165 4174 doi 10 1080 09638288 2022 2146911 PMID 36398698 S2CID 253627372 Ryan S 2013 Care of patients with fibromyalgia assessment and management Nursing Standard 28 13 37 43 doi 10 7748 ns2013 11 28 13 37 e7722 PMID 24279570 Majdoub F Ben Nessib D Ferjani HL Kaffel D Triki W Maatallah K Hamdi W February 2023 Non pharmacological therapies in Fibromyalgia New horizons for physicians new hopes for patients Musculoskeletal Care 21 3 603 610 doi 10 1002 msc 1741 PMID 36757930 S2CID 256696861 Bidonde J Busch AJ Schachter CL Overend TJ Kim SY Goes SM et al June 2017 Aerobic exercise training for adults with fibromyalgia The Cochrane Database of Systematic Reviews 2017 6 CD012700 doi 10 1002 14651858 cd012700 PMC 6481524 PMID 28636204 a b Bidonde J Busch AJ Schachter CL Webber SC Musselman KE Overend TJ et al May 2019 Mixed exercise training for adults with fibromyalgia The Cochrane Database of Systematic Reviews 2019 5 CD013340 doi 10 1002 14651858 cd013340 PMC 6931522 PMID 31124142 Kim SY Busch AJ Overend TJ Schachter CL van der Spuy I Boden C et al September 2019 Flexibility exercise training for adults with fibromyalgia The Cochrane Database of Systematic Reviews 2019 9 CD013419 doi 10 1002 14651858 CD013419 PMC 6718217 PMID 31476271 Vilarino GT Andreato LV de Souza LC Branco JH Andrade A November 2021 Effects of resistance training on the mental health of patients with fibromyalgia a systematic review Clinical Rheumatology 40 11 4417 4425 doi 10 1007 s10067 021 05738 z PMID 33987785 S2CID 234489153 Rodriguez Dominguez A Rebollo Salas M Chillon Martinez R Rosales Tristancho A Jimenez Rejano J 17 July 2023 Clinical relevance of resistance training in women with fibromyalgia A systematic review and meta analysis European Journal of Pain 28 1 21 36 doi 10 1002 ejp 2161 ISSN 1090 3801 PMID 37458315 S2CID 259949000 Bastos AC Vilarino GT de Souza LC Dominski FH Branco JH Andrade A 15 May 2023 Effects of resistance training on sleep of patients with fibromyalgia A systematic review Journal of Health Psychology 28 11 1072 1084 doi 10 1177 13591053231172288 ISSN 1359 1053 PMID 37183814 S2CID 258687258 a b c d da Silva JM de Barros BS Almeida GJ O Neil J Imoto AM March 2022 Dosage of resistance exercises in fibromyalgia evidence synthesis for a systematic literature review up date and meta analysis Rheumatology International 42 3 413 429 doi 10 1007 s00296 021 05025 9 PMID 34652480 S2CID 238991065 Li H Chen J Xu G Duan Y Huang D Tang C Liu J September 2020 The Effect of Tai Chi for Improving Sleep Quality A Systematic Review and Meta analysis Journal of Affective Disorders 274 1102 1112 doi 10 1016 j jad 2020 05 076 PMID 32663938 S2CID 219743962 Vasileios P Styliani P Nifon G Pavlos S Aris F Ioannis P November 2022 Managing fibromyalgia with complementary and alternative medical exercise a systematic review and meta analysis of clinical trials Rheumatology International 42 11 1909 1923 doi 10 1007 s00296 022 05151 y PMID 35796820 S2CID 250317143 Cheng CA Chiu YW Wu D Kuan YC Chen SN Tam KW October 2019 Effectiveness of Tai Chi on fibromyalgia patients A meta analysis of randomized controlled trials Complementary Therapies in Medicine 46 1 8 doi 10 1016 j ctim 2019 07 007 PMID 31519264 S2CID 199039433 Bidonde J Busch AJ Webber SC Schachter CL Danyliw A Overend TJ et al October 2014 Aquatic exercise training for fibromyalgia The Cochrane Database of Systematic Reviews 2014 10 CD011336 doi 10 1002 14651858 cd011336 PMC 10638613 PMID 25350761 Lima TB Dias JM Mazuquin BF da Silva CT Nogueira RM Marques AP et al October 2013 The effectiveness of aquatic physical therapy in the treatment of fibromyalgia a systematic review with meta analysis Clinical Rehabilitation 27 10 892 908 doi 10 1177 0269215513484772 PMID 23818412 S2CID 25701866 Perraton L Machotka Z Kumar S November 2009 Components of effective randomized controlled trials of hydrotherapy programs for fibromyalgia syndrome A systematic review Journal of Pain Research 2 165 173 doi 10 2147 JPR S8052 PMC 3004626 PMID 21197303 Galvao Moreira LV de Castro LO Moura EC de Oliveira CM Nogueira Neto J Gomes LM Leal PD July 2021 Pool based exercise for amelioration of pain in adults with fibromyalgia syndrome A systematic review and meta analysis Modern Rheumatology 31 4 904 911 doi 10 1080 14397595 2020 1829339 PMID 32990113 S2CID 222167851 a b Calles Plata I Ortiz Rubio A Torres Sanchez I Cabrera Martos I Calvache Mateo A Heredia Ciuro A Valenza MC February 2023 Effectiveness of aquatic therapy on sleep in persons with fibromyalgia A meta analysis Sleep Medicine 102 76 83 doi 10 1016 j sleep 2022 12 016 PMID 36603514 S2CID 255217819 Ma J Zhang T Li X Chen X Zhao Q September 2022 Effects of aquatic physical therapy on clinical symptoms physical function and quality of life in patients with fibromyalgia A systematic review and meta analysis Physiotherapy Theory and Practice 40 2 205 223 doi 10 1080 09593985 2022 2119906 PMID 36062580 S2CID 252079586 Correyero Leon M Medrano de la Fuente R Hernando Garijo I Jimenez Del Barrio S Hernandez Lazaro H Ceballos Laita L Mingo Gomez MT July 2023 Effectiveness of aquatic training based on aerobic and strengthening exercises in patients with fibromyalgia systematic review with meta analysis Explore doi 10 1016 j explore 2023 07 003 PMID 37460329 S2CID 259580881 Bidonde J Busch AJ van der Spuy I Tupper S Kim SY Boden C September 2017 Whole body vibration exercise training for fibromyalgia The Cochrane Database of Systematic Reviews 2017 9 CD011755 doi 10 1002 14651858 cd011755 pub2 PMC 6483692 PMID 28950401 FDA Approves First Drug for Treating Fibromyalgia Press release U S Food and Drug Administration 21 June 2007 Archived from the original on 21 February 2008 Retrieved 14 January 2008 European Medicines Agency Questions and answers on the recommendati on for the refusal of the marketing authorisation for Milnacipran Pierre Fabre Medicament Impulsor PDF European Medicines Agency Archived PDF from the original on 22 February 2014 Retrieved 30 May 2013 Hauser W Wolfe F Tolle T Uceyler N Sommer C April 2012 The role of antidepressants in the management of fibromyalgia syndrome a systematic review and meta analysis CNS Drugs 26 4 297 307 doi 10 2165 11598970 000000000 00000 PMID 22452526 S2CID 207301478 Cording M Derry S Phillips T Moore RA Wiffen PJ October 2015 Milnacipran for pain in fibromyalgia in adults The Cochrane Database of Systematic Reviews 2015 10 CD008244 doi 10 1002 14651858 CD008244 pub3 PMC 6481368 PMID 26482422 a b Welsch P Uceyler N Klose P Walitt B Hauser W February 2018 Serotonin and noradrenaline reuptake inhibitors SNRIs for fibromyalgia The Cochrane Database of Systematic Reviews 2 2 CD010292 doi 10 1002 14651858 CD010292 pub2 PMC 5846183 PMID 29489029 Moore RA Derry S Aldington D Cole P Wiffen PJ May 2019 Amitriptyline for fibromyalgia in adults The Cochrane Database of Systematic Reviews 5 7 CD011824 doi 10 1002 14651858 CD011824 PMC 6485478 PMID 35658166 Migliorini F Maffulli N Eschweiler J Baroncini A Bell A Colarossi G 17 July 2023 Duloxetine for fibromyalgia syndrome a systematic review and meta analysis Journal of Orthopaedic Surgery and Research 18 1 504 doi 10 1186 s13018 023 03995 z ISSN 1749 799X PMC 10351165 PMID 37461044 Walitt B Urrutia G Nishishinya MB Cantrell SE Hauser W June 2015 Selective serotonin reuptake inhibitors for fibromyalgia syndrome The Cochrane Database of Systematic Reviews 2015 6 CD011735 doi 10 1002 14651858 cd011735 PMC 4755337 PMID 26046493 a b Moore RA Derry S Aldington D Cole P Wiffen PJ July 2015 Amitriptyline for neuropathic pain in adults The Cochrane Database of Systematic Reviews 2015 7 CD008242 doi 10 1002 14651858 CD011824 PMC 6485478 PMID 26146793 Welsch P Bernardy K Derry S Moore RA Hauser W August 2018 Mirtazapine for fibromyalgia in adults The Cochrane Database of Systematic Reviews 8 8 CD012708 doi 10 1002 14651858 CD012708 pub2 PMC 6513659 PMID 30080242 a b c Tort S Urrutia G Nishishinya MB Walitt B April 2012 Monoamine oxidase inhibitors MAOIs for fibromyalgia syndrome The Cochrane Database of Systematic Reviews 4 CD009807 doi 10 1002 14651858 cd009807 PMID 22513976 Wiffen PJ Derry S Bell RF Rice AS Tolle TR Phillips T Moore RA June 2017 Gabapentin for chronic neuropathic pain in adults The Cochrane Database of Systematic Reviews 6 6 CD007938 doi 10 1002 14651858 CD007938 pub4 PMC 6452908 PMID 28597471 Derry S Cording M Wiffen PJ Law S Phillips T Moore RA September 2016 Pregabalin for pain in fibromyalgia in adults The Cochrane Database of Systematic Reviews 9 9 CD011790 doi 10 1002 14651858 CD011790 pub2 PMC 6457745 PMID 27684492 Straube S Moore RA Paine J Derry S Phillips CJ Hallier E McQuay HJ June 2011 Interference with work in fibromyalgia effect of treatment with pregabalin and relation to pain response BMC Musculoskeletal Disorders 12 125 doi 10 1186 1471 2474 12 125 PMC 3118156 PMID 21639874 Nowell WB Gavigan K L Silverman S May 2022 Cannabis for Rheumatic Disease Pain a Review of Current Literature Current Rheumatology Reports 24 5 119 131 doi 10 1007 s11926 022 01065 7 PMID 35486218 S2CID 248423563 Boehnke KF Hauser W Fitzcharles MA July 2022 Cannabidiol CBD in Rheumatic Diseases Musculoskeletal Pain Current Rheumatology Reports 24 7 238 246 doi 10 1007 s11926 022 01077 3 PMC 9062628 PMID 35503198 Bourke SL Schlag AK O Sullivan SE Nutt DJ Finn DP December 2022 Cannabinoids and the endocannabinoid system in fibromyalgia A review of preclinical and clinical research Pharmacology amp Therapeutics 240 108216 doi 10 1016 j pharmthera 2022 108216 PMID 35609718 S2CID 248973512 Jain N Moorthy A June 2022 Cannabinoids in rheumatology Friend foe or a bystander Musculoskeletal Care 20 2 416 428 doi 10 1002 msc 1636 PMC 9322323 PMID 35476898 a b MacLean AJ Schwartz TL May 2015 Tramadol for the treatment of fibromyalgia Expert Review of Neurotherapeutics 15 5 469 475 doi 10 1586 14737175 2015 1034693 PMID 25896486 S2CID 26613022 Gaskell H Moore RA Derry S Stannard C et al Cochrane Pain Palliative and Supportive Care Group September 2016 Oxycodone for pain in fibromyalgia in adults The Cochrane Database of Systematic Reviews 2016 9 CD012329 doi 10 1002 14651858 CD012329 PMC 6457853 PMID 27582266 Thorpe J Shum B Moore RA Wiffen PJ Gilron I February 2018 Combination pharmacotherapy for the treatment of fibromyalgia in adults The Cochrane Database of Systematic Reviews 2 2 CD010585 doi 10 1002 14651858 CD010585 pub2 PMC 6491103 PMID 29457627 Goldenberg DL Clauw DJ Palmer RE Clair AG May 2016 Opioid Use in Fibromyalgia A Cautionary Tale Mayo Clinic Proceedings Review 91 5 640 648 doi 10 1016 j mayocp 2016 02 002 PMID 26975749 S2CID 20228209 Berger A Patterns of use of opioids in patients with fibromyalgia In EULAR 2009 SAT0461 Elijah J Powell K Smith MA June 2022 The Efficacy of Capsaicin on Sleep Quality and Fatigue in Fibromyalgia Journal of Pain amp Palliative Care Pharmacotherapy 36 2 112 116 doi 10 1080 15360288 2022 2063468 PMID 35471125 S2CID 248389141 Staud R August 2011 Sodium oxybate for the treatment of fibromyalgia Expert Opinion on Pharmacotherapy 12 11 1789 1798 doi 10 1517 14656566 2011 589836 PMID 21679091 S2CID 33026097 See S Ginzburg R August 2008 Choosing a skeletal muscle relaxant American Family Physician 78 3 365 370 PMID 18711953 Archived from the original on 1 April 2016 Kaltsas G Tsiveriotis K 2000 Fibromyalgia Endotext MDText com Inc PMID 25905317 Heymann RE Paiva ED Helfenstein M Pollak DF Martinez JE Provenza JR et al 2010 Brazilian consensus on the treatment of fibromyalgia Revista Brasileira de Reumatologia 50 1 56 66 doi 10 1590 S0482 50042010000100006 PMID 21125141 Derry S Wiffen PJ Hauser W Mucke M Tolle TR Bell RF Moore RA March 2017 Oral nonsteroidal anti inflammatory drugs for fibromyalgia in adults The Cochrane Database of Systematic Reviews 3 3 CD012332 doi 10 1002 14651858 CD012332 pub2 PMC 6464559 PMID 28349517 Walitt B Klose P Uceyler N Phillips T Hauser W June 2016 Antipsychotics for fibromyalgia in adults The Cochrane Database of Systematic Reviews 2016 6 CD011804 doi 10 1002 14651858 cd011804 pub2 PMC 6457603 PMID 27251337 Walitt B Klose P Fitzcharles MA Phillips T Hauser W July 2016 Cannabinoids for fibromyalgia The Cochrane Database of Systematic Reviews 7 7 CD011694 doi 10 1002 14651858 cd011694 pub2 PMC 6457965 PMID 27428009 a b Kadayifci FZ Bradley MJ Onat AM Shi HN Zheng S November 2022 Review of nutritional approaches to fibromyalgia Nutrition Reviews 80 12 2260 2274 doi 10 1093 nutrit nuac036 PMID 35674686 Nadal Nicolas Y Miralles Amoros L Martinez Olcina M Sanchez Ortega M Mora J Martinez Rodriguez A May 2021 Vegetarian and Vegan Diet in Fibromyalgia A Systematic Review International Journal of Environmental Research and Public Health 18 9 4955 doi 10 3390 ijerph18094955 PMC 8125538 PMID 34066603 Haddad HW Mallepalli NR Scheinuk JE Bhargava P Cornett EM Urits I Kaye AD December 2021 The Role of Nutrient Supplementation in the Management of Chronic Pain in Fibromyalgia A Narrative Review Pain and Therapy 10 2 827 848 doi 10 1007 s40122 021 00266 9 PMC 8586285 PMID 33909266 a b Qu K Li MX Zhou YL Yu P Dong M April 2022 The efficacy of vitamin D in treatment of fibromyalgia a meta analysis of randomized controlled studies and systematic review Expert Review of Clinical Pharmacology 15 4 433 442 doi 10 1080 17512433 2022 2081151 PMID 35596576 S2CID 248948241 Mehrabani S Askari G Miraghajani M Tavakoly R Arab A April 2019 Effect of coenzyme Q10 supplementation on fatigue A systematic review of interventional studies Complementary Therapies in Medicine 43 181 187 doi 10 1016 j ctim 2019 01 022 PMID 30935528 S2CID 86467031 Hargreaves IP Mantle D 2021 Targeted Treatment of Age Related Fibromyalgia with Supplemental Coenzyme Q10 PDF In Guest PC ed Reviews on New Drug Targets in Age Related Disorders Advances in Experimental Medicine and Biology Vol 1286 Cham Springer International Publishing pp 77 85 doi 10 1007 978 3 030 55035 6 5 ISBN 978 3 030 55034 9 PMID 33725346 S2CID 232261388 Erkilic B Dalgic GS January 2023 The preventive role of vitamin D in the prevention and management of Fibromyalgia syndrome Nutrition and Health 29 2 223 229 doi 10 1177 02601060221144801 a ti, wikipedia, wiki, book, books, library,

article

, read, download, free, free download, mp3, video, mp4, 3gp, jpg, jpeg, gif, png, picture, music, song, movie, book, game, games.